<!doctype html>
<html data-n-head-ssr lang="en" data-n-head="%7B%22lang%22:%7B%22ssr%22:%22en%22%7D%7D">

<head >
  <link data-n-head="ssr" rel="icon" type="image/png" sizes="16x16" href="https://brand.frontiersin.org/m/ed3f9ce840a03d7/favicon_16-tenantFavicon-Frontiers.png">
  <link data-n-head="ssr" rel="icon" type="image/png" sizes="32x32" href="https://brand.frontiersin.org/m/ed3f9ce840a03d7/favicon_32-tenantFavicon-Frontiers.png">
  <link data-n-head="ssr" rel="apple-touch-icon" type="image/png" sizes="180x180" href="https://brand.frontiersin.org/m/ed3f9ce840a03d7/favicon_180-tenantFavicon-Frontiers.png">

  <title>Frontiers | A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure</title><meta data-n-head="ssr" charset="utf-8"><meta data-n-head="ssr" name="viewport" content="width=device-width, initial-scale=1"><meta data-n-head="ssr" data-hid="charset" charset="utf-8"><meta data-n-head="ssr" data-hid="mobile-web-app-capable" name="mobile-web-app-capable" content="yes"><meta data-n-head="ssr" data-hid="apple-mobile-web-app-title" name="apple-mobile-web-app-title" content="Frontiers | Articles"><meta data-n-head="ssr" data-hid="theme-color" name="theme-color" content="#0C4DED"><meta data-n-head="ssr" data-hid="description" property="description" name="description" content=""><meta data-n-head="ssr" data-hid="og:title" property="og:title" name="title" content="Frontiers | A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure"><meta data-n-head="ssr" data-hid="og:description" property="og:description" name="description" content=""><meta data-n-head="ssr" data-hid="keywords" name="keywords" content="chronic hepatitis B,hepatitis B virus,metabolism-associated fatty liver disease,HBsAg clearance,clinical cure,peginterferon"><meta data-n-head="ssr" data-hid="og:site_name" property="og:site_name" name="site_name" content="Frontiers"><meta data-n-head="ssr" data-hid="og:image" property="og:image" name="image" content="https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/7CCE4235-8BF4-4D52-8022020C57AC98C1/D992F897-6BC2-466D-90902EADFBEAB887/WebsiteWebP_XL-FPUBH_Main Visual_Cyan_Website.webp"><meta data-n-head="ssr" data-hid="og:type" property="og:type" name="type" content="article"><meta data-n-head="ssr" data-hid="og:url" property="og:url" name="url" content="https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1546182/full"><meta data-n-head="ssr" data-hid="twitter:card" name="twitter:card" content="summary_large_image"><meta data-n-head="ssr" data-hid="citation_volume" name="citation_volume" content="13"><meta data-n-head="ssr" data-hid="citation_journal_title" name="citation_journal_title" content="Frontiers in Public Health"><meta data-n-head="ssr" data-hid="citation_publisher" name="citation_publisher" content="Frontiers"><meta data-n-head="ssr" data-hid="citation_journal_abbrev" name="citation_journal_abbrev" content="Front. Public Health"><meta data-n-head="ssr" data-hid="citation_issn" name="citation_issn" content="2296-2565"><meta data-n-head="ssr" data-hid="citation_doi" name="citation_doi" content="10.3389/fpubh.2025.1546182"><meta data-n-head="ssr" data-hid="citation_firstpage" name="citation_firstpage" content="1546182"><meta data-n-head="ssr" data-hid="citation_language" name="citation_language" content="English"><meta data-n-head="ssr" data-hid="citation_title" name="citation_title" content="A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure"><meta data-n-head="ssr" data-hid="citation_keywords" name="citation_keywords" content="chronic hepatitis B; hepatitis B virus; metabolism-associated fatty liver disease; HBsAg clearance; clinical cure; peginterferon"><meta data-n-head="ssr" data-hid="citation_abstract" name="citation_abstract" content=""><meta data-n-head="ssr" data-hid="citation_pdf_url" name="citation_pdf_url" content="https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1546182/pdf"><meta data-n-head="ssr" data-hid="citation_online_date" name="citation_online_date" content="2025/02/17"><meta data-n-head="ssr" data-hid="citation_publication_date" name="citation_publication_date" content="2025/03/14"><meta data-n-head="ssr" data-hid="citation_author_0" name="citation_author" content="Zhou, Daqiong"><meta data-n-head="ssr" data-hid="citation_author_institution_0" name="citation_author_institution" content="Beijing Youan Hospital, Capital Medical University, China"><meta data-n-head="ssr" data-hid="citation_author_1" name="citation_author" content="Zhang, Chao"><meta data-n-head="ssr" data-hid="citation_author_institution_1" name="citation_author_institution" content="The Fifth Medical Center of Chinese PLA General Hospital, China"><meta data-n-head="ssr" data-hid="citation_author_2" name="citation_author" content="Zhang, Lu"><meta data-n-head="ssr" data-hid="citation_author_institution_2" name="citation_author_institution" content="Beijing Ditan Hospital, Capital Medical University, China"><meta data-n-head="ssr" data-hid="citation_author_3" name="citation_author" content="Jia, Jianru"><meta data-n-head="ssr" data-hid="citation_author_institution_3" name="citation_author_institution" content="Baoding Municipal People&#x27;s Hospital, China"><meta data-n-head="ssr" data-hid="citation_author_4" name="citation_author" content="Fu, Junliang"><meta data-n-head="ssr" data-hid="citation_author_institution_4" name="citation_author_institution" content="The Fifth Medical Center of Chinese PLA General Hospital, China"><meta data-n-head="ssr" data-hid="citation_author_5" name="citation_author" content="Cao, Zhenhuan"><meta data-n-head="ssr" data-hid="citation_author_institution_5" name="citation_author_institution" content="Beijing Youan Hospital, Capital Medical University, China"><meta data-n-head="ssr" data-hid="dc.identifier" name="dc.identifier" content="doi:10.3389/fpubh.2025.1546182"><link data-n-head="ssr" rel="manifest" href="/article-pages/_nuxt/manifest.c499fc0a.json" data-hid="manifest"><link data-n-head="ssr" rel="canonical" href="https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1546182/full"><script data-n-head="ssr" data-hid="newrelic-browser-script" type="text/javascript">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"588603994","agentToken":null,"applicationTime":5.469334,"transactionName":"MQcDMkECCkNSW0YMWghNIgldDQFTRxd1IGFJTQ==","queueTime":0,"ttGuid":"e2cd1bd39345c4cd"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594400880",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIXFdSBAgOUg==",licenseKey:"598a124f17",applicationID:"588603994"};;/*! For license information please see nr-loader-spa-1.284.1.min.js.LICENSE.txt */
(()=>{var e,t,r={8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{if(null===e[a]){r[a]=null;continue}Array.isArray(e[a])&&Array.isArray(t[a])?r[a]=Array.from(new Set([...e[a],...t[a]])):"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},2555:(e,t,r)=>{"use strict";r.d(t,{Vp:()=>c,fn:()=>s,x1:()=>u});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){try{const t=c(e);return!!t.licenseKey&&!!t.errorBeacon&&!!t.applicationID}catch(e){return!1}}function c(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function u(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.info=a[e])}},9417:(e,t,r)=>{"use strict";r.d(t,{D0:()=>h,gD:()=>g,xN:()=>p});var n=r(3333);const i=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var o=r(2614),a=r(944),s=r(384),c=r(8122);const u="[data-nr-mask]",d=()=>{const e={feature_flags:[],experimental:{marks:!1,measures:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{get capture_marks(){return e.feature_flags.includes(n.$v.MARKS)||e.experimental.marks},set capture_marks(t){e.experimental.marks=t},get capture_measures(){return e.feature_flags.includes(n.$v.MEASURES)||e.experimental.measures},set capture_measures(t){e.experimental.measures=t},capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(n.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:o.wk,inactiveMs:o.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){i(t)?e.mask_selector="".concat(t,",").concat(u):""===t||null===t?e.mask_selector=u:(0,a.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){i(t)?e.block_selector+=",".concat(t):""!==t&&(0,a.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,a.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}},l={},f="All configuration objects require an agent identifier!";function h(e){if(!e)throw new Error(f);if(!l[e])throw new Error("Configuration for ".concat(e," was never set"));return l[e]}function p(e,t){if(!e)throw new Error(f);l[e]=(0,c.a)(t,d());const r=(0,s.nY)(e);r&&(r.init=l[e])}function g(e,t){if(!e)throw new Error(f);var r=h(e);if(r){for(var n=t.split("."),i=0;i<n.length-1;i++)if("object"!=typeof(r=r[n[i]]))return;r=r[n[n.length-1]]}return r}},5603:(e,t,r)=>{"use strict";r.d(t,{a:()=>c,o:()=>s});var n=r(384),i=r(8122);const o={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},a={};function s(e){if(!e)throw new Error("All loader-config objects require an agent identifier!");if(!a[e])throw new Error("LoaderConfig for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All loader-config objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.loader_config=a[e])}},3371:(e,t,r)=>{"use strict";r.d(t,{V:()=>f,f:()=>l});var n=r(8122),i=r(384),o=r(6154),a=r(9324);let s=0;const c={buildEnv:a.F3,distMethod:a.Xs,version:a.xv,originTime:o.WN},u={customTransaction:void 0,disabled:!1,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,onerror:void 0,ptid:void 0,releaseIds:{},appMetadata:{},session:void 0,denyList:void 0,timeKeeper:void 0,obfuscator:void 0,harvester:void 0},d={};function l(e){if(!e)throw new Error("All runtime objects require an agent identifier!");if(!d[e])throw new Error("Runtime for ".concat(e," was never set"));return d[e]}function f(e,t){if(!e)throw new Error("All runtime objects require an agent identifier!");d[e]={...(0,n.a)(t,u),...c},Object.hasOwnProperty.call(d[e],"harvestCount")||Object.defineProperty(d[e],"harvestCount",{get:()=>++s});const r=(0,i.nY)(e);r&&(r.runtime=d[e])}},9324:(e,t,r)=>{"use strict";r.d(t,{F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.284.1",i="PROD",o="CDN",a="^2.0.0-alpha.18"},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>s,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>a,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),a=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),s="complete"===a?.document?.readyState,c=Boolean("hidden"===a?.document?.visibilityState),u=""+a?.location,d=/iPad|iPhone|iPod/.test(a.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=a.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>a,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(s(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function a(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,a;i>0?(o=r.substring(0,i),a=r.substring(i)):(o=r,a="");let[s]=o.split(":");n.push({hostname:s,pathname:a})}}function s(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>c,Ze:()=>l,x3:()=>u});var n=r(7836),i=r(3606),o=r(860),a=r(2646);const s={};function c(e,t){const r={staged:!1,priority:o.P3[t]||0};d(e),s[e].get(t)||s[e].set(t,r)}function u(e,t){e&&s[e]&&(s[e].get(t)&&s[e].delete(t),h(e,t,!1),s[e].size&&f(e))}function d(e){if(!e)throw new Error("agentIdentifier required");s[e]||(s[e]=new Map)}function l(e="",t="feature",r=!1){if(d(e),!e||!s[e].get(t)||r)return h(e,t);s[e].get(t).staged=!0,f(e)}function f(e){const t=Array.from(s[e]);t.every((([e,t])=>t.staged))&&(t.sort(((e,t)=>e[1].priority-t[1].priority)),t.forEach((([t])=>{s[e].delete(t),h(e,t)})))}function h(e,t,r=!0){const o=e?n.ee.get(e):n.ee,s=i.i.handlers;if(!o.aborted&&o.backlog&&s){if(r){const e=o.backlog[t],r=s[t];if(r){for(let t=0;e&&t<e.length;++t)p(e[t],r);Object.entries(r).forEach((([e,t])=>{Object.values(t||{}).forEach((t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])}))}))}}o.isolatedBacklog||delete s[t],o.backlog[t]=null,o.emit("drain-"+t,[])}}function p(e,t){var r=e[1];Object.values(t[r]||{}).forEach((t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}}))}},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>c,ee:()=>u});var n=r(384),i=r(8990),o=r(3371),a=r(2646),s=r(5607);const c="nr@context:".concat(s.W),u=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&(0,o.f)(r).isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(u.aborted&&!i)return;t&&o&&t.emit(e,r,n);for(var a=h(n),c=g(e),d=c.length,l=0;l<d;l++)c[l].apply(a,r);var p=v()[s[e]];p&&p.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach((([e,n])=>{s[n]=t,t in r||(r[t]=[])}))},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach((e=>{delete f.backlog[e]}))},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof a.y?e:e?(0,i.I)(e,c,(()=>new a.y(c))):new a.y(c)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),d=(0,n.Zm)();d.ee||(d.ee=u)},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.d,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>s,ZF:()=>c,bz:()=>a,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map((e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const a=[];for(var s=0;s<e;s++)a.push(o(r,i++).toString(16));return a.join("")}function c(){return s(16)}function u(){return s(32)}},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>a,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>s,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,a=18e5,s={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},944:(e,t,r)=>{"use strict";function n(e,t){"function"==typeof console.debug&&console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t)}r.d(t,{R:()=>n})},5284:(e,t,r)=>{"use strict";r.d(t,{t:()=>c,B:()=>s});var n=r(7836),i=r(6154);const o="newrelic";const a=new Set,s={};function c(e,t){const r=n.ee.get(t);s[t]??={},e&&"object"==typeof e&&(a.has(t)||(r.emit("rumresp",[e]),s[t]=e,a.add(t),function(e={}){try{i.gm.dispatchEvent(new CustomEvent(o,{detail:e}))}catch(e){}}({loaded:!0})))}},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout((()=>{i=clearTimeout(i)}),t)),n||(clearTimeout(i),i=setTimeout((()=>{e.apply(this,r)}),t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,sB:()=>a});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function a(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}},384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>o,US:()=>d,Zm:()=>a,bQ:()=>c,dV:()=>s,nY:()=>u,pV:()=>l});var n=r(6154),i=r(1863);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function s(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket}),e}function c(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function u(e){let t=a();return t.initializedAgents?.[e]}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",(function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)}),r,i)}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),a=r(6154);const s={},c=a.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(s[t.debugId]++)return t;s[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(a.RI&&h(document,f),c&&h(c.prototype,f),h(a.gm,f)),t.on(u+"-start",(function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var i=(0,o.I)(n,l,(function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n}));this.wrapped=e[1]=i}})),t.on(d+"-start",(function(e){e[1]=this.wrapped||e[1]})),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>c});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W);var a=Object.prototype.hasOwnProperty,s=!1;function c(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const a="-"===n.charAt(0);for(let s=0;s<t.length;s++){const c=t[s],u=e[c];d(u)||(e[c]=r(u,a?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,s,c){return d(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){u([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,d,l;try{a=this,o=[...arguments],d="function"==typeof n?n(o,a):n||{}}catch(t){u([t,"",[o,a,s],d],e)}i(r+"start",[o,a,s],d,c);try{return l=t.apply(a,o)}catch(e){throw i(r+"err",[o,a,e],d,c),e}finally{i(r+"end",[o,a,l],d,c)}}}function i(r,n,i,o){if(!s||t){var a=s;s=!0;try{e.emit(r,n,i,t,o)}catch(t){u([t,r,n,i],e)}s=a}}}function u(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function d(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},9414:(e,t,r)=>{"use strict";r.d(t,{J:()=>c});var n=r(7836),i=r(2646),o=r(944),a=r(3434);const s=new Map;function c(e,t,r,c){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,o.R)(29);const u=function(e){return(e||n.ee).get("logger")}(e),d=(0,a.YM)(u),l=new i.y(n.P);l.level=c.level,l.customAttributes=c.customAttributes;const f=t[r]?.[a.Jt]||t[r];return s.set(f,l),d.inPlace(t,[r],"wrap-logger-",(()=>s.get(f))),u}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>u,TZ:()=>n,Zp:()=>i,kd:()=>c,mq:()=>s,nf:()=>a,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],a=4,s=1e3,c=["PageAction","UserAction","BrowserPerformance"],u={MARKS:"experimental.marks",MEASURES:"experimental.measures",RESOURCES:"experimental.resources"}},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>a,TZ:()=>s,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},a="log",s=n.K7.logging},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),a=r(8154),s=r(993);function c(e,t,r={},c=s.p_.INFO){(0,n.p)(a.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(s.ET,[(0,i.t)(),t,r,c],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(s.p_).some((t=>t===e.toUpperCase().trim()))}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>s,TZ:()=>n,rs:()=>i,xV:()=>a});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,G4:()=>o,Qb:()=>l,TZ:()=>i,Ug:()=>a,_s:()=>s,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o={RECORD:"recordReplay",PAUSE:"pauseReplay",REPLAY_RUNNING:"replayRunning",ERROR_DURING_REPLAY:"errorDuringReplay"},a=.12,s={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api"}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>c,CT:()=>u,SR:()=>s});var n=r(384),i=r(9417),o=r(7767),a=r(6154);function s(e){return!!(0,n.dV)().o.MO&&(0,o.V)(e)&&!0===(0,i.gD)(e,"session_trace.enabled")}function c(e){return!0===(0,i.gD)(e,"session_replay.preload")&&s(e)}function u(e,t){const r=t.correctAbsoluteTimestamp(e);return{originalTimestamp:e,correctedTimestamp:r,timestampDiff:e-r,originTime:a.WN,correctedOriginTime:t.correctedOriginTime,originTimeDiff:Math.floor(a.WN-t.correctedOriginTime)}}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>s,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>a,jx:()=>l,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState",l=1e3},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>o,O2:()=>c,Qu:()=>u,TZ:()=>s,ih:()=>d,pP:()=>a,tC:()=>i});var n=r(860);const i=["click","keydown","submit","popstate"],o="api",a="initialPageLoad",s=n.K7.softNav,c={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},u={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},d={IP:"in progress",FIN:"finished",CAN:"cancelled"}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>A,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>T,uP:()=>s,wW:()=>E,xq:()=>a});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",E="cb"+R,A="jsTime",T="fetch"},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>o});var n=r(9417),i=r(6154);const o=e=>i.RI&&!0===(0,n.gD)(e,"privacy.cookies_enabled")},8969:(e,t,r)=>{"use strict";r.d(t,{j:()=>O});var n=r(860),i=r(2555),o=r(3371),a=r(9908),s=r(7836),c=r(1687),u=r(5289),d=r(6154),l=r(944),f=r(8154),h=r(384),p=r(6344);const g=["setErrorHandler","finished","addToTrace","addRelease","recordCustomEvent","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId","setApplicationVersion","start",p.G4.RECORD,p.G4.PAUSE,"log","wrapLogger"],m=["setErrorHandler","finished","addToTrace","addRelease"];var v=r(1863),b=r(2614),y=r(993),w=r(3785),R=r(9414);function x(){const e=(0,h.pV)();g.forEach((t=>{e[t]=(...r)=>function(t,...r){let n=[];return Object.values(e.initializedAgents).forEach((e=>{e&&e.api?e.exposed&&e.api[t]&&n.push(e.api[t](...r)):(0,l.R)(38,t)})),n.length>1?n:n[0]}(t,...r)}))}const E={};var A=r(9417),T=r(5603),N=r(5284);const S=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};let _=!1;function O(e,t={},g,O){let{init:I,info:P,loader_config:j,runtime:C={},exposed:k=!0}=t;C.loaderType=g;const L=(0,h.pV)();P||(I=L.init,P=L.info,j=L.loader_config),(0,A.xN)(e.agentIdentifier,I||{}),(0,T.a)(e.agentIdentifier,j||{}),P.jsAttributes??={},d.bv&&(P.jsAttributes.isWorker=!0),(0,i.x1)(e.agentIdentifier,P);const H=(0,A.D0)(e.agentIdentifier),M=[P.beacon,P.errorBeacon];_||(H.proxy.assets&&(S(H.proxy.assets),M.push(H.proxy.assets)),H.proxy.beacon&&M.push(H.proxy.beacon),x(),(0,h.US)("activatedFeatures",N.B),e.runSoftNavOverSpa&&=!0===H.soft_navigations.enabled&&H.feature_flags.includes("soft_nav")),C.denyList=[...H.ajax.deny_list||[],...H.ajax.block_internal?M:[]],C.ptid=e.agentIdentifier,(0,o.V)(e.agentIdentifier,C),e.ee=s.ee.get(e.agentIdentifier),void 0===e.api&&(e.api=function(e,t,h=!1){t||(0,c.Ak)(e,"api");const g={};var x=s.ee.get(e),A=x.get("tracer");E[e]=b.g.OFF,x.on(p.G4.REPLAY_RUNNING,(t=>{E[e]=t}));var T="api-",N=T+"ixn-";function S(t,r,n,o){const a=(0,i.Vp)(e);return null===r?delete a.jsAttributes[t]:(0,i.x1)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),I(T,n,!0,o||null===r?"session":void 0)(t,r)}function _(){}g.log=function(e,{customAttributes:t={},level:r=y.p_.INFO}={}){(0,a.p)(f.xV,["API/log/called"],void 0,n.K7.metrics,x),(0,w.R)(x,e,t,r)},g.wrapLogger=(e,t,{customAttributes:r={},level:i=y.p_.INFO}={})=>{(0,a.p)(f.xV,["API/wrapLogger/called"],void 0,n.K7.metrics,x),(0,R.J)(x,e,t,{customAttributes:r,level:i})},m.forEach((e=>{g[e]=I(T,e,!0,"api")})),g.addPageAction=I(T,"addPageAction",!0,n.K7.genericEvents),g.recordCustomEvent=I(T,"recordCustomEvent",!0,n.K7.genericEvents),g.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,o.f)(e).customTransaction=(r||"http://custom.transaction")+t,I(T,"setPageViewName",!0)()},g.setCustomAttribute=function(e,t,r=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof t)||null===t)return S(e,t,"setCustomAttribute",r);(0,l.R)(40,typeof t)}else(0,l.R)(39,typeof e)},g.setUserId=function(e){if("string"==typeof e||null===e)return S("enduser.id",e,"setUserId",!0);(0,l.R)(41,typeof e)},g.setApplicationVersion=function(e){if("string"==typeof e||null===e)return S("application.version",e,"setApplicationVersion",!1);(0,l.R)(42,typeof e)},g.start=()=>{try{(0,a.p)(f.xV,["API/start/called"],void 0,n.K7.metrics,x),x.emit("manual-start-all")}catch(e){(0,l.R)(23,e)}},g[p.G4.RECORD]=function(){(0,a.p)(f.xV,["API/recordReplay/called"],void 0,n.K7.metrics,x),(0,a.p)(p.G4.RECORD,[],void 0,n.K7.sessionReplay,x)},g[p.G4.PAUSE]=function(){(0,a.p)(f.xV,["API/pauseReplay/called"],void 0,n.K7.metrics,x),(0,a.p)(p.G4.PAUSE,[],void 0,n.K7.sessionReplay,x)},g.interaction=function(e){return(new _).get("object"==typeof e?e:{})};const O=_.prototype={createTracer:function(e,t){var r={},i=this,o="function"==typeof t;return(0,a.p)(f.xV,["API/createTracer/called"],void 0,n.K7.metrics,x),h||(0,a.p)(N+"tracer",[(0,v.t)(),e,r],i,n.K7.spa,x),function(){if(A.emit((o?"":"no-")+"fn-start",[(0,v.t)(),i,o],r),o)try{return t.apply(this,arguments)}catch(e){const t="string"==typeof e?new Error(e):e;throw A.emit("fn-err",[arguments,this,t],r),t}finally{A.emit("fn-end",[(0,v.t)()],r)}}}};function I(e,t,r,i){return function(){return(0,a.p)(f.xV,["API/"+t+"/called"],void 0,n.K7.metrics,x),i&&(0,a.p)(e+t,[r?(0,v.t)():performance.now(),...arguments],r?null:this,i,x),r?void 0:this}}function P(){r.e(478).then(r.bind(r,8778)).then((({setAPI:t})=>{t(e),(0,c.Ze)(e,"api")})).catch((e=>{(0,l.R)(27,e),x.abort()}))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{O[e]=I(N,e,void 0,h?n.K7.softNav:n.K7.spa)})),g.setCurrentRouteName=h?I(N,"routeName",void 0,n.K7.softNav):I(T,"routeName",!0,n.K7.spa),g.noticeError=function(t,r){"string"==typeof t&&(t=new Error(t)),(0,a.p)(f.xV,["API/noticeError/called"],void 0,n.K7.metrics,x),(0,a.p)("err",[t,(0,v.t)(),!1,r,!!E[e]],void 0,n.K7.jserrors,x)},d.RI?(0,u.GG)((()=>P()),!0):P(),g}(e.agentIdentifier,O,e.runSoftNavOverSpa)),void 0===e.exposed&&(e.exposed=k),_=!0}},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>u,K7:()=>s,P3:()=>c,XX:()=>i,qY:()=>n,v4:()=>a});const n="events",i="jserrors",o="browser/blobs",a="rum",s={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},c={[s.pageViewEvent]:1,[s.pageViewTiming]:2,[s.metrics]:3,[s.jserrors]:4,[s.spa]:5,[s.ajax]:6,[s.sessionTrace]:7,[s.softNav]:8,[s.sessionReplay]:9,[s.logging]:10,[s.genericEvents]:11},u={[s.pageViewEvent]:a,[s.pageViewTiming]:n,[s.ajax]:n,[s.spa]:n,[s.softNav]:n,[s.metrics]:i,[s.jserrors]:i,[s.sessionTrace]:o,[s.sessionReplay]:o,[s.logging]:"browser/logs",[s.genericEvents]:"ins"}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.284.1.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.284.1.PROD:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){s=l;break}}if(!s){c=!0;var f={478:"sha512-VWXyHiJymB8Fhqc5jWlZ1CWrtlNWMPhm+PNnjWX1CfW9gQedReF5MFo3k8skdB5TlR837ofwtBeSzIE69RbCwQ==",249:"sha512-e1fXm1ZkMilKv1yUjmoJw7TU5bCKK/7Xaa/Ta9opkyurmkWtIKPd4CMfU2dRHGr9+brXynQnY3wwY838aQPhVw==",212:"sha512-zX52gEnN9DOzLrxU+zqxDl8R/t9rkdZavljSVjdAYS3BNoZH304PhVRnFEdwyYNCN9QcuGDBMMJ8U6XYtxAL0g=="};(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&&s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+o),s.src=r,0!==s.src.indexOf(window.location.origin+"/")&&(s.crossOrigin="anonymous"),f[a]&&(s.integrity=f[a])}e[r]=[n];var h=(t,n)=>{s.onerror=s.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=h.bind(null,s.onerror),s.onload=h.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u<a.length;u++)o=a[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.284.1.PROD"]=self["webpackChunk:NRBA-1.284.1.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(944),t=i(6344),r=i(9566);class n{agentIdentifier;constructor(){this.agentIdentifier=(0,r.LA)(16)}#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}addPageAction(e,t){return this.#e("addPageAction",e,t)}recordCustomEvent(e,t){return this.#e("recordCustomEvent",e,t)}setPageViewName(e,t){return this.#e("setPageViewName",e,t)}setCustomAttribute(e,t,r){return this.#e("setCustomAttribute",e,t,r)}noticeError(e,t){return this.#e("noticeError",e,t)}setUserId(e){return this.#e("setUserId",e)}setApplicationVersion(e){return this.#e("setApplicationVersion",e)}setErrorHandler(e){return this.#e("setErrorHandler",e)}addRelease(e,t){return this.#e("addRelease",e,t)}log(e,t){return this.#e("log",e,t)}}class o extends n{#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}start(){return this.#e("start")}finished(e){return this.#e("finished",e)}recordReplay(){return this.#e(t.G4.RECORD)}pauseReplay(){return this.#e(t.G4.PAUSE)}addToTrace(e){return this.#e("addToTrace",e)}setCurrentRouteName(e){return this.#e("setCurrentRouteName",e)}interaction(){return this.#e("interaction")}wrapLogger(e,t,r){return this.#e("wrapLogger",e,t,r)}}var a=i(860),s=i(9417);const c=Object.values(a.K7);function u(e){const t={};return c.forEach((r=>{t[r]=function(e,t){return!0===(0,s.gD)(t,"".concat(e,".enabled"))}(r,e)})),t}var d=i(8969);var l=i(1687),f=i(4234),h=i(5289),p=i(6154),g=i(5270),m=i(7767),v=i(6389);class b extends f.W{constructor(e,t,r=!0){super(e.agentIdentifier,t),this.auto=r,this.abortHandler=void 0,this.featAggregate=void 0,this.onAggregateImported=void 0,!1===e.init[this.featureName].autoStart&&(this.auto=!1),this.auto?(0,l.Ak)(e.agentIdentifier,t):this.ee.on("manual-start-all",(0,v.J)((()=>{(0,l.Ak)(e.agentIdentifier,this.featureName),this.auto=!0,this.importAggregator(e)})))}importAggregator(t,r={}){if(this.featAggregate||!this.auto)return;let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let o;try{if((0,m.V)(this.agentIdentifier)){const{setupAgentSession:e}=await i.e(478).then(i.bind(i,6526));o=e(t)}}catch(t){(0,e.R)(20,t),this.ee.emit("internal-error",[t]),this.featureName===a.K7.sessionReplay&&this.abortHandler?.()}try{if(!this.#t(this.featureName,o))return(0,l.Ze)(this.agentIdentifier,this.featureName),void n(!1);const{lazyFeatureLoader:e}=await i.e(478).then(i.bind(i,6103)),{Aggregate:a}=await e(this.featureName,"aggregate");this.featAggregate=new a(t,r),t.runtime.harvester.initializedAggregates.push(this.featAggregate),n(!0)}catch(t){(0,e.R)(34,t),this.abortHandler?.(),(0,l.Ze)(this.agentIdentifier,this.featureName,!0),n(!1),this.ee&&this.ee.abort()}};p.RI?(0,h.GG)((()=>o()),!0):o()}#t(e,t){switch(e){case a.K7.sessionReplay:return(0,g.SR)(this.agentIdentifier)&&!!t;case a.K7.sessionTrace:return!!t;default:return!0}}}var y=i(6630);class w extends b{static featureName=y.T;constructor(e,t=!0){super(e,y.T,t),this.importAggregator(e)}}var R=i(384);var x=i(9908),E=i(2843),A=i(3878),T=i(782),N=i(1863);class S extends b{static featureName=T.T;constructor(e,t=!0){super(e,T.T,t),p.RI&&((0,E.u)((()=>(0,x.p)("docHidden",[(0,N.t)()],void 0,T.T,this.ee)),!0),(0,A.sp)("pagehide",(()=>(0,x.p)("winPagehide",[(0,N.t)()],void 0,T.T,this.ee))),this.importAggregator(e))}}var _=i(8154);class O extends b{static featureName=_.TZ;constructor(e,t=!0){super(e,_.TZ,t),p.RI&&document.addEventListener("securitypolicyviolation",(e=>{(0,x.p)(_.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)})),this.importAggregator(e)}}var I=i(6774),P=i(3304);class j{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,P.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function C(e){return H(e)?e:new j(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic)}function k(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(H(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return C(e.reason)}const r=C(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function L(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new j(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic);return t.name=SyntaxError.name,t}return H(e.error)?e.error:C(e)}function H(e){return e instanceof Error&&!!e.stack}class M extends b{static featureName=I.T;#r=!1;constructor(e,r=!0){super(e,I.T,r);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",((e,t)=>{this.abortHandler&&(0,x.p)("ierr",[C(e),(0,N.t)(),!0,{},this.#r,t],void 0,this.featureName,this.ee)})),this.ee.on(t.G4.REPLAY_RUNNING,(e=>{this.#r=e})),p.gm.addEventListener("unhandledrejection",(e=>{this.abortHandler&&(0,x.p)("err",[k(e),(0,N.t)(),!1,{unhandledPromiseRejection:1},this.#r],void 0,this.featureName,this.ee)}),(0,A.jT)(!1,this.removeOnAbort?.signal)),p.gm.addEventListener("error",(e=>{this.abortHandler&&(0,x.p)("err",[L(e),(0,N.t)(),!1,{},this.#r],void 0,this.featureName,this.ee)}),(0,A.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e)}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var D=i(8990);let K=1;const U="nr@id";function V(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===p.gm?0:(0,D.I)(e,U,(function(){return K++}))}function G(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,P.A)(e).length}catch(e){return}}}var F=i(8139),B=i(7836),W=i(3434);const z={},q=["open","send"];function Z(t){var r=t||B.ee;const n=function(e){return(e||B.ee).get("xhr")}(r);if(void 0===p.gm.XMLHttpRequest)return n;if(z[n.debugId]++)return n;z[n.debugId]=1,(0,F.u)(r);var i=(0,W.YM)(n),o=p.gm.XMLHttpRequest,a=p.gm.MutationObserver,s=p.gm.Promise,c=p.gm.setInterval,u="readystatechange",d=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],l=[],f=p.gm.XMLHttpRequest=function(t){const r=new o(t),a=n.context(r);try{n.emit("new-xhr",[r],a),r.addEventListener(u,(s=a,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,n.emit("xhr-resolved",[],e)),i.inPlace(e,d,"fn-",y)}),(0,A.jT)(!1))}catch(t){(0,e.R)(15,t);try{n.emit("internal-error",[t])}catch(e){}}var s;return r};function h(e,t){i.inPlace(t,["onreadystatechange"],"fn-",y)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,f),f.prototype=o.prototype,i.inPlace(f.prototype,q,"-xhr-",y),n.on("send-xhr-start",(function(e,t){h(e,t),function(e){l.push(e),a&&(g?g.then(b):c?c(b):(m=-m,v.data=m))}(t)})),n.on("open-xhr-start",h),a){var g=s&&s.resolve();if(!c&&!s){var m=1,v=document.createTextNode(m);new a(b).observe(v,{characterData:!0})}}else r.on("fn-end",(function(e){e[0]&&e[0].type===u||b()}));function b(){for(var e=0;e<l.length;e++)h(0,l[e]);l.length&&(l=[])}function y(e,t){return t}return n}var Y="fetch-",J=Y+"body-",X=["arrayBuffer","blob","json","text","formData"],Q=p.gm.Request,ee=p.gm.Response,te="prototype";const re={};function ne(e){const t=function(e){return(e||B.ee).get("fetch")}(e);if(!(Q&&ee&&p.gm.fetch))return t;if(re[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[B.P]&&o[B.P].dt&&(e=o[B.P].dt);var a=i.apply(this,r);return t.emit(n+"start",[r,e],a),a.then((function(e){return t.emit(n+"end",[null,e],a),e}),(function(e){throw t.emit(n+"end",[e],a),e}))})}return re[t.debugId]=1,X.forEach((e=>{r(Q[te],e,J),r(ee[te],e,J)})),r(p.gm,"fetch",Y),t.on(Y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(Y+"done",[null,r],n)}else t.emit(Y+"done",[e],n)})),t}var ie=i(7485),oe=i(5603);class ae{constructor(e){this.agentIdentifier=e}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var t=(0,oe.o)(this.agentIdentifier);if(!t)return null;var n=(t.accountID||"").toString()||null,i=(t.agentID||"").toString()||null,o=(t.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,r.ZF)(),s=(0,r.el)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof p.gm?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,P.A)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1,r={};if((0,s.gD)(this.agentIdentifier,"distributed_tracing")&&(r=(0,s.D0)(this.agentIdentifier).distributed_tracing),e.sameOrigin)t=!0;else if(r.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ie.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}isDtEnabled(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.enabled}excludeNewrelicHeader(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.cors_use_tracecontext_headers}}var se=i(9300),ce=i(7295),ue=["load","error","abort","timeout"],de=ue.length,le=(0,R.dV)().o.REQ,fe=(0,R.dV)().o.XHR;const he="X-NewRelic-App-Data";class pe extends b{static featureName=se.T;constructor(e,t=!0){super(e,se.T,t),this.dt=new ae(e.agentIdentifier),this.handler=(e,t,r,n)=>(0,x.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};p.gm?.performance?.getEntriesByType("resource").forEach((t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},n={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};ge(r,t.name),this.handler("xhr",[r,n,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,a.K7.ajax)}}))}catch(e){}ne(this.ee),Z(this.ee),function(e,t,r,n){function i(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=R,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){E(t,e)}),(0,A.jT)(!1)),p.lR||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,A.jT)(!1))}function o(e){this.params={method:e[0]},ge(this,e[1]),this.metrics={}}function s(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var i=n.generateTracePayload(this.parsedOrigin);if(i){var o=!1;i.newrelicHeader&&(r.setRequestHeader("newrelic",i.newrelicHeader),o=!0),i.traceContextParentHeader&&(r.setRequestHeader("traceparent",i.traceContextParentHeader),i.traceContextStateHeader&&r.setRequestHeader("tracestate",i.traceContextStateHeader),o=!0),o&&(this.dt=i)}}function c(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var a=G(i);a&&(n.txSize=a)}this.startTime=(0,N.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var s=0;s<de;s++)r.addEventListener(ue[s],this.listener,(0,A.jT)(!1))}function u(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function d(e,t){var r=""+V(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function l(e,t){var r=""+V(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function f(){this.endTime=(0,N.t)()}function h(e,r){r instanceof fe&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function g(e,r){r instanceof fe&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function m(e,t,r){t instanceof fe&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,N.t)()))}function v(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,N.t)()-this.xhrCbStart,this.onload,r],r)}function b(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&p.RI&&(t=""+p.gm.location.href):e[0]&&e[0].url?t=e[0].url:p.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ie.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var i=n.generateTracePayload(this.parsedOrigin);if(i&&(i.newrelicHeader||i.traceContextParentHeader))if(e[0]&&e[0].headers)s(e[0].headers,i)&&(this.dt=i);else{var o={};for(var a in r)o[a]=r[a];o.headers=new Headers(r.headers||{}),s(o.headers,i)&&(this.dt=i),e.length>1?e[1]=o:e.push(o)}}function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function y(e,t){this.params={},this.metrics={},this.startTime=(0,N.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof le?r=i.url:p.gm?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),ge(this,r);var o=(""+(i&&i instanceof le&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.body=n.body,this.txSize=G(n.body)||0}function w(e,t){if(this.endTime=(0,N.t)(),this.params||(this.params={}),(0,ce.iW)(this.params))return;let n;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);const i={txSize:this.txSize,rxSize:n,duration:(0,N.t)()-this.startTime};r("xhr",[this.params,i,this.startTime,this.endTime,"fetch"],this,a.K7.ajax)}function R(e){const t=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<de;t++)e.removeEventListener(ue[t],this.listener,!1);t.aborted||(0,ce.iW)(t)||(n.duration=(0,N.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):E(this,e),n.cbTime=this.cbTime,r("xhr",[t,n,this.startTime,this.endTime,"xhr"],this,a.K7.ajax))}}function E(e,r){e.params.status=r.status;var n=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?G(e.response):"text"===r||""===r||void 0===r?G(e.responseText):void 0}(r,e.lastSize);if(n&&(e.metrics.rxSize=n),e.sameOrigin&&r.getAllResponseHeaders().indexOf(he)>=0){var i=r.getResponseHeader(he);i&&((0,x.p)(_.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,a.K7.metrics,t),e.params.cat=i.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",i),t.on("open-xhr-start",o),t.on("open-xhr-end",s),t.on("send-xhr-start",c),t.on("xhr-cb-time",u),t.on("xhr-load-added",d),t.on("xhr-load-removed",l),t.on("xhr-resolved",f),t.on("addEventListener-end",h),t.on("removeEventListener-end",g),t.on("fn-end",v),t.on("fetch-before-start",b),t.on("fetch-start",y),t.on("fn-start",m),t.on("fetch-done",w)}(e,this.ee,this.handler,this.dt),this.importAggregator(e)}}function ge(e,t){var r=(0,ie.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const me={},ve=["pushState","replaceState"];function be(e){const t=function(e){return(e||B.ee).get("history")}(e);return!p.RI||me[t.debugId]++||(me[t.debugId]=1,(0,W.YM)(t).inPlace(window.history,ve,"-")),t}var ye=i(3738);const{He:we,bD:Re,d3:xe,Kp:Ee,TZ:Ae,Lc:Te,uP:Ne,Rz:Se}=ye;class _e extends b{static featureName=Ae;constructor(e,t=!0){super(e,Ae,t);if(!(0,m.V)(this.agentIdentifier))return void this.deregisterDrain();const r=this.ee;let n;be(r),this.eventsEE=(0,F.u)(r),this.eventsEE.on(Ne,(function(e,t){this.bstStart=(0,N.t)()})),this.eventsEE.on(Te,(function(e,t){(0,x.p)("bst",[e[0],t,this.bstStart,(0,N.t)()],void 0,a.K7.sessionTrace,r)})),r.on(Se+xe,(function(e){this.time=(0,N.t)(),this.startPath=location.pathname+location.hash})),r.on(Se+Ee,(function(e){(0,x.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,a.K7.sessionTrace,r)}));try{n=new PerformanceObserver((e=>{const t=e.getEntries();(0,x.p)(we,[t],void 0,a.K7.sessionTrace,r)})),n.observe({type:Re,buffered:!0})}catch(e){}this.importAggregator(e,{resourceObserver:n})}}var Oe=i(2614);class Ie extends b{static featureName=t.TZ;#i;#o;constructor(e,r=!0){let n;super(e,t.TZ,r),this.replayRunning=!1,this.#o=e;try{n=JSON.parse(localStorage.getItem("".concat(Oe.H3,"_").concat(Oe.uh)))}catch(e){}(0,g.SR)(e.agentIdentifier)&&this.ee.on(t.G4.RECORD,(()=>this.#a())),this.#s(n)?(this.#i=n?.sessionReplayMode,this.#c()):this.importAggregator(e),this.ee.on("err",(e=>{this.replayRunning&&(this.errorNoticed=!0,(0,x.p)(t.G4.ERROR_DURING_REPLAY,[e],void 0,this.featureName,this.ee))})),this.ee.on(t.G4.REPLAY_RUNNING,(e=>{this.replayRunning=e}))}#s(e){return e&&(e.sessionReplayMode===Oe.g.FULL||e.sessionReplayMode===Oe.g.ERROR)||(0,g.Aw)(this.agentIdentifier)}#u=!1;async#c(e){if(!this.#u){this.#u=!0;try{const{Recorder:t}=await Promise.all([i.e(478),i.e(249)]).then(i.bind(i,8589));this.recorder??=new t({mode:this.#i,agentIdentifier:this.agentIdentifier,trigger:e,ee:this.ee,agentRef:this.#o}),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording}catch(e){}this.importAggregator(this.#o,{recorder:this.recorder,errorNoticed:this.errorNoticed})}}#a(){this.featAggregate?this.featAggregate.mode!==Oe.g.FULL&&this.featAggregate.initializeRecording(Oe.g.FULL,!0):(this.#i=Oe.g.FULL,this.#c(t.Qb.API),this.recorder&&this.recorder.parent.mode!==Oe.g.FULL&&(this.recorder.parent.mode=Oe.g.FULL,this.recorder.stopRecording(),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording))}}var Pe=i(3962);class je extends b{static featureName=Pe.TZ;constructor(e,t=!0){if(super(e,Pe.TZ,t),!p.RI||!(0,R.dV)().o.MO)return;const r=be(this.ee);Pe.tC.forEach((e=>{(0,A.sp)(e,(e=>{a(e)}),!0)}));const n=()=>(0,x.p)("newURL",[(0,N.t)(),""+window.location],void 0,this.featureName,this.ee);r.on("pushState-end",n),r.on("replaceState-end",n);try{this.removeOnAbort=new AbortController}catch(e){}(0,A.sp)("popstate",(e=>(0,x.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)),!0,this.removeOnAbort?.signal);let i=!1;const o=new((0,R.dV)().o.MO)(((e,t)=>{i||(i=!0,requestAnimationFrame((()=>{(0,x.p)("newDom",[(0,N.t)()],void 0,this.featureName,this.ee),i=!1})))})),a=(0,v.s)((e=>{(0,x.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})}),100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,{domObserver:o})}}var Ce=i(7378);const ke={},Le=["appendChild","insertBefore","replaceChild"];function He(e){const t=function(e){return(e||B.ee).get("jsonp")}(e);if(!p.RI||ke[t.debugId])return t;ke[t.debugId]=!0;var r=(0,W.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function a(e,t){if(!e)return t;const r=e.match(o),n=r[1];return a(r[3],t[n])}return r.inPlace(Node.prototype,Le,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(s=e.src,c=s.match(n),c?c[1]:null);var s,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:a(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,A.jT)(!1)),e.removeEventListener("error",f,(0,A.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,A.jT)(!1)),e.removeEventListener("error",f,(0,A.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,A.jT)(!1)),e.addEventListener("error",f,(0,A.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}const Me={};function De(e){const t=function(e){return(e||B.ee).get("promise")}(e);if(Me[t.debugId])return t;Me[t.debugId]=!0;var r=t.context,n=(0,W.YM)(t),i=p.gm.Promise;return i&&function(){function e(r){var o=t.context(),a=n(r,"executor-",o,null,!1);const s=Reflect.construct(i,[a],e);return t.context(s).getCtx=function(){return o},s}p.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach((function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,a=r(i);a.promise=i,e[0]=n(e[0],"cb-",a,null,!1),e[1]=n(e[1],"cb-",a,null,!1);const s=o.apply(this,e);return a.nextPromise=s,t.emit("propagate",[i,!0],s,!1,!1),s},i.prototype.then[W.Jt]=o,t.on("executor-start",(function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)})),t.on("executor-err",(function(e,t,r){e[1](r)})),t.on("cb-end",(function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)})),t.on("propagate",(function(e,r,n){this.getCtx&&!r||(this.getCtx=function(){if(e instanceof Promise)var r=t.context(e);return r&&r.getCtx?r.getCtx():this})}))}(),t}const Ke={},Ue="setTimeout",Ve="setInterval",Ge="clearTimeout",Fe="-start",Be=[Ue,"setImmediate",Ve,Ge,"clearImmediate"];function We(e){const t=function(e){return(e||B.ee).get("timer")}(e);if(Ke[t.debugId]++)return t;Ke[t.debugId]=1;var r=(0,W.YM)(t);return r.inPlace(p.gm,Be.slice(0,2),Ue+"-"),r.inPlace(p.gm,Be.slice(2,3),Ve+"-"),r.inPlace(p.gm,Be.slice(3),Ge+"-"),t.on(Ve+Fe,(function(e,t,n){e[0]=r(e[0],"fn-",null,n)})),t.on(Ue+Fe,(function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)})),t}const ze={};function qe(e){const t=function(e){return(e||B.ee).get("mutation")}(e);if(!p.RI||ze[t.debugId])return t;ze[t.debugId]=!0;var r=(0,W.YM)(t),n=p.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:Ze,d3:Ye,Kp:Je,$p:Xe,wW:$e,e5:Qe,tH:et,uP:tt,rw:rt,Lc:nt}=Ce;class it extends b{static featureName=Ze;constructor(e,t=!0){if(super(e,Ze,t),!p.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let r,n=0;const i=this.ee.get("tracer"),o=He(this.ee),a=De(this.ee),s=We(this.ee),c=Z(this.ee),u=this.ee.get("events"),d=ne(this.ee),l=be(this.ee),f=qe(this.ee);function h(e,t){l.emit("newURL",[""+window.location,t])}function g(){n++,r=window.location.hash,this[tt]=(0,N.t)()}function m(){n--,window.location.hash!==r&&h(0,!0);var e=(0,N.t)();this[Qe]=~~this[Qe]+e-this[tt],this[nt]=e}function v(e,t){e.on(t,(function(){this[t]=(0,N.t)()}))}this.ee.on(tt,g),a.on(rt,g),o.on(rt,g),this.ee.on(nt,m),a.on($e,m),o.on($e,m),this.ee.on("fn-err",((...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,x.p)("function-err",[...t],void 0,this.featureName,this.ee)})),this.ee.buffer([tt,nt,"xhr-resolved"],this.featureName),u.buffer([tt],this.featureName),s.buffer(["setTimeout"+Je,"clearTimeout"+Ye,tt],this.featureName),c.buffer([tt,"new-xhr","send-xhr"+Ye],this.featureName),d.buffer([et+Ye,et+"-done",et+Xe+Ye,et+Xe+Je],this.featureName),l.buffer(["newURL"],this.featureName),f.buffer([tt],this.featureName),a.buffer(["propagate",rt,$e,"executor-err","resolve"+Ye],this.featureName),i.buffer([tt,"no-"+tt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),v(d,et+Ye),v(d,et+"-done"),v(o,"new-jsonp"),v(o,"jsonp-end"),v(o,"cb-start"),l.on("pushState-end",h),l.on("replaceState-end",h),window.addEventListener("hashchange",h,(0,A.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",h,(0,A.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){h(0,n>1)}),(0,A.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e)}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var ot=i(3333);class at extends b{static featureName=ot.TZ;constructor(e,t=!0){super(e,ot.TZ,t);const r=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];if(p.RI&&(e.init.user_actions.enabled&&(ot.Zp.forEach((e=>(0,A.sp)(e,(e=>(0,x.p)("ua",[e],void 0,this.featureName,this.ee)),!0))),ot.qN.forEach((e=>{const t=(0,v.s)((e=>{(0,x.p)("ua",[e],void 0,this.featureName,this.ee)}),500,{leading:!0});(0,A.sp)(e,t)}))),e.init.performance.resources.enabled&&p.gm.PerformanceObserver?.supportedEntryTypes.includes("resource"))){new PerformanceObserver((e=>{e.getEntries().forEach((e=>{(0,x.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)}))})).observe({type:"resource",buffered:!0})}r.some((e=>e))?this.importAggregator(e):this.deregisterDrain()}}var st=i(993),ct=i(3785),ut=i(9414);class dt extends b{static featureName=st.TZ;constructor(e,t=!0){super(e,st.TZ,t);const r=this.ee;(0,ut.J)(r,p.gm.console,"log",{level:"info"}),(0,ut.J)(r,p.gm.console,"error",{level:"error"}),(0,ut.J)(r,p.gm.console,"warn",{level:"warn"}),(0,ut.J)(r,p.gm.console,"info",{level:"info"}),(0,ut.J)(r,p.gm.console,"debug",{level:"debug"}),(0,ut.J)(r,p.gm.console,"trace",{level:"trace"}),this.ee.on("wrap-logger-end",(function([e]){const{level:t,customAttributes:n}=this;(0,ct.R)(r,e,n,t)})),this.importAggregator(e)}}new class extends o{constructor(t){super(),p.gm?(this.features={},(0,R.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(t.features||[]),this.desiredFeatures.add(w),this.runSoftNavOverSpa=[...this.desiredFeatures].some((e=>e.featureName===a.K7.softNav)),(0,d.j)(this,t,t.loaderType||"agent"),this.run()):(0,e.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}run(){try{const t=u(this.agentIdentifier),r=[...this.desiredFeatures];r.sort(((e,t)=>a.P3[e.featureName]-a.P3[t.featureName])),r.forEach((r=>{if(!t[r.featureName]&&r.featureName!==a.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&r.featureName===a.K7.spa)return;if(!this.runSoftNavOverSpa&&r.featureName===a.K7.softNav)return;const n=function(e){switch(e){case a.K7.ajax:return[a.K7.jserrors];case a.K7.sessionTrace:return[a.K7.ajax,a.K7.pageViewEvent];case a.K7.sessionReplay:return[a.K7.sessionTrace];case a.K7.pageViewTiming:return[a.K7.pageViewEvent];default:return[]}}(r.featureName).filter((e=>!(e in this.features)));n.length>0&&(0,e.R)(36,{targetFeature:r.featureName,missingDependencies:n}),this.features[r.featureName]=new r(this)}))}catch(t){(0,e.R)(22,t);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,R.Zm)();delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return r.ee.get(this.agentIdentifier).abort(),!1}}}({features:[pe,w,S,_e,Ie,O,M,at,dt,je,it],loaderType:"spa"})})()})();</script><link rel="preload" href="/article-pages/_nuxt/e397d1a.js" as="script"><link rel="preload" href="/article-pages/_nuxt/2abb6c5.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/66101cf.css" as="style"><link rel="preload" href="/article-pages/_nuxt/701e3a3.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/dac93f2.css" as="style"><link rel="preload" href="/article-pages/_nuxt/71728a1.js" as="script"><link rel="preload" href="/article-pages/_nuxt/a5e7651.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/e5cdfa1.css" as="style"><link rel="preload" href="/article-pages/_nuxt/f548f7f.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/868b092.css" as="style"><link rel="preload" href="/article-pages/_nuxt/e3c5a8f.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/97e04e3.css" as="style"><link rel="preload" href="/article-pages/_nuxt/0d6d8e5.js" as="script"><link rel="preload" href="/article-pages/_nuxt/ed7fc59.js" as="script"><link rel="stylesheet" href="/article-pages/_nuxt/css/66101cf.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/dac93f2.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/e5cdfa1.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/868b092.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/97e04e3.css">

  <meta property="fb:admins" content="1841006843">
</head>

<body >
  <button class="BypassBlock__firstEl"></button>
  <a href="#main-content" class="BypassBlock__wrapper">
    <span class="BypassBlock__button">Skip to main content</span>
  </a>

  <!-- Google Tag Manager (noscript) -->
  <noscript>
    <iframe src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x" height="0" width="0" style="display:none;visibility:hidden"></iframe>
  </noscript>
  <!-- End Google Tag Manager (noscript) -->
  <div data-server-rendered="true" id="__nuxt"><div id="__layout"><div theme="cyan" class="ArticleLayout"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button aria-label="Open Menu" data-event="iBar-btn-openMenu" class="Ibar__burger"></button> <div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg" class="Ibar__logo__svg"><path d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF" class="Ibar__logo__text"></path> <path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path> <path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path> <path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path> <path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path> <path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path> <path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path> <path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path> <path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path> <path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div> <a aria-label="Frontiers in Public Health" href="//www.frontiersin.org/journals/public-health" data-event="iBar-a-journalHome" class="Ibar__journalName"><div logoClass="Ibar__logo--mixed" class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Public Health</span></div></div></a> <div parent-data-event="iBar" class="Ibar__dropdown Ibar__dropdown--aboutUs"><button class="Ibar__dropdown__trigger"><!---->
    About us
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        About us
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers' impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://progressreport.frontiersin.org/?utm_source=fweb&amp;utm_medium=frep&amp;utm_campaign=pr20" target="_blank" data-event="iBar-aboutUs_1-a_impactAndProgress">Progress Report 2022</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">All annual reports</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR² Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li> <li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li> <li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersplanetprize.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.orgabout/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li></ul></div></div></div> <a href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals" class="Ibar__link">All journals</a><a href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles" class="Ibar__link">All articles</a> <a href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=70&amp;specialtyid=0&amp;entitytype=2&amp;entityid=609" data-event="iBar-a-submit" class="Ibar__button Ibar__submit">Submit your research</a> <div class="Ibar__spacer"></div> <a href="/search" aria-label="Search" data-event="iBar-a-search" class="Ibar__icon Ibar__icon--search"><span>Search</span></a> <!----> <!----> <!----> <div class="Ibar__userArea"></div></div></div> <div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg" class="Ibar__logo__svg"><path d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF" class="Ibar__logo__text"></path> <path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path> <path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path> <path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path> <path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path> <path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path> <path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path> <path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path> <path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path> <path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div> <button aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu" class="Ibar__close"></button></div> <div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/public-health" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Public Health</span></div></div></a> <div parent-data-event="iBarMenu" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    Sections
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        Sections
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <ul class="Ibar__dropdown__sections"><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/aging-and-public-health" data-event="iBarJournal-sections-a_id_1560">Aging and Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/children-and-health" data-event="iBarJournal-sections-a_id_621">Children and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/digital-public-health" data-event="iBarJournal-sections-a_id_753">Digital Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/disaster-and-emergency-medicine" data-event="iBarJournal-sections-a_id_702">Disaster and Emergency Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/environmental-health-and-exposome" data-event="iBarJournal-sections-a_id_690">Environmental Health and Exposome</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/health-economics" data-event="iBarJournal-sections-a_id_1310">Health Economics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/infectious-diseases-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_3460">Infectious Diseases: Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/injury-prevention-and-control" data-event="iBarJournal-sections-a_id_3297">Injury Prevention and Control</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/life-course-epidemiology-and-social-inequalities-in-health" data-event="iBarJournal-sections-a_id_1495">Life-Course Epidemiology and Social Inequalities in Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/occupational-health-and-safety" data-event="iBarJournal-sections-a_id_744">Occupational Health and Safety</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/planetary-health" data-event="iBarJournal-sections-a_id_1458">Planetary Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-education-and-promotion" data-event="iBarJournal-sections-a_id_637">Public Health Education and Promotion</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-policy" data-event="iBarJournal-sections-a_id_652">Public Health Policy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-and-nutrition" data-event="iBarJournal-sections-a_id_2192">Public Health and Nutrition</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-mental-health" data-event="iBarJournal-sections-a_id_695">Public Mental Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/radiation-and-health" data-event="iBarJournal-sections-a_id_778">Radiation and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/substance-use-disorders-and-behavioral-addictions" data-event="iBarJournal-sections-a_id_3408">Substance Use Disorders and Behavioral Addictions</a></li></ul></div></div> <a href="//www.frontiersin.org/journals/public-health/articles" data-event="iBar-a-articles" class="Ibar__link">Articles</a><a href="//www.frontiersin.org/journals/public-health/research-topics" data-event="iBar-a-researchTopics" class="Ibar__link">Research Topics</a><a href="//www.frontiersin.org/journals/public-health/editors" data-event="iBar-a-editorialBoard" class="Ibar__link">Editorial board</a> <div parent-data-event="iBarMenu" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    About journal
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        About journal
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Scope</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_scope">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-scope" target="_self" data-event="iBar-aboutJournal_0-a_scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-facts" target="_self" data-event="iBar-aboutJournal_0-a_scope">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-submission" target="_self" data-event="iBar-aboutJournal_0-a_scope">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-open" target="_self" data-event="iBar-aboutJournal_0-a_scope">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_0-a_scope">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-quality" target="_self" data-event="iBar-aboutJournal_0-a_scope">Quality</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">For authors</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Contact editorial office</a></li></ul></div></div></div></div> <div parent-data-event="iBarMenu" class="Ibar__dropdown Ibar__dropdown--aboutUs"><button class="Ibar__dropdown__trigger"><!---->
    About us
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        About us
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers' impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://progressreport.frontiersin.org/?utm_source=fweb&amp;utm_medium=frep&amp;utm_campaign=pr20" target="_blank" data-event="iBar-aboutUs_1-a_impactAndProgress">Progress Report 2022</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">All annual reports</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR² Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li> <li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li> <li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersplanetprize.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.orgabout/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li></ul></div></div></div> <a href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals" class="Ibar__link">All journals</a><a href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles" class="Ibar__link">All articles</a> <!----> <!----> <!----> <a href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=70&amp;specialtyid=0&amp;entitytype=2&amp;entityid=609" data-event="iBarMenu-a-submit" class="Ibar__button Ibar__submit">Submit your research</a></div></div> <div class="Ibar__journal"><div class="Ibar__wrapper Ibar__wrapper--journal"><a aria-label="Frontiers in Public Health" href="//www.frontiersin.org/journals/public-health" data-event="iBarJournal-a-journalHome" class="Ibar__journalName"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Public Health</span></div></div></a> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    Sections
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        Sections
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <ul class="Ibar__dropdown__sections"><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/aging-and-public-health" data-event="iBarJournal-sections-a_id_1560">Aging and Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/children-and-health" data-event="iBarJournal-sections-a_id_621">Children and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/digital-public-health" data-event="iBarJournal-sections-a_id_753">Digital Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/disaster-and-emergency-medicine" data-event="iBarJournal-sections-a_id_702">Disaster and Emergency Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/environmental-health-and-exposome" data-event="iBarJournal-sections-a_id_690">Environmental Health and Exposome</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/health-economics" data-event="iBarJournal-sections-a_id_1310">Health Economics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/infectious-diseases-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_3460">Infectious Diseases: Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/injury-prevention-and-control" data-event="iBarJournal-sections-a_id_3297">Injury Prevention and Control</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/life-course-epidemiology-and-social-inequalities-in-health" data-event="iBarJournal-sections-a_id_1495">Life-Course Epidemiology and Social Inequalities in Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/occupational-health-and-safety" data-event="iBarJournal-sections-a_id_744">Occupational Health and Safety</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/planetary-health" data-event="iBarJournal-sections-a_id_1458">Planetary Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-education-and-promotion" data-event="iBarJournal-sections-a_id_637">Public Health Education and Promotion</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-policy" data-event="iBarJournal-sections-a_id_652">Public Health Policy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-and-nutrition" data-event="iBarJournal-sections-a_id_2192">Public Health and Nutrition</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-mental-health" data-event="iBarJournal-sections-a_id_695">Public Mental Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/radiation-and-health" data-event="iBarJournal-sections-a_id_778">Radiation and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/substance-use-disorders-and-behavioral-addictions" data-event="iBarJournal-sections-a_id_3408">Substance Use Disorders and Behavioral Addictions</a></li></ul></div></div> <a href="//www.frontiersin.org/journals/public-health/articles" data-event="iBar-a-articles" class="Ibar__link">Articles</a><a href="//www.frontiersin.org/journals/public-health/research-topics" data-event="iBar-a-researchTopics" class="Ibar__link">Research Topics</a><a href="//www.frontiersin.org/journals/public-health/editors" data-event="iBar-a-editorialBoard" class="Ibar__link">Editorial board</a> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    About journal
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        About journal
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Scope</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_scope">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-scope" target="_self" data-event="iBar-aboutJournal_0-a_scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-facts" target="_self" data-event="iBar-aboutJournal_0-a_scope">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-submission" target="_self" data-event="iBar-aboutJournal_0-a_scope">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-open" target="_self" data-event="iBar-aboutJournal_0-a_scope">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_0-a_scope">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-quality" target="_self" data-event="iBar-aboutJournal_0-a_scope">Quality</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">For authors</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Contact editorial office</a></li></ul></div></div></div> <div class="Ibar__spacer"></div></div></div> <div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg" class="Ibar__logo__svg"><path d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF" class="Ibar__logo__text"></path> <path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path> <path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path> <path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path> <path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path> <path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path> <path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path> <path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path> <path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path> <path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div> <a aria-label="Frontiers in Public Health" href="//www.frontiersin.org/journals/public-health" data-event="iBarJournal-a-journalHome" class="Ibar__journalName"><div logoClass="Ibar__logo--mixed" class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Public Health</span></div></div></a> <div class="Ibar__spacer"></div> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    Sections
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        Sections
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <ul class="Ibar__dropdown__sections"><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/aging-and-public-health" data-event="iBarJournal-sections-a_id_1560">Aging and Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/children-and-health" data-event="iBarJournal-sections-a_id_621">Children and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/digital-public-health" data-event="iBarJournal-sections-a_id_753">Digital Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/disaster-and-emergency-medicine" data-event="iBarJournal-sections-a_id_702">Disaster and Emergency Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/environmental-health-and-exposome" data-event="iBarJournal-sections-a_id_690">Environmental Health and Exposome</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/health-economics" data-event="iBarJournal-sections-a_id_1310">Health Economics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/infectious-diseases-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_3460">Infectious Diseases: Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/injury-prevention-and-control" data-event="iBarJournal-sections-a_id_3297">Injury Prevention and Control</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/life-course-epidemiology-and-social-inequalities-in-health" data-event="iBarJournal-sections-a_id_1495">Life-Course Epidemiology and Social Inequalities in Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/occupational-health-and-safety" data-event="iBarJournal-sections-a_id_744">Occupational Health and Safety</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/planetary-health" data-event="iBarJournal-sections-a_id_1458">Planetary Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-education-and-promotion" data-event="iBarJournal-sections-a_id_637">Public Health Education and Promotion</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-policy" data-event="iBarJournal-sections-a_id_652">Public Health Policy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-and-nutrition" data-event="iBarJournal-sections-a_id_2192">Public Health and Nutrition</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-mental-health" data-event="iBarJournal-sections-a_id_695">Public Mental Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/radiation-and-health" data-event="iBarJournal-sections-a_id_778">Radiation and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/substance-use-disorders-and-behavioral-addictions" data-event="iBarJournal-sections-a_id_3408">Substance Use Disorders and Behavioral Addictions</a></li></ul></div></div> <a href="//www.frontiersin.org/journals/public-health/articles" data-event="iBar-a-articles" class="Ibar__link">Articles</a><a href="//www.frontiersin.org/journals/public-health/research-topics" data-event="iBar-a-researchTopics" class="Ibar__link">Research Topics</a><a href="//www.frontiersin.org/journals/public-health/editors" data-event="iBar-a-editorialBoard" class="Ibar__link">Editorial board</a> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    About journal
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        About journal
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Scope</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_scope">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-scope" target="_self" data-event="iBar-aboutJournal_0-a_scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-facts" target="_self" data-event="iBar-aboutJournal_0-a_scope">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-submission" target="_self" data-event="iBar-aboutJournal_0-a_scope">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-open" target="_self" data-event="iBar-aboutJournal_0-a_scope">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_0-a_scope">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-quality" target="_self" data-event="iBar-aboutJournal_0-a_scope">Quality</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">For authors</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Contact editorial office</a></li></ul></div></div></div> <div class="Ibar__spacer"></div> <a href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=70&amp;specialtyid=0&amp;entitytype=2&amp;entityid=609" data-event="iBarJournal-a-submit" class="Ibar__button Ibar__submit"><span>Submit</span> <span> your research</span></a> <a href="/search" aria-label="Search" data-event="iBar-a-search" class="Ibar__icon Ibar__icon--search"><span>Search</span></a> <!----> <!----> <!----> <div class="Ibar__userArea"></div></div></div></nav> <div class="ArticlePage"><div><div class="Layout Layout--withAside Layout--withIbarMix ArticleDetails"><!----> <main class="Layout__main"><!----> <div class="ArticleDetails__main"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">
      STUDY PROTOCOL article
    </p> <p class="ArticleLayoutHeader__info__journalDate"><span>Front. Public Health</span> <span>, 14 March 2025</span></p> <p class="ArticleLayoutHeader__info__journalDate">
      Sec. Infectious Diseases: Epidemiology and Prevention
    </p> <p class="ArticleLayoutHeader__info__doiVolume"><span> Volume 13 - 2025 | </span> <a href="https://doi.org/10.3389/fpubh.2025.1546182" class="ArticleLayoutHeader__info__doi">
        https://doi.org/10.3389/fpubh.2025.1546182
      </a></p> <!----></div> <!----> <p class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span> <span class="ArticleLayoutHeader__isPartOfRT__title">World Hepatitis Day 2024: Advancing Hepatitis Elimination, Public Health Strategies and Innovations</span> <span class="Link__wrapper"><a aria-label="View all 11 articles" href="https://www.frontiersin.org/research-topics/66031/world-hepatitis-day-2024-advancing-hepatitis-elimination-public-health-strategies-and-innovations/articles" target="_self" data-event="customLink-link-a_viewAll11Articles" class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right"><span>View all 11 articles</span></a></span></p></div> <div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure</h1> <!----></div> <!----></div> <div class="JournalFullText"><div class="JournalAbstract"> <a id="h1" name="h1"></a>
 <div class="authors"><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Daqiong Zhou" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Daqiong Zhou<sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/670990" class="user-id-670990"><img class="pr5" src="https://loop.frontiersin.org/images/profile/670990/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Chao Zhang">Chao Zhang</a><sup>2</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1585997" class="user-id-1585997"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1585997/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Lu Zhang">Lu Zhang</a><sup>3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jianru Jia" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jianru Jia<sup>4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1805685" class="user-id-1805685"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1805685/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Junliang Fu">Junliang Fu</a><sup>2</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1640317" class="user-id-1640317"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1640317/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Zhenhuan Cao&#xA;">Zhenhuan Cao</a><sup>1</sup><sup>&#x0002A;</sup></span></div> <ul class="notes"> <li><span><sup>1</sup></span>Beijing Youan Hospital, Capital Medical University, Beijing, China</li> <li><span><sup>2</sup></span>The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China</li> <li><span><sup>3</sup></span>Beijing Ditan Hospital, Capital Medical University, Beijing, China</li> <li><span><sup>4</sup></span>Baoding Municipal People's Hospital, Baoding, Hebei, China</li> </ul>
<p class="mb15"><b>Introduction:</b> The incidence of chronic hepatitis B (CHB) combined with metabolism-associated fatty liver disease (MAFLD) is increasing annually, and the presence of MAFLD may influence the clinical assessment of viral activity and transaminase levels. However, it remains unclear whether MAFLD impacts the achievement of clinical cure in CHB patients treated with polyethylene glycol interferon (Peg-IFN).</p>
<p class="mb15"><b>Methods:</b> A prospective cohort study was conducted to enroll patients with dominant CHB (on NA treatment, HBsAg &#x0003C;1,500&#x202F;IU/mL, HBeAg negative, HBV DNA &#x0003C;10&#x202F;IU/mL) and patients with dominant CHB combined with MAFLD, all of whom were treated with Peg-IFN. The study aimed to assess the efficacy and safety of Peg-IFN treatment and to elucidate the effect of MAFLD on achieving HBsAg clearance in these patients. Additionally, the study explored the T-lymphocyte characteristics of patients with CHB combined with MAFLD, analyzed the role of T-lymphocytes expressing inhibitory receptors in HBsAg clearance, and investigated the immunological mechanisms of HBsAg clearance through single-cell transcriptome sequencing technology.</p>
<p class="mb15"><b>Ethics and dissemination:</b> Patients will be recruited at four medical centers in Beijing and Hebei, and written informed consent will be obtained to inform participants of the purpose of the study, potential risks, and benefits. Ethical approval has been granted for the study, which will focus on 48-week HBsAg clearance, and a detailed follow-up and adverse event monitoring plan has been developed.</p>
<p class="mb15"><b>Strengths and limitations of this study:</b> Strengths are that this study fills the gap in treatment strategies for patients with CHB combined with MAFLD and provides important treatment guidance to clinicians; the multicenter design may increase the diversity of the sample size, reduce the bias of single-center studies, and improve the external validity of the results. Limitations are that interferon therapy is often associated with side effects, which may lead to lower patient adherence and affect long-term follow-up and outcome monitoring of the study; the heterogeneity of the MAFLD population may have different effects on the efficacy of interferon therapy.</p>
<p class="mb0"><b>Clinical trial registration:</b> <a href="http://www.chictr.org.cn/bin/project/edit?pid=231498">http://www.chictr.org.cn/bin/project/edit?pid=231498</a>, identifier ChiCTR2400084913.</p> <div class="clear"></div> </div> <div class="JournalFullText"> <a id="h2" name="h2"></a>
<h2>Introduction</h2>
<h3>Background and rationale</h3>
<p class="mb15">In 2016, the World Health Organization (WHO) proposed &#x201C;eliminating viral hepatitis as a major public health threat by 2030&#x201D; (<a href="#ref1">1</a>). In recent years, the incidence of HBV infection has shown a significant downward trend; however, due to its large patient population, China continues to bear the highest disease burden of HBV infection globally, with 74 million affected individuals (<a href="#ref2">2</a>). This reality indicates that China remains far from meeting the WHO&#x2019;s target, making the task of elimination particularly challenging.</p>
<p class="mb15">Previous studies have concluded that HBV DNA seroclearance significantly reduces the risk of hepatocellular carcinoma (HCC) (<a href="#ref3">3</a>). However, these patients may still face the risk of reactivation. Among those with undetectable viral loads, patients with low serum HBsAg levels (&#x0003C;1,000&#x202F;IU/mL) have the lowest risk of HCC (<a href="#ref4">4</a>). Thus, further HBsAg seroclearance is considered the best marker of HBV immune clearance. The 2022 Chinese Guidelines for the Prevention and Control of Chronic Hepatitis B emphasize that &#x201C;for some patients with suitable conditions, a cure for hepatitis B should be pursued.&#x201D; The guidelines further state that patients with undetectable HBV DNA, HBeAg conversion, and HBsAg &#x0003C;1,500&#x202F;IU/mL after nucleotide analog (NA) treatment represent an advantageous population for achieving HBsAg clearance. These patients may be considered for additional treatment with polyethylene glycol interferon (Peg-IFN) in pursuit of a clinical cure (<a href="#ref5">5</a>).</p>
<p class="mb15">In addition, non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease in both China and globally. The most recent data report the global prevalence of NAFLD to be 30% and rising (<a href="#ref6">6</a>, <a href="#ref7">7</a>). In 2020, the International Fatty Liver Nomenclature Panel redefined fatty liver in individuals with overweight/obesity, type 2 diabetes mellitus, or multiple metabolic disorders as metabolism-associated fatty liver disease (MAFLD) (<a href="#ref8">8</a>). In 2023, the European Annual Congress of Liver Diseases, along with the Liver Disease Associations of the United States, Europe, and Latin America, proposed that the alternative term for NAFLD should be metabolic dysfunction-associated steatohepatopathy (MASLD) (<a href="#ref9">9</a>). The prevalence of MAFLD in China was about 17.6% in 2016, with an estimated 246 million individuals affected, and is projected to rise to 29.1% by 2030, reaching 315 million cases, making MAFLD the most common chronic liver disease (<a href="#ref10">10</a>). The international expert consensus on metabolism-associated fatty liver disease notes that, with the dramatic global increase in MAFLD prevalence, it often coexists with other liver diseases, such as viral hepatitis. Large North American cohort studies have shown the prevalence of CHB combined with MAFLD to be 31.4% (<a href="#ref11">11</a>), while a single-center retrospective study in the Netherlands reported an increase from 17.2 to 24.3% in such patients (<a href="#ref12">12</a>). A recent meta-analysis of 53 studies found the prevalence of MAFLD in patients with CHB to be 32.83% (<a href="#ref13">13</a>).</p>
<p class="mb15">Whether MAFLD affects the antiviral efficacy of hepatitis B treatments, including HBV DNA suppression, HBeAg conversion, and HBsAg clearance, remains controversial. Most current studies focus on NA treatment, with goals primarily related to HBV DNA suppression and HBeAg conversion. However, research on HBsAg clearance, an indicator of clinical cure, is limited. Notably, the impact of MAFLD on achieving clinical cure in the Peg-IFN treatment-advantaged CHB population has not yet been reported and is in urgent need of investigation. Some studies suggest that the presence of MAFLD could potentially hinder the response to interferon therapy, possibly due to alterations in immune function or liver metabolism (<a href="#ref14">14</a>). However, the findings are inconsistent, with certain studies indicating no significant impact of MAFLD on Peg-IFN efficacy (<a href="#ref15">15</a>), while others suggest that MAFLD may contribute to reduced treatment efficacy or slower rates of HBsAg clearance (<a href="#ref16">16</a>).</p>
<p class="mb0">These conflicting results highlight a major gap in the current understanding of how MAFLD affects Peg-IFN therapy outcomes, particularly regarding HBsAg clearance, and underscore the need for further investigation. Our study aims to address this gap by evaluating the impact of MAFLD on the response to Peg-IFN treatment in chronic hepatitis B patients, specifically focusing on the achievement of HBsAg clearance as a marker of clinical cure. Additionally, the impact of hepatic steatosis on the immune status of CHB patients, such as T-lymphocyte function, has not been previously reported, and it remains unclear whether MAFLD affects clinical cure by influencing the immune status of the body.</p>
<h3>Objectives</h3>
<p class="mb0">In this study, a prospective clinical cohort of Peg-IFN-treated patients with advantageous CHB combined with MAFLD was established to verify the efficacy and safety of Peg-IFN in achieving HBsAg clearance. The study aims to elucidate the impact of MAFLD on HBsAg clearance in these patients and to provide practical guidance for clinicians in accurately screening suitable candidates and adjusting treatment regimens as needed. Flow cytometry was used to examine the number and function of peripheral blood T-lymphocytes expressing inhibitory receptors in both HBsAg-cleared and non-cleared patients at baseline and various time points during treatment. This was done to explore the characteristics of T-lymphocytes in CHB combined with MAFLD and to clarify the role of inhibitory receptor-expressing T-lymphocytes in HBsAg clearance. Additionally, single-cell transcriptome sequencing technology was applied to analyze changes in the gene expression profiles of immune cells in CHB patients with MAFLD treated with Peg-IFN, aiming to trace the genetic information profile changes in immune cells during HBsAg clearance and to explore the genetic-immunological mechanisms underlying HBsAg clearance.</p>
<h3>Trial design</h3>
<p class="mb0">This prospective study investigates the impact of MAFLD on HBsAg clearance in CHB patients treated with PEG-IFN (135ug/180ug/week for 48&#x202F;weeks). Patients are divided into two groups: CHB patients (<i>n</i>&#x202F;=&#x202F;100) and CHB with MAFLD patients (<i>n</i>&#x202F;=&#x202F;100). After treatment, participants are categorized into HBsAg clearance responders and non-responders. For HBsAg responders and HBsAg non-responders, analyzes differences in HBsAg clearance rates between CHB and CHB with MAFLD patients. Explores the impact of MAFLD on HBsAg clearance mechanisms using IHC and other methods. Compares the immunosuppressive microenvironment between responders and non-responders, focusing on T-cell characteristics. Identifies immune mechanisms contributing to HBsAg clearance. The flow chart of this study is shown in <a href="#fig1">Figure 1</a>.</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 1</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g001.jpg" name="figure1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g001.jpg" alt="www.frontiersin.org" id="fig1" loading="lazy">
  </picture>
</a>
<p><b>Figure 1</b>. Flow chart of the research program.</p></div> <div class="clear"></div> <div class="DottedLine"></div> <a id="h3" name="h3"></a>
<h2>Methods: subjects, interventions, and outcomes</h2>
<h3>Study setting</h3>
<p class="mb0">This prospective, multicenter, open cohort study will include HBV-infected patients from four large tertiary hospitals in North China. A total of 200 participants are planned, comprising 100 patients with CHB and 100 patients with CHB combined with MAFLD. We used the SPIRIT checklist when writing our report (<a href="#ref17">17</a>). The Institutional Review Board of Beijing You&#x2019;an Hospital affiliated with Capital Medical University approved the trial protocol (version 9.1, reference number LL-2024-051-K, dated May 10, 2024).</p>
<h3>Eligibility criteria</h3>
<p class="mb0">Inclusion Criteria:</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;">1. Chronic Hepatitis B (CHB): Meets the 2022 Guidelines for the Management of Chronic Hepatitis B: (1) HBsAg positive for &#x0003E;6&#x202F;months; (2) On NA treatment; (3) HBsAg &#x0003C;1,500&#x202F;IU/mL; (4) HBeAg negative; (5) HBV DNA &#x0003C;10&#x202F;IU/mL.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;">2. Metabolism-Associated Fatty Liver Disease (MAFLD):</p>
<p class="mb0">(1) Diagnosis of hepatic steatosis confirmed by abdominal ultrasound, Fibroscan, or liver steatosis measurement via MRI. Steatosis is categorized as mild, moderate, or severe based on the thresholds of the above tests. (2) Additionally, the patient must meet one of the following three conditions: &#x2460;. Overweight or obesity (BMI&#x202F;&#x02265;&#x202F;23&#x202F;kg/m<sup>2</sup>); &#x02461;. Diabetes mellitus; &#x02462;. Lean or normal-weight patients meeting at least 2 metabolic abnormalities (e.g., <a href="#fig2">Figure 2</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 2</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g002.jpg" name="figure2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g002.jpg" alt="www.frontiersin.org" id="fig2" loading="lazy">
  </picture>
</a>
<p><b>Figure 2</b>. MAFLD diagnostic process and criteria.</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb0">Exclusion Criteria: (1) Patients with combined HCV infection or autoimmune liver disease; (2) History of heavy alcohol consumption (alcohol intake &#x0003E;210&#x202F;g/day for men and&#x202F;&#x0003E;&#x202F;140&#x202F;g/day for women); (3) Drug-induced secondary hepatic steatosis (e.g., tamoxifen, hormones); (4) Pregnant or lactating women, and those planning to conceive shortly; (5) Patients with a history of or current cirrhosis or hepatocellular carcinoma; (6) Comorbidities with other serious diseases that may affect nutritional status, such as malignant tumors, severe cardiac, pulmonary, renal, or other organic or psychiatric diseases; (7) Neutrophil counts &#x0003C;2&#x202F;&#x000D7;&#x202F;10<sup>9</sup>/L and/or platelet counts &#x0003C;80&#x202F;&#x000D7;&#x202F;10<sup>9</sup>/L, and total bilirubin &#x0003E;34&#x202F;&#x03BC;mol/L before treatment.</p>
<h3>Intervention description</h3>
<p style="margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;">1 Peg-IFN dosing:</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;">(1) For patients with body weight&#x202F;&#x02265;&#x202F;70&#x202F;kg: 180&#x202F;&#x03BC;g once a week, subcutaneous injection.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;">(2) For patients with body weight&#x202F;&#x0003C;&#x202F;70&#x202F;kg: 135&#x202F;&#x03BC;g once a week, subcutaneous injection.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;">2 Duration:</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;">(1) The treatment duration is 48&#x202F;weeks.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;">(2) If the patient achieves HBsAg serologic conversion (HBsAb &#x0003E;300&#x202F;IU/L) and maintains this response for 24&#x202F;weeks, the treatment can be discontinued for observation, even if the full 48&#x202F;weeks have not been completed.</p>
<h3>Criteria for discontinuing or modifying allocated interventions</h3>
<p class="mb0">Discontinuation Due to Special Requirements: If the patient requires discontinuation of Peg-IFN due to special circumstances (e.g., trauma, surgery, personal preference), the treatment can be resumed once the conditions for using Peg-IFN are met again. Serious Adverse Events (SAEs): If SAEs occur, the necessity to discontinue Peg-IFN will be assessed, and treatment will be adjusted accordingly.</p>
<h3>Strategies to improve adherence to the intervention</h3>
<p class="mb0">In this study, we provided around-the-clock (24-h) health consultation services to ensure that patients could access professional support and guidance from healthcare providers at any time. Our team offered continuous attention and necessary assistance throughout the study, addressing a range of needs including study-related treatment guidance, management of adverse drug reactions, monitoring of virological breakthroughs, and general health inquiries from patients.</p>
<h3>Relevant concomitant intervention permitted or prohibited during the trial</h3>
<p class="mb0">Adverse effects of PEG-IFN&#x03B1;-2b include transient, early-onset flu-like symptoms such as fatigue, fever, muscle aches, headache, chills, and joint pain, which typically resolve within a few days to a few weeks. Some patients may experience reduced appetite, nausea, abdominal pain, and diarrhea. Additional symptoms include dizziness, hair loss, weight loss, visual disturbances, dry and itchy skin, injection site discomfort, and rashes. Furthermore, patients may encounter cognitive and psychological issues, such as difficulty concentrating, memory impairment, anxiety, irritability, and sleep disorders. Temporary changes in laboratory parameters, including decreases in white blood cell, neutrophil, and platelet counts, as well as alterations in liver biochemical function, have also been observed. PEG-IFN&#x03B1;-2b can cause thyroid dysfunction, exacerbate diabetes, or induce certain immune system disorders. To address these adverse effects, a dedicated team conducts regular follow-ups and provides timely interventions. Management strategies for adverse effects may involve discontinuing therapy, dose modifications, or targeted supportive treatments for specific side effects.</p>
<h3>Outcome</h3>
<p class="mb0">Primary outcome indicators: 48-week HBsAg clearance rate. Secondary outcome indicators: 48-week HBsAg quantitative decline, HBV DNA undetectable rate, HBsAg serologic conversion rate, Peg-IFN adverse reactions.</p>
<h3>Participant timeline</h3>
<p class="mb0">A Case Report Form (CRF) form will be established and completed for each enrolled patient, with follow-up visits scheduled every 12&#x202F;weeks (&#x000B1;2&#x202F;weeks) at baseline and throughout the treatment period. Clinical symptoms and signs will be observed during each follow-up visit, and peripheral blood PBMC and plasma specimens will be collected and stored at &#x02212;80&#x000B0;C for future research. The clinical test items at the follow-up visit are shown in <a href="#fig3">Figure 3</a>.</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 3</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g003.jpg" name="figure3" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1546182/fpubh-13-1546182-HTML/image_m/fpubh-13-1546182-g003.jpg" alt="www.frontiersin.org" id="fig3" loading="lazy">
  </picture>
</a>
<p><b>Figure 3</b>. Schedule of enrollment and follow-up.</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<h3>Sample size</h3>
<p class="mb0">Since there are no existing literature reports on Peg-IFN treatment for combined MAFLD in the CHB-advantaged population, the sample size for this study is based on the results of our team&#x2019;s previous research. In that study, Peg-IFN treatment of CHB and CHB combined with MAFLD patients for 48&#x202F;weeks resulted in HBsAg clearance rates of 35 and 60%, respectively. Given the lack of established data in this specific population, we chose to use this estimate as it is reflective of our previous work, which involved similar patient profiles and treatment conditions. Setting the test level at <i>&#x03B1;</i>&#x202F;=&#x202F;0.05 and the power of the study (1-<i>&#x03B2;</i>) at 0.90, the required sample size was calculated using the test module for two independent sample rates in PASS 11.0. The calculation indicated that 79 patients should be enrolled in each group. Considering a 15% dropout rate, 92 participants are needed in each group, thus expanding the sample size to 100 cases per group.</p>
<h3>Recruitment</h3>
<p class="mb15">Participants will be recruited from four medical centers in Beijing and Hebei, China: Beijing You&#x2019;an Hospital of Capital Medical University, Fifth Medical Center of General Hospital of the People&#x2019;s Liberation Army, Beijing Ditan Hospital of Capital Medical University, and Baoding People&#x2019;s Hospital. Each hospital will have a study coordinator to facilitate and coordinate the trial. Patients will be informed of the study&#x2019;s purpose, procedures, and potential risks and benefits. Written informed consent will be obtained from all participants. They will also be allowed to withdraw from the trial at any time without any consequences.</p>
<p class="mb15">Patients will be invited to participate in this study shortly after diagnosis. At the screening follow-up, a clinically experienced researcher (physician) will confirm eligibility for enrollment by reviewing symptoms, laboratory results, and imaging such as ultrasound or CT, ensuring that each inclusion and exclusion criterion is met. Recruitment will occur over 24&#x202F;months, from January 2024 to December 2025.</p>
<p class="mb0">No patients or members of the public other than professional clinicians and researchers were involved in the design, conduct, reporting, or dissemination plans for this study.</p> <a id="h4" name="h4"></a>
<h2>Methods: data collection, management, and analysis</h2>
<h3>Plans for assessment and collection of outcomes</h3>
<p class="mb0">Data will be collected using specially designed paper-based CRFs. Once completed, these forms will be entered into a database by designated personnel after prior data inspection. The Schedule of enrollment and follow-up (<a href="#fig3">Figure 3</a>) provides a detailed illustration of both the schedule and the specific nature of data collection required throughout the study period.</p>
<h3>Plans to promote participant retention and complete follow-up</h3>
<p class="mb0">Upon study completion, if a patient achieves HBsAg seroclearance, this outcome is considered the optimal result approaching &#x201C;clinical cure,&#x201D; indicating significantly improved long-term prognosis. For such cases, our research team will develop a follow-up monitoring and health management plan to maintain the therapeutic effect. Conversely, if HBsAg seroclearance is not achieved, clinicians will tailor the treatment strategy based on the patient&#x2019;s specific health condition, aiming to optimize therapeutic outcomes and continue to control disease progression. Regardless of treatment outcomes, we are committed to providing patients with the most suitable personalized follow-up care to ensure they receive optimal health support.</p>
<h3>Data management</h3>
<p class="mb0">The number of sample cases in this subject is large, and the nodes of retained specimens and test items are more, in order to ensure the uniformity and accuracy of the test, we take the following measures: in the process of specimen retention and separation, there are people responsible for the registration, sampling, separation of cells and serum, and freezing; specimens retained at different time nodes are uniformly detected by the specialized inspectors to ensure the reliability and accuracy of the test results. Trial data were collected and stored in accordance with GCP guidelines [China National Medical Products Administration, National Health Committee. Notice on the publication of Good Clinical Practice (no. 57 of 2020). April 26, 2020 (in Chinese). <a href="https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ypggtg/ypqtggtg/20200426162401243.html">https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ypggtg/ypqtggtg/20200426162401243.html</a>]. Final approval of the research database will only be granted after successful implementation of these protocols has been confirmed.</p>
<h3>Statistical methods for primary and secondary outcomes</h3>
<h4>Primary outcomes</h4>
<p class="mb0">The Kaplan&#x2013;Meier method was used to estimate the cumulative incidence of HBsAg seroclearance, and the log-rank test was used to compare the cumulative probabilities of different subgroups.</p>
<h4>Secondary outcomes</h4>
<p class="mb0">A linear mixed-effects model was employed to analyze the trends in HBsAg levels over time. Random effects were included to account for inter-individual variability among patients. Fixed effects in the model included time (measured in months), group classification (e.g., responder vs. non-responder, MASLD group vs. non-MASLD group, male vs. female), and the interaction between time and group classification. Additionally, marginal effects of changes in HBsAg levels over time for different groups were estimated using generalized estimating equations (GEE). This approach provided a comprehensive assessment of the temporal variation in HBsAg levels across various patient subgroups.</p>
<h3>Methods for any additional analyses</h3>
<p class="mb0">SPSS 27.0 statistical software was used for data analysis. Categorical variables were expressed as counts and percentages, while continuous variables were expressed as mean and standard deviation. Clinical data were statistically analyzed using the Kruskal-Wallis test. Variance homogeneity across groups was assessed for each test index. If the variance was homogeneous, the LSD method of one-way ANOVA was applied; if the variance was not homogeneous, the Kruskal-Wallis test was used for comparisons across multiple groups. For comparisons between the two groups, the Mann&#x2013;Whitney <i>U</i> test was employed. Immunological data, including HBsAg levels, HBV DNA titers, and immune marker levels (e.g., T-cell responses, cytokine profiles), will be analyzed using appropriate statistical methods based on the data distribution. Descriptive statistics (mean, SD, median, and IQR) will be used to summarize the data. For longitudinal analysis of immune markers (such as HBsAg clearance and T-cell responses) over the course of treatment, mixed-effects models will be employed to account for repeated measures and correlations within subjects. If immunological data are not normally distributed, non-parametric tests such as the Mann-Whitney U test (for comparisons between two independent groups) or the Kruskal-Wallis test (for comparisons across more than two groups) will be used. Cox proportional hazards regression will be utilized to assess the relationship between immunological markers (e.g., HBsAg clearance, T-cell response) and clinical outcomes, such as sustained HBsAg seroclearance or progression to clinical cure. In addition, we will conduct correlation analyses (Spearman&#x2019;s rank correlation) to explore potential associations between immune parameters (e.g., cytokine levels, T-cell counts) and clinical variables (e.g., liver function, ALT/AST levels). A <i>p</i>-value of &#x0003C;0.05 was considered statistically significant.</p>
<h3>Methods used to analyze population and missing data</h3>
<p class="mb0">The missing values of all variables were adjusted by applying Multiple Imputation (MI). If more than 15 per cent of data points are missing, sensitivity analyses of the main results are conducted using multiple imputation techniques. If the missing data is determined to be not missing at random (NMAR), we will explore sensitivity analyses to assess the impact of different assumptions about the missing data mechanism. We will also provide a drop-out analysis to evaluate any potential bias introduced by participant attrition.</p> <a id="h5" name="h5"></a>
<h2>Methods: monitoring</h2>
<h3>Data monitoring committee (DMC)</h3>
<p class="mb0">This project adopts a three-tier management system involving the principal investigator, the hospital&#x2019;s Research Department, and the hospital leadership. The principal investigator is responsible for the implementation and management of the project, coordinating periodic inspections and supervision conducted by the Beijing Municipal Health Commission and the hospital. Regular progress reports will be submitted to the higher-level supervisory departments and the hospital&#x2019;s Research Department. Upon completion of the project, the principal investigator will assist relevant supervisory bodies in organizing the acceptance and conclusion of the project in accordance with the implementation plan.</p>
<h3>Interim analyses</h3>
<p class="mb0">The superior CHB cohort and the CHB combined MEFLD cohort continued to be maintained between 2025&#x2013;01 and 2025&#x2013;12. Regular follow-up observations were made every 12&#x202F;weeks to record HBsAg and HBsAb, HBeAg and HBV DNA data and adverse events. For some of those who completed 48&#x202F;weeks of antiviral therapy, the difference in efficacy between the two groups was initially analyzed.</p>
<h3>Adverse event reporting</h3>
<p class="mb0">All serious adverse events (SAEs) or unexpected incidents that may impact the safety or rights of study participants must be reported within 24&#x202F;h of detection by the research personnel at the study institution. A comprehensive incident report must be submitted to the principal investigator and the relevant regulatory authorities. Following the report, the coordinating center will oversee the initiation of an investigation by the Ethics Committee supervising drug-related affairs to determine the cause of the adverse event. All SAEs must be thoroughly documented in the participant&#x2019;s medical records or trial files. This documentation must be signed and dated by the investigator responsible for the participant to facilitate future audits and monitoring activities. Furthermore, all reported adverse events must be communicated to the Ethics Committee regularly, at intervals of 6&#x202F;months, in accordance with the specific requirements of the Ethics Committee.</p>
<h3>Frequency and procedures for auditing trial conduct</h3>
<p class="mb0">In this study, each participating research institution will assign two independent researchers to conduct an initial review and verification of the standardized reporting format (CRF) to ensure accuracy and completeness. Following the preliminary review, a data manager will perform centralized verification to identify and correct any discrepancies or errors, with assistance from clinical monitors before the data is finalized. Additionally, a designated auditor, independent of both the investigators and the principal investigator, will conduct regular audits of the standardized reporting format at each research institution. Throughout the trial, the CRFs will undergo routine review every 6&#x202F;months to ensure data integrity and compliance.</p> <a id="h6" name="h6"></a>
<h2>Ethics and dissemination</h2>
<h3>Protocol amendments and approvals</h3>
<p class="mb15">Any changes to the study protocol that may affect the study&#x2019;s progress, the potential benefits to participants, or the safety of participants&#x2014;such as modifications to the study objectives, design, patient demographics, sample size, procedures, or significant management details&#x2014;must be formally revised. These amendments must receive approval from the Trial Steering Committee and the Ethics Committee before implementation.</p>
<p class="mb0">Modifications proposed due to trial execution must be submitted by the principal investigator and discussed with the Multicenter Coordination Committee. These proposed amendments should be documented and signed by the principal investigator and relevant centers. The modifications can only be implemented after receiving formal approval from the Ethics Committee.</p>
<h3>Informed consent</h3>
<p class="mb0">In this study, we will thoroughly communicate with the patients to emphasize the importance of antiviral treatment and the significant impact of HBsAg clearance on improving patient prognosis. Informed consent will be obtained from each patient.</p>
<h3>Additional consent provisions</h3>
<p class="mb0">Patients will be required to visit the hospital for assessments at baseline, Week 12, Week 24, Week 36, and Week 48 after enrollment. Routine examinations will include blood routine tests, liver function biochemistry, thyroid function, HBsAg quantification, and HBV DNA levels. Additionally, 20&#x202F;mL of blood will be collected for immunological and host genetic susceptibility marker analysis.</p>
<h3>Patient medical record confidentiality</h3>
<p class="mb0">The patient&#x2019;s medical records will be kept securely and in full at the hospital where the patient receives treatment. The physician will document the results of laboratory tests and examinations in the patient&#x2019;s medical records. Any public reports related to the results of this study will not disclose any personal information about the patients. We will make every effort, within the limits of the law, to protect the privacy of the patient&#x2019;s personal medical information.</p>
<h3>Financial management of research funds</h3>
<p class="mb0">In strict accordance with the financial management regulations for research projects established by the Beijing Municipal Health Commission&#x2019;s First Fund, the use of research funds will be applied for by the project leader, signed, recorded by the hospital&#x2019;s research office, and approved by hospital leadership before being specifically allocated or reimbursed by the finance department. The project leader will regularly check and supervise the research progress and the usage of funds. Based on the project&#x2019;s implementation, the project leader will propose adjustments to the funding and submit them for review and filing with the hospital&#x2019;s finance department and research office.</p>
<h3>Management of adverse events and health changes during the study</h3>
<p class="mb0">If, during the study, a patient experiences any discomfort, new changes in their condition, or any unexpected events, whether related to the study or not, they must promptly notify the relevant research center physician. The physician will assess the situation and provide appropriate medical treatment. The treatment measures may include discontinuation of medication, dose reduction, or other supportive therapies. Adverse reactions during interferon therapy are considered normal; most symptoms will resolve after appropriate management. The research team will closely monitor these reactions and provide timely and appropriate interventions.</p>
<h3>Plan for dissemination of research findings</h3>
<p class="mb0">By the applicant&#x2019;s previous research foundation and domestic and international literature, this prospective clinical study is expected to obtain a high HBsAg clearance rate, enable more patients with hepatitis B to obtain the clinical cure, greatly improve the prognosis of the patients, which can significantly reduce the transmission of HBV, reduce the incidence of cirrhosis and hepatocellular carcinoma, reduce the long-term expenditures, save more labor force, and create higher socio-economic benefits. It will provide evidence-based medical evidence for the updating of China&#x2019;s chronic hepatitis B prevention and treatment guidelines. The specific research area of this topic is attributed to viral hepatitis. One of the promotion methods is to promote the experience gained in clinical and basic research of PEG-IFN treatment of advantageous CHB to colleagues in the field of hepatology through academic lectures or international and domestic academic conference exchanges. Secondly, we will publish the important experience gained from our research in the form of papers for reference by our colleagues; thirdly, we will organize a workshop on hepatitis B antiviral treatment to promote our experience.</p> <a id="h7" name="h7"></a>
<h2>Discussion</h2>
<p class="mb15">The prevalence of MAFLD is steadily increasing both in the general population and among patients with CHB worldwide. Although fatty liver is recognized as a risk factor for adverse liver outcomes, including cirrhosis and hepatocellular carcinoma, its interactions with HBV and the resulting clinical effects remain complex and not fully understood.</p>
<p class="mb15">Some studies have identified fatty liver as an unfavorable factor affecting antiviral efficacy. In a study of 213 Chinese patients with CHB treated with entecavir (ETV), the rate of HBV DNA undetectability at 24&#x202F;weeks was significantly lower in patients with comorbid steatosis compared to those without hepatic steatosis (47.7% vs. 58.8%, <i>p</i>&#x202F;=&#x202F;0.01) (<a href="#ref18">18</a>). Additionally, in a study of 89 HBeAg-positive CHB patients treated with Peg-IFN for 48&#x202F;weeks, those with comorbid steatosis had significantly lower HBV DNA undetectability rates 48&#x202F;weeks after discontinuation compared to those without steatosis. Multifactorial analysis showed that steatosis was an unfavorable factor for sustained viral response (OR&#x202F;=&#x202F;0.012, <i>p</i>&#x202F;=&#x202F;0.02) (<a href="#ref19">19</a>). The EFFORT study suggests that new-onset and persistent MAFLD in patients with HBeAg-positive CHB treated with NA may counteract the benefits of antiviral therapy, reduce the rate of ALT normalization, and negatively influence fibrosis improvement (<a href="#ref20">20</a>).</p>
<p class="mb15">In contrast, some studies have shown that patients with hepatic steatosis are more likely to achieve HBsAg clearance. The metabolic components and immune alterations associated with MAFLD progression may directly inhibit HBV replication or indirectly induce antiviral immune responses. In patients with chronic HBV infection, comorbid MAFLD has been found to inhibit HBV replication and is associated with spontaneous HBsAg clearance (<a href="#ref21">21</a>). An international multicenter randomized controlled study of 4,769 patients with treatment-na&#x000EF;ve CHB, treated with either entecavir (ETV) or tenofovir (TDF), with a median follow-up time of approximately 5.16&#x202F;years, found that 58 patients achieved HBsAg clearance, and hepatic steatosis was identified as a favorable factor for HBsAg clearance (HR&#x202F;=&#x202F;1.84) (<a href="#ref22">22</a>). Additionally, a previous study by our group showed that the 96-week HBsAg clearance rate was higher in inactive HBsAg carriers with moderate steatosis compared to those without steatosis (<a href="#ref23">23</a>).</p>
<p class="mb15">In contrast, some studies have shown that steatosis is not associated with antiviral efficacy. In a retrospective study of 555 CHB patients treated with lamivudine (LAM), adefovir (ADV), entecavir (ETV), or tenofovir (TDF), multivariate analysis revealed no significant difference in HBV DNA suppression between patients with or without comorbid NAFLD (<a href="#ref24">24</a>). Another retrospective study from Taiwan involving 196 patients with HBeAg-positive CHB treated with NA monotherapy (LAM, ADV, LdT, ETV, or TDF) found that steatosis had no significant effect on HBeAg clearance (54.9% vs. 57.4%) (<a href="#ref25">25</a>).</p>
<p class="mb15">There are differing conclusions and opinions on whether MAFLD affects antiviral efficacy. Most current studies have primarily focused on NA treatment, with therapeutic targets related to HBV DNA suppression and HBeAg conversion. However, studies on HBsAg clearance, the indicator of clinical cure, are rare. Notably, it remains unreported whether MAFLD affects the clinical cure in patients with predominantly CHB undergoing Peg-IFN treatment. This study aims to elucidate the impact of MAFLD on the clinical cure of dominant CHB patients, with the hope of guiding clinicians to more accurately screen suitable patients and promptly adjust treatment regimens.</p>
<p class="mb15">T lymphocytes play a crucial role in the progression of HBV disease, including viral clearance, the development of hepatitis, cirrhosis, and hepatocellular carcinoma, as well as in response to antiviral therapy. CD8+ T cells are particularly important, as they can induce apoptosis in virus-infected hepatocytes. Additionally, they inhibit HBV gene expression and replication in hepatocytes through a non-cytolytic mechanism by secreting IFN-<i>&#x03B3;</i>. This dual function of CD8+ T cells&#x2014;mediating apoptosis and inhibiting viral replication&#x2014;highlights their essential role in controlling HBV infection. When HBV infection becomes chronic, T cells gradually become dysfunctional and lose their immune efficacy as the infection progresses and antigen exposure continues. This dysfunction is characterized by a decrease in the secretion of cytotoxic factors, such as IL-2, IFN-&#x03B3;, and TNF (<a href="#ref26">26</a>, <a href="#ref27">27</a>), and an increase in the secretion of immunosuppressive factors like IL-10 and transforming growth factor-beta (TGF-<i>&#x03B2;</i>). Additionally, there is increased expression of inhibitory receptors such as programmed death protein 1 (PD-1), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and T-cell immunoglobulin and mucin structural domain-3 (Tim-3) (<a href="#ref28">28</a>, <a href="#ref29">29</a>). Inhibitory receptors are likely the primary reason for the loss of T-lymphocyte function, leading to the body&#x2019;s inability to effectively clear HBV (<a href="#ref30">30</a>). A therapeutic strategy that rescues functionally exhausted T cells by blocking inhibitory receptor signaling pathways, thereby enhancing the immune response, could integrate immunotherapy with antiviral therapy. This approach holds promise as a reliable option for patients with chronic HBV infection to achieve a functional cure.</p>
<p class="mb15">Recent studies have reported that hepatic CD8+ T cells in MAFLD mice may play a role in alleviating hepatic inflammation and fibrosis (<a href="#ref31">31</a>). Additionally, the number of peripheral blood Th1 cells in patients with MAFLD is significantly higher than in healthy individuals, leading to the hypothesis that Th1 cells may have a pro-inflammatory role (<a href="#ref32">32</a>). However, the state of T-lymphocyte immunocompetence in patients with CHB combined with MAFLD has not yet been reported.</p>
<p class="mb15">Based on a cohort of CHB or CHB-combined MAFLD patients receiving Peg-IFN antiviral therapy, along with a comprehensive clinical database and specimen bank, this study aims to investigate the number and function of T lymphocytes expressing inhibitory receptors in the peripheral blood of HBsAg-cleared and non-cleared patients at various time points, both at baseline and during treatment, using flow cytometry. The goal is to characterize the T-lymphocytes in patients with CHB combined with MAFLD, clarify the role of T lymphocytes expressing inhibitory receptors in HBsAg clearance, explore potential therapeutic targets, and provide insights for the development of new drugs aimed at achieving a clinical cure for hepatitis B.</p>
<p class="mb0">Sequencing of immune cells, such as T lymphocytes and DC cells, from liver cancer patients has revealed the characteristics of immune cells within the liver cancer environment, aiding in the development of more effective immunotherapeutic targets (<a href="#ref33">33</a>). However, the application of single-cell sequencing technology in populations with CHB combined with MAFLD has not yet been explored, particularly in investigating the mechanisms involved in HBsAg clearance. In this study, we aim to use transcriptome single-cell sequencing to explore the immunomolecular mechanisms of HBsAg clearance in CHB patients with MAFLD who are receiving Peg-IFN treatment. This approach will provide a multi-stage, dynamic, and high-resolution immune landscape of the HBsAg clearance process, clarify the gene regulation of immune cells during HBsAg clearance, uncover the immune cytogenetic basis of this clearance, and identify the molecular immunogenetic markers that determine successful HBsAg clearance. In addition, although this study has adopted a prospective and multicenter study protocol to reduce sampling and follow-up bias, there are still some limitations: (1) Given that the study is multicenter and cohort-based, there may be variability in treatment outcomes due to differences in patient populations, hospital settings, and clinician practices. While we aim to include a representative sample, the findings may not be generalizable to all HBV patients, particularly those outside of the study centers or those with more advanced liver disease. (2) The study relies on patient adherence to treatment protocols, including Peg-IFN therapy, and the potential for non-compliance or early dropout could impact the results, particularly the achievement of HBsAg clearance. (3) While we will attempt to control for common confounding factors such as age, gender, and baseline liver function, there may be other unmeasured factors (e.g., genetic predispositions, lifestyle habits, or co-infections) that could influence the treatment response and the success of Peg-IFN therapy.</p> <a id="h8" name="h8"></a>
<h2>Experimental state</h2>
<p class="mb15">The study has received all approvals from the Ethics Committee to start in all participating hospitals. The study was registered on May 28, 2024 (ChiCTR2400084913). Patient enrollment started on June 1, 2024.</p>
<p class="mb15">Timeline and Milestones:</p>
<p class="mb0">By December 2024:</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;">(1) Develop and finalize various SOPs.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;">(2) Enroll eligible CHB patients.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;">(3) Peg-IFN combined with NA therapy should be administered to both the dominant CHB population and the CHB combined with MAFLD patients.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;">(4) Conduct regular follow-ups to monitor patient progress.</p>
<p class="mb15">January 2025 to December 2025:</p>
<p class="mb15">Complete the enrollment of all patients.</p>
<p class="mb0">January 2026 to December 2026:</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;">(1) Analyze and compare the number and function of inhibitory receptor T-lymphocytes between the two groups.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;">(2) Assess differences in HBsAg clearance rates.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;">(3) Compare the number and function of inhibitory receptor T-lymphocytes between HBsAg-cleared and non-cleared patients.</p>
<p style="margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;">(4) Use single-cell sequencing technology to analyze the mechanisms underlying HBsAg clearance.</p> <a id="h9" name="h9"></a>
<h2>Ethics statement</h2>
<p class="mb0">The studies involving humans were approved by Ethics Committee of Beijing You&#x2019;an Hospital affiliated with Capital Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p> <a id="h10" name="h10"></a>
<h2>Author contributions</h2>
<p class="mb0">DZ: Writing &#x2013; original draft. CZ: Conceptualization, Data curation, Resources, Writing &#x2013; review &#x00026; editing. LZ: Conceptualization, Data curation, Investigation, Writing &#x2013; review &#x00026; editing. JJ: Conceptualization, Investigation, Resources, Writing &#x2013; review &#x00026; editing. JF: Formal analysis, Methodology, Supervision, Writing &#x2013; review &#x00026; editing. ZC: Conceptualization, Data curation, Project administration, Writing &#x2013; review &#x00026; editing.</p> <a id="h11" name="h11"></a>
<h2>Funding</h2>
<p class="mb0">The author(s) declare that financial support was received for the research and/or publication of this article. Capitals&#x2019;s Funds for Health Improvement and Research, No. 2024-1-2182.</p> <a id="h12" name="h12"></a>
<h2>Acknowledgments</h2>
<p class="mb0">The study involves a range of disciplines including clinical practice, immunology, and molecular biology. Clinical experts will oversee patient recruitment, clinical treatment protocols, and management of coexisting conditions such as diabetes and obesity. Immunology and molecular biology specialists will be responsible for performing in-depth analyses of immune markers and evaluating their correlation with treatment response, as well as investigating genetic factors that may influence treatment outcomes and the molecular mechanisms of the interaction between HBV and MAFLD. These disciplines are critical to addressing the complexities of chronic hepatitis B (CHB) and metabolism-associated fatty liver disease (MAFLD). The research team is comprised of experts in these fields, and their collaborative efforts are critical to the success of the study.</p> <a id="h13" name="h13"></a>
<h2>Conflict of interest</h2>
<p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p> <a id="h14" name="h14"></a>
<h2>Generative AI statement</h2>
<p class="mb0">The authors declare that no Gen AI was used in the creation of this manuscript.</p> <a id="h15" name="h15"></a>
<h2>Publisher&#x2019;s note</h2>
<p class="mb0">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p> <a id="h16" name="h16"></a>
<h2>References</h2>
<div class="References">
<p class="ReferencesCopy1"><a name="ref1" id="ref1"></a>1. Njuguna, HN, Hiebert, L, Harris, A, Morgan, RL, Gupta, N, and Ward, JW. An assessment of National Strategic Action Plans for viral hepatitis elimination, 2016-2021. <i>J Infect Dis</i>. (2023) 228:S148&#x2013;s153. doi: 10.1093/infdis/jiad346 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/37703342" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/infdis/jiad346" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=HN+Njuguna&#x00026;author=L+Hiebert&#x00026;author=A+Harris&#x00026;author=RL+Morgan&#x00026;author=N+Gupta&#x00026;author=JW+Ward&#x00026;publication_year=2023&#x00026;title=An+assessment+of+National+Strategic+Action+Plans+for+viral+hepatitis+elimination+2016-2021&#x00026;journal=J+Infect+Dis&#x00026;volume=228&#x00026;pages=S148-s153" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref2" id="ref2"></a>2. Sandhu, HS, Roesel, S, Sharifuzzaman, M, Chunsuttiwat, S, and Tohme, RA. Progress toward hepatitis B control - South-East Asia region, 2016-2019. <i>MMWR Morb Mortal Wkly Rep</i>. (2020) 69:988&#x2013;92. doi: 10.15585/mmwr.mm6930a2 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32730237" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.15585/mmwr.mm6930a2" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=HS+Sandhu&#x00026;author=S+Roesel&#x00026;author=M+Sharifuzzaman&#x00026;author=S+Chunsuttiwat&#x00026;author=RA+Tohme&#x00026;publication_year=2020&#x00026;title=Progress+toward+hepatitis+B+control+-+South-East+Asia+region+2016-2019&#x00026;journal=MMWR+Morb+Mortal+Wkly+Rep&#x00026;volume=69&#x00026;pages=988-92" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref3" id="ref3"></a>3. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. <i>J Viral Hepat</i>. (2004) 11:97&#x2013;107. doi: 10.1046/j.1365-2893.2003.00487.x </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/14996343" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1046/j.1365-2893.2003.00487.x" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Lavanchy&#x00026;publication_year=2004&#x00026;title=Hepatitis+B+virus+epidemiology+disease+burden+treatment+and+current+and+emerging+prevention+and+control+measures&#x00026;journal=J+Viral+Hepat&#x00026;volume=11&#x00026;pages=97-107" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref4" id="ref4"></a>4. Liu, J, Yang, HI, Lee, MH, Lu, SN, Jen, CL, Batrla-Utermann, R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. <i>Gut</i>. (2014) 63:1648&#x2013;57. doi: 10.1136/gutjnl-2013-305785 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24225939" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/gutjnl-2013-305785" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Liu&#x00026;author=HI+Yang&#x00026;author=MH+Lee&#x00026;author=SN+Lu&#x00026;author=CL+Jen&#x00026;author=R+Batrla-Utermann&#x00026;publication_year=2014&#x00026;title=Spontaneous+seroclearance+of+hepatitis+B+seromarkers+and+subsequent+risk+of+hepatocellular+carcinoma&#x00026;journal=Gut&#x00026;volume=63&#x00026;pages=1648-57" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref5" id="ref5"></a>5. Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). <i>Zhonghua Gan Zang Bing Za Zhi</i>. (2022) 30:1309&#x2013;31. doi: 10.3760/cma.j.cn501113-20221204-00607</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.3760/cma.j.cn501113-20221204-00607" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?publication_year=2022&#x00026;title=Guidelines+for+the+prevention+and+treatment+of+chronic+hepatitis+B+(version+2022)&#x00026;journal=Zhonghua+Gan+Zang+Bing+Za+Zhi&#x00026;volume=30&#x00026;pages=1309-31" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref6" id="ref6"></a>6. Younossi, ZM, Golabi, P, Paik, JM, Henry, A, Van Dongen, C, and Henry, L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. <i>Hepatology</i>. (2023) 77:1335&#x2013;47. doi: 10.1097/hep.0000000000000004 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/36626630" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/hep.0000000000000004" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=ZM+Younossi&#x00026;author=P+Golabi&#x00026;author=JM+Paik&#x00026;author=A+Henry&#x00026;author=C+Van+Dongen&#x00026;author=L+Henry&#x00026;publication_year=2023&#x00026;title=The+global+epidemiology+of+nonalcoholic+fatty+liver+disease+(NAFLD)+and+nonalcoholic+steatohepatitis+(NASH):+a+systematic+review&#x00026;journal=Hepatology&#x00026;volume=77&#x00026;pages=1335-47" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref7" id="ref7"></a>7. Quek, J, Chan, KE, Wong, ZY, Tan, C, Tan, B, Lim, WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. <i>Lancet Gastroenterol Hepatol</i>. (2023) 8:20&#x2013;30. doi: 10.1016/s2468-1253(22)00317-x </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/36400097" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/s2468-1253(22)00317-x" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Quek&#x00026;author=KE+Chan&#x00026;author=ZY+Wong&#x00026;author=C+Tan&#x00026;author=B+Tan&#x00026;author=WH+Lim&#x00026;publication_year=2023&#x00026;title=Global+prevalence+of+non-alcoholic+fatty+liver+disease+and+non-alcoholic+steatohepatitis+in+the+overweight+and+obese+population:+a+systematic+review+and+meta-analysis&#x00026;journal=Lancet+Gastroenterol+Hepatol&#x00026;volume=8&#x00026;pages=20-30" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref8" id="ref8"></a>8. Eslam, M, Newsome, PN, Sarin, SK, Anstee, QM, Targher, G, Romero-Gomez, M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. <i>J Hepatol</i>. (2020) 73:202&#x2013;9. doi: 10.1016/j.jhep.2020.03.039 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32278004" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jhep.2020.03.039" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Eslam&#x00026;author=PN+Newsome&#x00026;author=SK+Sarin&#x00026;author=QM+Anstee&#x00026;author=G+Targher&#x00026;author=M+Romero-Gomez&#x00026;publication_year=2020&#x00026;title=A+new+definition+for+metabolic+dysfunction-associated+fatty+liver+disease:+an+international+expert+consensus+statement&#x00026;journal=J+Hepatol&#x00026;volume=73&#x00026;pages=202-9" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref9" id="ref9"></a>9. Rinella, ME, Lazarus, JV, Ratziu, V, Francque, SM, Sanyal, AJ, Kanwal, F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. <i>J Hepatol</i>. (2023) 79:1542&#x2013;56. doi: 10.1016/j.jhep.2023.06.003 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/37364790" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jhep.2023.06.003" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=ME+Rinella&#x00026;author=JV+Lazarus&#x00026;author=V+Ratziu&#x00026;author=SM+Francque&#x00026;author=AJ+Sanyal&#x00026;author=F+Kanwal&#x00026;publication_year=2023&#x00026;title=A+multisociety+Delphi+consensus+statement+on+new+fatty+liver+disease+nomenclature&#x00026;journal=J+Hepatol&#x00026;volume=79&#x00026;pages=1542-56" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref10" id="ref10"></a>10. Younossi, ZM, Koenig, AB, Abdelatif, D, Fazel, Y, Henry, L, and Wymer, M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i>. (2016) 64:73&#x2013;84. doi: 10.1002/hep.28431 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26707365" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/hep.28431" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=ZM+Younossi&#x00026;author=AB+Koenig&#x00026;author=D+Abdelatif&#x00026;author=Y+Fazel&#x00026;author=L+Henry&#x00026;author=M+Wymer&#x00026;publication_year=2016&#x00026;title=Global+epidemiology+of+nonalcoholic+fatty+liver+disease-Meta-analytic+assessment+of+prevalence+incidence+and+outcomes&#x00026;journal=Hepatology&#x00026;volume=64&#x00026;pages=73-84" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref11" id="ref11"></a>11. Khalili, M, Kleiner, DE, King, WC, Sterling, RK, Ghany, MG, Chung, RT, et al. Hepatic steatosis and steatohepatitis in a large north American cohort of adults with chronic hepatitis B. <i>Am J Gastroenterol</i>. (2021) 116:1686&#x2013;97. doi: 10.14309/ajg.0000000000001257 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33840726" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.14309/ajg.0000000000001257" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Khalili&#x00026;author=DE+Kleiner&#x00026;author=WC+King&#x00026;author=RK+Sterling&#x00026;author=MG+Ghany&#x00026;author=RT+Chung&#x00026;publication_year=2021&#x00026;title=Hepatic+steatosis+and+steatohepatitis+in+a+large+north+American+cohort+of+adults+with+chronic+hepatitis+B&#x00026;journal=Am+J+Gastroenterol&#x00026;volume=116&#x00026;pages=1686-97" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref12" id="ref12"></a>12. van der Spek, DPC, Katwaroe, WK, van Kleef, LA, Brakenhoff, S, de Man, RA, de Knegt, RJ, et al. Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020. <i>Eur J Intern Med</i>. (2023) 107:86&#x2013;92. doi: 10.1016/j.ejim.2022.11.012 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/36396524" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ejim.2022.11.012" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=DPC+van+der+Spek&#x00026;author=WK+Katwaroe&#x00026;author=LA+van+Kleef&#x00026;author=S+Brakenhoff&#x00026;author=RA+de+Man&#x00026;author=RJ+de+Knegt&#x00026;publication_year=2023&#x00026;title=Time-trends+in+disease+characteristics+and+comorbidities+in+patients+with+chronic+hepatitis+B+in+the+period+1980-2020&#x00026;journal=Eur+J+Intern+Med&#x00026;volume=107&#x00026;pages=86-92" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref13" id="ref13"></a>13. Zheng, Q, Zou, B, Wu, Y, Yeo, Y, Wu, H, Stave, CD, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. <i>Aliment Pharmacol Ther</i>. (2021) 54:1100&#x2013;9. doi: 10.1111/apt.16595 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34469587" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/apt.16595" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Q+Zheng&#x00026;author=B+Zou&#x00026;author=Y+Wu&#x00026;author=Y+Yeo&#x00026;author=H+Wu&#x00026;author=CD+Stave&#x00026;publication_year=2021&#x00026;title=Systematic+review+with+meta-analysis:+prevalence+of+hepatic+steatosis+fibrosis+and+associated+factors+in+chronic+hepatitis+B&#x00026;journal=Aliment+Pharmacol+Ther&#x00026;volume=54&#x00026;pages=1100-9" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref14" id="ref14"></a>14. Enomoto, H, Aizawa, N, Hasegawa, K, Ikeda, N, Sakai, Y, Yoh, K, et al. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients. <i>Int J Mol Sci</i> (2020) 21 (In eng). doi: 10.3390/ijms21093089</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.3390/ijms21093089" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Enomoto&#x00026;author=N+Aizawa&#x00026;author=K+Hasegawa&#x00026;author=N+Ikeda&#x00026;author=Y+Sakai&#x00026;author=K+Yoh&#x00026;publication_year=2020&#x00026;title=Possible+Relevance+of+PNPLA3+and+TLL1+Gene+Polymorphisms+to+the+Efficacy+of+PEG-IFN+Therapy+for+HBV-Infected+Patients&#x00026;journal=Int+J+Mol+Sci&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref15" id="ref15"></a>15. Zhong, W, Wang, C, Wang, J, and Chen, T. Machine learning models to further identify advantaged populations that can achieve functional cure of chronic hepatitis B virus infection after receiving Peg-IFN alpha treatment. <i>Int J Med Inform</i> (2025) 193:105660. (In eng). doi: 10.1016/j.ijmedinf.2024.105660</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/j.ijmedinf.2024.105660" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=W+Zhong&#x00026;author=C+Wang&#x00026;author=J+Wang&#x00026;author=T+Chen&#x00026;publication_year=2025&#x00026;title=Machine+learning+models+to+further+identify+advantaged+populations+that+can+achieve+functional+cure+of+chronic+hepatitis+B+virus+infection+after+receiving+Peg-IFN+alpha+treatment&#x00026;journal=Int+J+Med+Inform&#x00026;volume=193&#x00026;pages=105660" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref16" id="ref16"></a>16. Liang, H, Liu, Y, Jiang, X, Zheng, X, Tang, J, Yang, J, et al. Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFN&#x03B1;-2a in Patients with Chronic Hepatitis B and the Associated Mechanism. <i>Gastroenterol Res Pract</i> (2020) 2020:1794769. (In eng). doi: 10.1155/2020/1794769</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1155/2020/1794769" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Liang&#x00026;author=Y+Liu&#x00026;author=X+Jiang&#x00026;author=X+Zheng&#x00026;author=J+Tang&#x00026;author=J+Yang&#x00026;publication_year=2020&#x00026;title=Impact+of+Hepatic+Steatosis+on+the+Antiviral+Effects+of+PEG-IFN&#x03B1;-2a+in+Patients+with+Chronic+Hepatitis+B+and+the+Associated+Mechanism&#x00026;journal=Gastroenterol+Res+Pract&#x00026;volume=2020&#x00026;pages=1794769" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref17" id="ref17"></a>17. Chan, AW, Tetzlaff, JM, G&#x000F8;tzsche, PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. <i>BMJ</i>. (2013) 346:e7586. doi: 10.1136/bmj.e7586 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23303884" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/bmj.e7586" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AW+Chan&#x00026;author=JM+Tetzlaff&#x00026;author=PC+G&#x000F8;tzsche&#x00026;publication_year=2013&#x00026;title=SPIRIT+2013+explanation+and+elaboration:+guidance+for+protocols+of+clinical+trials&#x00026;journal=BMJ&#x00026;volume=346&#x00026;pages=e7586" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref18" id="ref18"></a>18. Jin, X, Chen, YP, Yang, YD, Li, YM, Zheng, L, and Xu, CQ. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. <i>PLoS One</i>. (2012) 7:e34198. doi: 10.1371/journal.pone.0034198 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22479562" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0034198" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=X+Jin&#x00026;author=YP+Chen&#x00026;author=YD+Yang&#x00026;author=YM+Li&#x00026;author=L+Zheng&#x00026;author=CQ+Xu&#x00026;publication_year=2012&#x00026;title=Association+between+hepatic+steatosis+and+entecavir+treatment+failure+in+Chinese+patients+with+chronic+hepatitis+B&#x00026;journal=PLoS+One&#x00026;volume=7&#x00026;pages=e34198" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref19" id="ref19"></a>19. Gong, L, Liu, J, Wang, J, Lou, GQ, and Shi, JP. Hepatic steatosis as a predictive factor of antiviral effect of Pegylated interferon therapy in patients with hepatitis B. <i>Transplant Proc</i>. (2015) 47:2886&#x2013;91. doi: 10.1016/j.transproceed.2015.10.023 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26707308" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.transproceed.2015.10.023" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Gong&#x00026;author=J+Liu&#x00026;author=J+Wang&#x00026;author=GQ+Lou&#x00026;author=JP+Shi&#x00026;publication_year=2015&#x00026;title=Hepatic+steatosis+as+a+predictive+factor+of+antiviral+effect+of+Pegylated+interferon+therapy+in+patients+with+hepatitis+B&#x00026;journal=Transplant+Proc&#x00026;volume=47&#x00026;pages=2886-91" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref20" id="ref20"></a>20. Tang, Y, Fan, R, Lan, Z, Xie, Q, Zhang, J, Liang, X, et al. Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B. <i>J Med Virol</i>. (2023) 95:e28501. doi: 10.1002/jmv.28501 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/36655747" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/jmv.28501" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Tang&#x00026;author=R+Fan&#x00026;author=Z+Lan&#x00026;author=Q+Xie&#x00026;author=J+Zhang&#x00026;author=X+Liang&#x00026;publication_year=2023&#x00026;title=Impact+of+nonalcoholic+fatty+liver+disease+status+change+on+antiviral+efficacy+of+nucleos(t)ide+analogues+in+HBeAg-positive+chronic+hepatitis+B&#x00026;journal=J+Med+Virol&#x00026;volume=95&#x00026;pages=e28501" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref21" id="ref21"></a>21. Liu, L, Li, H, Zhang, Y, Zhang, J, and Cao, Z. Hepatitis B virus infection combined with nonalcoholic fatty liver disease: interaction and prognosis. <i>Heliyon</i>. (2023) 9:e13113. doi: 10.1016/j.heliyon.2023.e13113 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/36747946" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.heliyon.2023.e13113" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Liu&#x00026;author=H+Li&#x00026;author=Y+Zhang&#x00026;author=J+Zhang&#x00026;author=Z+Cao&#x00026;publication_year=2023&#x00026;title=Hepatitis+B+virus+infection+combined+with+nonalcoholic+fatty+liver+disease:+interaction+and+prognosis&#x00026;journal=Heliyon&#x00026;volume=9&#x00026;pages=e13113" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref22" id="ref22"></a>22. Hsu, YC, Yeh, ML, Wong, GL, et al. Incidences and determinants of functional cure during Entecavir or Tenofovir Disoproxil fumarate for chronic hepatitis B. <i>J Infect Dis</i>. (2021) 224:1890&#x2013;9. doi: 10.1093/infdis/jiab241 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33999179" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/infdis/jiab241" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=YC+Hsu&#x00026;author=ML+Yeh&#x00026;author=GL+Wong&#x00026;publication_year=2021&#x00026;title=Incidences+and+determinants+of+functional+cure+during+Entecavir+or+Tenofovir+Disoproxil+fumarate+for+chronic+hepatitis+B&#x00026;journal=J+Infect+Dis&#x00026;volume=224&#x00026;pages=1890-9" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref23" id="ref23"></a>23. Li, H, Liang, S, Liu, L, Zhou, D, Liu, Y, Zhang, Y, et al. Clinical cure rate of inactive HBsAg carriers with HBsAg &#x0003C;200 IU/ml treated with pegylated interferon. <i>Front Immunol</i>. (2022) 13:1091786. doi: 10.3389/fimmu.2022.1091786 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/36618361" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fimmu.2022.1091786" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Li&#x00026;author=S+Liang&#x00026;author=L+Liu&#x00026;author=D+Zhou&#x00026;author=Y+Liu&#x00026;author=Y+Zhang&#x00026;publication_year=2022&#x00026;title=Clinical+cure+rate+of+inactive+HBsAg+carriers+with+HBsAg+&#x0003C;200+IU/ml+treated+with+pegylated+interferon&#x00026;journal=Front+Immunol&#x00026;volume=13&#x00026;pages=1091786" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref24" id="ref24"></a>24. Li, J, Le, AK, Chaung, KT, et al. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. <i>Liver Int</i>. (2020) 40:1052&#x2013;61. doi: 10.1111/liv.14415 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32086988" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/liv.14415" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Li&#x00026;author=AK+Le&#x00026;author=KT+Chaung&#x00026;publication_year=2020&#x00026;title=Fatty+liver+is+not+independently+associated+with+the+rates+of+complete+response+to+oral+antiviral+therapy+in+chronic+hepatitis+B+patients&#x00026;journal=Liver+Int&#x00026;volume=40&#x00026;pages=1052-61" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref25" id="ref25"></a>25. Chen, YC, Jeng, WJ, Hsu, CW, and Lin, CY. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. <i>BMC Gastroenterol</i>. (2020) 20:146. doi: 10.1186/s12876-020-01289-w </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32397963" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12876-020-01289-w" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=YC+Chen&#x00026;author=WJ+Jeng&#x00026;author=CW+Hsu&#x00026;author=CY+Lin&#x00026;publication_year=2020&#x00026;title=Impact+of+hepatic+steatosis+on+treatment+response+in+nuclesos(t)ide+analogue-treated+HBeAg-positive+chronic+hepatitis+B:+a+retrospective+study&#x00026;journal=BMC+Gastroenterol&#x00026;volume=20&#x00026;pages=146" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref26" id="ref26"></a>26. Wherry, EJ. T cell exhaustion. <i>Nat Immunol</i>. (2011) 12:492&#x2013;9. doi: 10.1038/ni.2035 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21739672" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ni.2035" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=EJ+Wherry&#x00026;publication_year=2011&#x00026;title=T+cell+exhaustion&#x00026;journal=Nat+Immunol&#x00026;volume=12&#x00026;pages=492-9" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref27" id="ref27"></a>27. Wherry, EJ, and Kurachi, M. Molecular and cellular insights into T cell exhaustion. <i>Nat Rev Immunol</i>. (2015) 15:486&#x2013;99. doi: 10.1038/nri3862 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26205583" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nri3862" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=EJ+Wherry&#x00026;author=M+Kurachi&#x00026;publication_year=2015&#x00026;title=Molecular+and+cellular+insights+into+T+cell+exhaustion&#x00026;journal=Nat+Rev+Immunol&#x00026;volume=15&#x00026;pages=486-99" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref28" id="ref28"></a>28. Blackburn, SD, Shin, H, Haining, WN, Zou, T, Workman, CJ, Polley, A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. <i>Nat Immunol</i>. (2009) 10:29&#x2013;37. doi: 10.1038/ni.1679 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19043418" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ni.1679" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SD+Blackburn&#x00026;author=H+Shin&#x00026;author=WN+Haining&#x00026;author=T+Zou&#x00026;author=CJ+Workman&#x00026;author=A+Polley&#x00026;publication_year=2009&#x00026;title=Coregulation+of+CD8++T+cell+exhaustion+by+multiple+inhibitory+receptors+during+chronic+viral+infection&#x00026;journal=Nat+Immunol&#x00026;volume=10&#x00026;pages=29-37" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref29" id="ref29"></a>29. Crawford, A, and Wherry, EJ. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. <i>Curr Opin Immunol</i>. (2009) 21:179&#x2013;86. doi: 10.1016/j.coi.2009.01.010 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19264470" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.coi.2009.01.010" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Crawford&#x00026;author=EJ+Wherry&#x00026;publication_year=2009&#x00026;title=The+diversity+of+costimulatory+and+inhibitory+receptor+pathways+and+the+regulation+of+antiviral+T+cell+responses&#x00026;journal=Curr+Opin+Immunol&#x00026;volume=21&#x00026;pages=179-86" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref30" id="ref30"></a>30. Keam, SJ. Tremelimumab: First Approval. <i>Drugs</i>. (2023) 83:93&#x2013;102. doi: 10.1007/s40265-022-01827-8 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/36571670" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s40265-022-01827-8" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SJ+Keam&#x00026;publication_year=2023&#x00026;title=Tremelimumab:+First+Approval&#x00026;journal=Drugs&#x00026;volume=83&#x00026;pages=93-102" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref31" id="ref31"></a>31. Koda, Y, Teratani, T, Chu, PS, Hagihara, Y, Mikami, Y, Harada, Y, et al. CD8(+) tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells. <i>Nat Commun</i>. (2021) 12:4474. doi: 10.1038/s41467-021-24734-0 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34294714" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41467-021-24734-0" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Koda&#x00026;author=T+Teratani&#x00026;author=PS+Chu&#x00026;author=Y+Hagihara&#x00026;author=Y+Mikami&#x00026;author=Y+Harada&#x00026;publication_year=2021&#x00026;title=CD8(+)+tissue-resident+memory+T+cells+promote+liver+fibrosis+resolution+by+inducing+apoptosis+of+hepatic+stellate+cells&#x00026;journal=Nat+Commun&#x00026;volume=12&#x00026;pages=4474" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref32" id="ref32"></a>32. Rau, M, Schilling, AK, Meertens, J, Hering, I, Weiss, J, Jurowich, C, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. <i>J Immunol</i>. (2016) 196:97&#x2013;105. doi: 10.4049/jimmunol.1501175 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26621860" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4049/jimmunol.1501175" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Rau&#x00026;author=AK+Schilling&#x00026;author=J+Meertens&#x00026;author=I+Hering&#x00026;author=J+Weiss&#x00026;author=C+Jurowich&#x00026;publication_year=2016&#x00026;title=Progression+from+nonalcoholic+fatty+liver+to+nonalcoholic+steatohepatitis+is+marked+by+a+higher+frequency+of+Th17+cells+in+the+liver+and+an+increased+Th17/resting+regulatory+T+cell+ratio+in+peripheral+blood+and+in+the+liver&#x00026;journal=J+Immunol&#x00026;volume=196&#x00026;pages=97-105" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref33" id="ref33"></a>33. Sun, Y, Wu, L, Zhong, Y, Zhou, K, Hou, Y, Wang, Z, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. <i>Cell</i>. (2021) 184:404&#x2013;421.e16. doi: 10.1016/j.cell.2020.11.041 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33357445" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.cell.2020.11.041" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Sun&#x00026;author=L+Wu&#x00026;author=Y+Zhong&#x00026;author=K+Zhou&#x00026;author=Y+Hou&#x00026;author=Z+Wang&#x00026;publication_year=2021&#x00026;title=Single-cell+landscape+of+the+ecosystem+in+early-relapse+hepatocellular+carcinoma&#x00026;journal=Cell&#x00026;volume=184&#x00026;pages=404-421.e16" target="_blank">Google Scholar</a></p></div>
</div> <div class="thinLineM20"></div> <div class="AbstractSummary">
<p><span>Keywords:</span> hepatitis B virus, chronic hepatitis B, metabolism-associated fatty liver disease, peginterferon, HBsAg clearance, clinical cure</p>
<p><span>Citation:</span> Zhou D, Zhang C, Zhang L, Jia J, Fu J and Cao Z (2025) A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure. <i>Front. Public Health</i>. 13:1546182. doi: 10.3389/fpubh.2025.1546182</p>
<p class="timestamps"><span>Received:</span> 16 December 2024; <span>Accepted:</span> 17 February 2025;<br> <span>Published:</span> 14 March 2025.</p> <div>
<p>Edited by:</p> <a href="https://loop.frontiersin.org/people/1702500/overview">Ritthideach Yorsaeng</a>, Chulalongkorn University, Thailand</div> <div>
<p>Reviewed by:</p> <a href="https://loop.frontiersin.org/people/1434331/overview">Wenjun Wang</a>, Xi&#x2019;an Jiaotong University, China<br> <a href="https://loop.frontiersin.org/people/1652166/overview">Xu Liang</a>, Tianjin Second People&#x2019;s Hospital, China</div>
<p><span>Copyright</span> &#x000A9; 2025 Zhou, Zhang, Zhang, Jia, Fu and Cao. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>&#x0002A;Correspondence:</span> Zhenhuan Cao, <a id="encmail">Y2Fvemhlbmh1YW55dUBtYWlsLmNjbXUuZWR1LmNu</a></p> <div class="clear"></div> </div></div></div> <p class="AbstractSummary__disclaimer"><span>Disclaimer: </span>
      All claims expressed in this article are solely those of the authors and
      do not necessarily represent those of their affiliated organizations, or
      those of the publisher, the editors and the reviewers. Any product that
      may be evaluated in this article or claim that may be made by its
      manufacturer is not guaranteed or endorsed by the publisher.
    </p></div></div></main> <aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div id="FloatingButtonsEl" class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--type ActionsDropDown__button--icon"><span class="ActionsDropDown__button__label">Download article</span></button> <div class="ActionsDropDown__menuWrapper"><!----> <ul class="ActionsDropDown__menu"><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/pdf" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-pdf" class="ActionsDropDown__option">
          Download PDF
        </a></li><li><a href="http://www.readcube.com/articles/10.3389/fpubh.2025.1546182" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-readCube" class="ActionsDropDown__option">
          ReadCube
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/epub" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-epub" class="ActionsDropDown__option">
          epub
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/xml/nlm" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-nlmXml" class="ActionsDropDown__option">
          XML (NLM)
        </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div> <div class="ArticleDetails__aside__responsiveButtons__items"><!----> <div class="ArticleDetailsShare__responsive"><button aria-label="Open share options" class="ArticleDetailsShare__trigger"></button> <div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p> <ul class="ArticleDetailsShare__list"><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1546182/full" target="_blank" title="Share on X" aria-label="Share on X" class="ArticleDetailsShare__link ArticleDetailsShare__link--x"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1546182/full" target="_blank" title="Share on Linkedin" aria-label="Share on Linkedin" class="ArticleDetailsShare__link ArticleDetailsShare__link--linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1546182/full" target="_blank" title="Share on Facebook" aria-label="Share on Facebook" class="ArticleDetailsShare__link ArticleDetailsShare__link--facebook"></a></li></ul></div></div> <div class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote"><!----></button> <div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">
      Export citation
    </div> <ul class="ActionsDropDown__menu"><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/endNote" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-endNote" class="ActionsDropDown__option">
          EndNote
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/reference" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-referenceManager" class="ActionsDropDown__option">
          Reference Manager
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/text" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-simpleTextFile" class="ActionsDropDown__option">
          Simple Text file
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/bibTex" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-bibTex" class="ActionsDropDown__option">
          BibTex
        </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div></div></div> <div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">
        130
      </div> <div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div> <div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">
        23
      </div> <div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div> <!----> <div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button> <div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button> <div class="ImpactMetricsInfoPopover__tooltip__text">
      Citation numbers are available from Dimensions
    </div></div></div></div> <div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/1546182#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact" class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right"><span>View article impact</span></a></span></div> <div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fpubh.2025.1546182" data-condensed="true" data-link-target="new" class="altmetric-embed"></div> <span class="Link__wrapper"><a aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fpubh.2025.1546182" target="_blank" data-event="customLink-link-a_viewAltmetricScore" class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right"><span>View altmetric score</span></a></span></div></div> <div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p> <ul class="ArticleDetailsShare__list"><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1546182/full" target="_blank" title="Share on X" aria-label="Share on X" class="ArticleDetailsShare__link ArticleDetailsShare__link--x"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1546182/full" target="_blank" title="Share on Linkedin" aria-label="Share on Linkedin" class="ArticleDetailsShare__link ArticleDetailsShare__link--linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1546182/full" target="_blank" title="Share on Facebook" aria-label="Share on Facebook" class="ArticleDetailsShare__link ArticleDetailsShare__link--facebook"></a></li></ul></div> <div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div> <a href="https://loop.frontiersin.org/people/1702500/overview" data-event="editorInfo-a-ritthideachYorsaeng" class="ArticleDetailsEditors__ediorInfo"><figure class="Avatar Avatar--size-32"><img src="https://loop.frontiersin.org/images/profile/1702500/32" alt="Ritthideach Yorsaeng" class="Avatar__img is-inside-mask"></figure> <div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">
      Ritthideach Yorsaeng
    </div> <div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">
      
    </div></div></a></div></div> <div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div> <a href="https://loop.frontiersin.org/people/1434331/overview" data-event="editorInfo-a-wenjunWang" class="ArticleDetailsEditors__ediorInfo"><figure class="Avatar Avatar--size-32"><img src="https://loop.frontiersin.org/images/profile/1434331/32" alt="Wenjun Wang" class="Avatar__img is-inside-mask"></figure> <div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">
      Wenjun Wang
    </div> <div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">
      
    </div></div></a><a href="https://loop.frontiersin.org/people/1652166/overview" data-event="editorInfo-a-xuLiang" class="ArticleDetailsEditors__ediorInfo"><figure class="Avatar Avatar--size-32"><img src="https://loop.frontiersin.org/images/profile/1652166/32" alt="Xu Liang" class="Avatar__img is-inside-mask"></figure> <div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">
      Xu Liang
    </div> <div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">
      
    </div></div></a></div></div> <div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div> <div class="ArticleDetailsGlossary__header__arrow"></div></button> <div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"> <li><a href="#h1">Abstract</a></li> <li><a href="#h2">Introduction</a></li> <li><a href="#h3">Methods: subjects, interventions, and outcomes</a></li> <li><a href="#h4">Methods: data collection, management, and analysis</a></li> <li><a href="#h5">Methods: monitoring</a></li> <li><a href="#h6">Ethics and dissemination</a></li> <li><a href="#h7">Discussion</a></li> <li><a href="#h8">Experimental state</a></li> <li><a href="#h9">Ethics statement</a></li> <li><a href="#h10">Author contributions</a></li> <li><a href="#h11">Funding</a></li> <li><a href="#h12">Acknowledgments</a></li> <li><a href="#h13">Conflict of interest</a></li> <li><a href="#h14">Generative AI statement</a></li> <li><a href="#h15">Publisher&#x2019;s note</a></li> <li><a href="#h16">References</a></li> </ul></div></div> <!----> <div class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote"><span class="ActionsDropDown__button__label">Export citation</span></button> <div class="ActionsDropDown__menuWrapper"><!----> <ul class="ActionsDropDown__menu"><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/endNote" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-endNote" class="ActionsDropDown__option">
          EndNote
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/reference" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-referenceManager" class="ActionsDropDown__option">
          Reference Manager
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/text" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-simpleTextFile" class="ActionsDropDown__option">
          Simple Text file
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/bibTex" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-bibTex" class="ActionsDropDown__option">
          BibTex
        </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div> <div class="CheckForUpdates"><button data-target="crossmark" data-event="checkForUpdates-btn-openModal" class="CheckForUpdates__link"><img src="/article-pages/_nuxt/img/crossmark.5c8ec60.svg" alt="Crossmark icon" class="CheckForUpdates__link__img"> <div class="CheckForUpdates__link__text">Check for updates</div></button></div> <div class="Announcement"><p class="Announcement__title">
    Research integrity at Frontiers
  </p> <article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media=""><source srcset="https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media=""> <img src="https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" alt="Man ultramarathon runner in the mountains he trains at sunset" loading="lazy" class="is-inside-mask"></picture> <!----></figure> <div class="CardA__info"><h2 class="CardA__title">94% of researchers rate our articles as excellent or good</h2> <p class="CardA__text">Learn more about the work of our research integrity team to safeguard the quality of each article we publish.</p> <br> <span class="Link__wrapper"><a aria-label="About our research integrity team" href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="customLink-link-a_findOutMore" class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right"><span>Find out more </span></a></span></div></div></article></div> <!----> <!----></div> <!----> <div><div class="FloatingButtons"><!----> <div class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--type ActionsDropDown__button--iconDownload"><span class="ActionsDropDown__button__label">Download article</span></button> <div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">
      Download
    </div> <ul class="ActionsDropDown__menu"><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/pdf" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-pdf" class="ActionsDropDown__option">
          Download PDF
        </a></li><li><a href="http://www.readcube.com/articles/10.3389/fpubh.2025.1546182" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-readCube" class="ActionsDropDown__option">
          ReadCube
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/epub" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-epub" class="ActionsDropDown__option">
          epub
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1546182/xml/nlm" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-nlmXml" class="ActionsDropDown__option">
          XML (NLM)
        </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div></div> <!----></div></div></aside></div> <div class="Announcement Announcement--Responsive"><p class="Announcement__title">
    Research integrity at Frontiers
  </p> <article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media=""><source srcset="https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media=""> <img src="https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" alt="Man ultramarathon runner in the mountains he trains at sunset" loading="lazy" class="is-inside-mask"></picture> <!----></figure> <div class="CardA__info"><h2 class="CardA__title">94% of researchers rate our articles as excellent or good</h2> <p class="CardA__text">Learn more about the work of our research integrity team to safeguard the quality of each article we publish.</p> <br> <span class="Link__wrapper"><a aria-label="About our research integrity team" href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="customLink-link-a_findOutMore" class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right"><span>Find out more </span></a></span></div></div></article></div> <div><!----></div></div></div> <!----> <footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><li class="Accordion__item"><button class="Accordion__headline"><!----> <div class="Accordion__title">Guidelines</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li></ul></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----> <div class="Accordion__title">Explore</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li></ul></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----> <div class="Accordion__title">Outreach</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersplanetprize.org/" target="_blank" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li></ul></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----> <div class="Accordion__title">Connect</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://loop.frontiersin.org/settings/email-preferences?a=publishers" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li></ul></div></li></ul> <div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div> <span class="Link__wrapper"><a aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right"><span></span></a></span><span class="Link__wrapper"><a aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right"><span></span></a></span><span class="Link__wrapper"><a aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right"><span></span></a></span><span class="Link__wrapper"><a aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right"><span></span></a></span></div></div> <div class="Footer__copyright"><div><span>© 2025 Frontiers Media S.A. All rights reserved</span></div> <div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a> <span>|</span> <a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer> <div class="SnackbarWrapper"><ul class="SnackbarContainer"></ul></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw,ax,ay,az,aA,aB,aC,aD,aE,aF,aG,aH,aI,aJ,aK,aL,aM,aN,aO,aP,aQ,aR,aS,aT,aU,aV,aW,aX,aY,aZ,a_,a$,ba,bb,bc,bd,be,bf,bg,bh,bi,bj,bk,bl,bm,bn,bo,bp,bq,br,bs,bt,bu,bv,bw,bx,by,bz,bA,bB,bC,bD,bE,bF,bG,bH,bI,bJ,bK,bL,bM,bN,bO,bP,bQ,bR,bS,bT,bU,bV,bW,bX,bY,bZ,b_,b$,ca,cb,cc,cd,ce,cf,cg,ch,ci,cj,ck,cl,cm,cn,co,cp,cq,cr,cs,ct,cu,cv,cw,cx,cy,cz,cA,cB,cC,cD,cE,cF,cG,cH,cI,cJ,cK){au.id=av;au.name=aw;au.slug=ax;au.specialtyId=3773;au.__typename="journal_section";return {layout:"ArticleLayout",data:[{}],fetch:{},error:e,state:{currentJournal:{identifier:t,name:o,slug:u,banner:[{id:"7CCE4235-8BF4-4D52-8022020C57AC98C1",src:T,name:"FPUBH_Main Visual_Cyan_Website",tags:["pandemic","c","safety","danger","smartphone","commuter","mode","inside","barrier"],type:E,width:3745,height:U,idHash:"199032aaf8eef874",archive:m,brandId:V,limited:m,fileSize:6620585,isPublic:c,original:"https:\u002F\u002Fbrand.frontiersin.org\u002Fm\u002F199032aaf8eef874\u002Foriginal\u002FFPUBH_Main-Visual_Cyan_Website.jpg",copyright:"Copyright (c) 2020 SmartPhotoLab\u002FShutterstock.  No use without permission.",extension:[W],thumbnails:{mini:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002Fmini-50226AC5-79DE-4DE1-ACC02582A564B0E1.png",thul:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002Fthul-B46E7F8F-CAF8-4A31-B91A262CA70C16DB.png",webimage:T,Guidelines:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002FD992F897-6BC2-466D-90902EADFBEAB887\u002FGuidelines-FPUBH_Main Visual_Cyan_Website.png",WebsiteJpg_XL:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002FD992F897-6BC2-466D-90902EADFBEAB887\u002FWebsiteJpg_XL-FPUBH_Main Visual_Cyan_Website.jpg",WebsiteWebP_L:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002FD992F897-6BC2-466D-90902EADFBEAB887\u002FWebsiteWebP_L-FPUBH_Main Visual_Cyan_Website.webp",WebsiteWebP_M:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002FD992F897-6BC2-466D-90902EADFBEAB887\u002FWebsiteWebP_M-FPUBH_Main Visual_Cyan_Website.webp",WebsiteWebP_XL:X},dateCreated:Y,description:"variety of passengers ride the subway car",orientation:F,userCreated:"Caroline Sutter",watermarked:m,dateModified:Y,datePublished:"2022-06-27T09:27:09Z",ecsArchiveFiles:[],propertyOptions:["414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF"],property_Channel:["frontiersin_org"],"property_Sub-Type":["Main_Visual"],property_Asset_Type:["Photography"],activeOriginalFocusPoint:{x:1873,y:1249},property_Office_Department:["Publishing"]}],description:"A multidisciplinary journal that promotes discussions on inter-sectoral public health challenges, from health promotion to climate change, transportation, environmental change, and species diversity.",mission:"\u003Cp\u003EFrontiers in Public Health publishes developments in all fields of public health research, aiming to advance our understanding of causal relationships for disease, promote community-based interventions and explore prevention at the community and individual level.\u003C\u002Fp\u003E\n\n\u003Cp\u003ELed by Field Chief Editor Paolo Vineis of Imperial College London, United Kingdom, Frontiers in Public Health welcomes submissions across all areas of the field that advances population health, furthers disease prevention and promotes health for all members of society. Topics include:\u003C\u002Fp\u003E\n \n\u003Cdiv\u003E &bull; aging and public health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; children and health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; clinical diabetes\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; digital public health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; disaster and emergency medicine\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; environmental health and exposome\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; health economics\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; infectious diseases: epidemiology and prevention\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; injury prevention and control\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; life-course epidemiology and social inequalities in health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; occupational health and safety\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; planetary health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; public health education and promotion\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; public health policy\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; public health and nutrition\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; public mental health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; radiation and health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; substance use disorders and behavioral addictions.\u003C\u002Fdiv\u003E\n \u003Cbr\u003E\n\u003Cp\u003EThe journal welcomes submissions which advance the UN’s Sustainable Development Goals (SDG), notably SDG 3, Good Health and Well-Being, in the effort to address significant global public health concerns, preparedness and develop appropriate mitigation measures.\u003C\u002Fp\u003E\n\n\u003Cp\u003EManuscripts that focus solely on health services, clinical trials on drugs, medical imaging, and disease-specific studies that do not have a clear public health relevance, are not suitable for publication in this journal. Additionally, studies that are purely predictive or prognostic models without a relevance to public health practice or policy will not be considered. The journal does not accept papers concerning simple bibliometric studies and discourages publication of cross-sectional studies, with exceptions. Authors are welcome to submit Systematic Reviews using publicly available data, but these must adhere to the PRISMA guidelines and have a conclusion related to public health. Manuscripts reporting findings from Mendelian Randomization studies need to be accompanied by a completed \u003Ca href=\"https:\u002F\u002Fwww.strobe-mr.org\u002F\"\u003ESTROBE-MR checklist\u003C\u002Fa\u003E.\u003C\u002Fp\u003E\n\n\u003Cp\u003EFrontiers in Public Health is committed to advancing developments in the field of public health by allowing unrestricted access to articles, welcoming trials on public health interventions, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C\u002Fp\u003E\n\n— \n\n\u003Cp\u003E\u003Cstrong\u003EEthics Statement for the Tobacco Industry\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E\n \n\u003Cp\u003EIn accordance with Frontiers’ Conflict of Interest (COI) policy, for any research article that is sponsored through commercial funding, the role of the funder must be declared to Frontiers in Public Health in full. If that source of funding is tied to the vested interests of the tobacco or commercial nicotine industries or affiliated organisations, it will be rejected without passing into peer review.\u003C\u002Fp\u003E\n\n\u003Cp\u003EIf undeclared funding information of this type comes to light post-publication, a formal correction or retraction in full will take place. If a researcher has past or present affiliations or has received incentives from commercial tobacco or nicotine industries or affiliated organisations, the research article will not pass into peer review.\u003C\u002Fp\u003E\n\n\u003Cp\u003EFor industries other than tobacco or commercial nicotine, a case-by-case evaluation will be made at Editorial level. There are potential situations of conflict of interest arising e.g. from the food or cosmetics industry or other industries that produce goods that are under scrutiny for safety or that may contribute to ill health.\u003C\u002Fp\u003E\n\n\u003Cp\u003EExamples of competing interests include the following: board membership, consultancy, employment, expert testimony grants (including pending), contract research, lectures\u002Fother education events, speakers’ bureaux, patents (planned, pending or issued), receipt of equipment or supplies, royalties, stock\u002Fstock options\u002Fother forms of ownership, additional expenses not included in COIs already specified, other personal or professional relationships that may influence or appear to influence.\u003C\u002Fp\u003E\n\n\u003Cp\u003EFor more information on Frontiers VALID acceptance criteria see: https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Freview-system.\u003C\u002Fp\u003E",palette:"cyan",impactFactor:"5.2",citeScore:"3.8",citations:"140000",showTagline:e,twitter:"@FrontPubHealth",__typename:"Journal"},currentFrontiersJournal:{id:t,name:o,slug:u,printISSN:e,shortName:G,electronicISSN:H,abbreviation:Z,specialtyId:e,publicationDate:e,isOnline:h,isOpenForSubmissions:h,spaceId:c,field:{id:_,domainId:n,__typename:$},__typename:a},articleHubSlug:f,articleHubPage:I,currentArticle:{id:1546182,doi:aa,title:J,acceptanceDate:new Date(1739782593000),receptionDate:new Date(1734355328000),publicationDate:new Date(1741910400000),isPublished:h,abstract:f,researchTopic:{id:66031,title:"World Hepatitis Day 2024: Advancing Hepatitis Elimination, Public Health Strategies and Innovations",articlesCount:K,isMagazinePage:l,slug:"world-hepatitis-day-2024-advancing-hepatitis-elimination-public-health-strategies-and-innovations",isOpenForSubmission:h},articleType:{id:145,name:"Study Protocol"},stage:{id:L,name:f},keywords:["chronic hepatitis B","hepatitis B virus","metabolism-associated fatty liver disease","HBsAg clearance","clinical cure","peginterferon"],authors:[{id:m,firstName:ab,lastName:"Zhou",givenNames:ab,isCorresponding:l,isProfilePublic:l,userId:m,affiliations:[{organizationName:ac,countryName:p,cityName:f,stateName:f,zipCode:f}]},{id:ad,firstName:ae,lastName:af,givenNames:ae,isCorresponding:l,isProfilePublic:h,userId:ad,affiliations:[{organizationName:ag,countryName:p,cityName:f,stateName:f,zipCode:f}]},{id:ah,firstName:ai,lastName:af,givenNames:ai,isCorresponding:l,isProfilePublic:h,userId:ah,affiliations:[{organizationName:"Beijing Ditan Hospital, Capital Medical University",countryName:p,cityName:f,stateName:f,zipCode:f}]},{id:m,firstName:aj,lastName:"Jia",givenNames:aj,isCorresponding:l,isProfilePublic:l,userId:m,affiliations:[{organizationName:"Baoding Municipal People's Hospital",countryName:p,cityName:f,stateName:f,zipCode:f}]},{id:ak,firstName:al,lastName:"Fu",givenNames:al,isCorresponding:l,isProfilePublic:h,userId:ak,affiliations:[{organizationName:ag,countryName:p,cityName:f,stateName:f,zipCode:f}]},{id:am,firstName:an,lastName:"Cao",givenNames:an,isCorresponding:l,isProfilePublic:h,userId:am,affiliations:[{organizationName:ac,countryName:p,cityName:f,stateName:f,zipCode:f}]}],editors:[{id:ao,firstName:ap,lastName:"Yorsaeng",givenNames:ap,isCorresponding:l,isProfilePublic:h,userId:ao,affiliations:[{organizationName:f,countryName:f,cityName:f,stateName:f,zipCode:f}]}],reviewers:[{id:aq,firstName:ar,lastName:"Wang",givenNames:ar,isCorresponding:l,isProfilePublic:h,userId:aq,affiliations:[{organizationName:f,countryName:f,cityName:f,stateName:f,zipCode:f}]},{id:as,firstName:at,lastName:"Liang",givenNames:at,isCorresponding:l,isProfilePublic:h,userId:as,affiliations:[{organizationName:f,countryName:f,cityName:f,stateName:f,zipCode:f}]}],journal:{id:t,slug:u,name:o,shortName:G,electronicISSN:H,field:{id:_,domainId:n,__typename:$},specialtyId:e,journalSectionPaths:[{section:au,__typename:"journal_journalSectionPath"}],__typename:a},section:au,impactMetrics:{views:130,downloads:23,citations:m},volume:M,articleVolume:"Volume 13 - 2025",relatedArticles:[],isPublishedV2:h,contents:{titleHtml:J,fullTextHtml:"\u003Cdiv class=\"JournalAbstract\"\u003E \u003Ca id=\"h1\" name=\"h1\"\u003E\u003C\u002Fa\u003E\n \u003Cdiv class=\"authors\"\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg\" alt=\"Daqiong Zhou\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\"\u003EDaqiong Zhou\u003Csup\u003E1\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F670990\" class=\"user-id-670990\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F670990\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"Chao Zhang\"\u003EChao Zhang\u003C\u002Fa\u003E\u003Csup\u003E2\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1585997\" class=\"user-id-1585997\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F1585997\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"Lu Zhang\"\u003ELu Zhang\u003C\u002Fa\u003E\u003Csup\u003E3\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg\" alt=\"Jianru Jia\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\"\u003EJianru Jia\u003Csup\u003E4\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1805685\" class=\"user-id-1805685\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F1805685\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"Junliang Fu\"\u003EJunliang Fu\u003C\u002Fa\u003E\u003Csup\u003E2\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1640317\" class=\"user-id-1640317\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F1640317\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"Zhenhuan Cao&#xA;\"\u003EZhenhuan Cao\u003C\u002Fa\u003E\u003Csup\u003E1\u003C\u002Fsup\u003E\u003Csup\u003E&#x0002A;\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003C\u002Fdiv\u003E \u003Cul class=\"notes\"\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E1\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EBeijing Youan Hospital, Capital Medical University, Beijing, China\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E2\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EThe Fifth Medical Center of Chinese PLA General Hospital, Beijing, China\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E3\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EBeijing Ditan Hospital, Capital Medical University, Beijing, China\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E4\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EBaoding Municipal People's Hospital, Baoding, Hebei, China\u003C\u002Fli\u003E \u003C\u002Ful\u003E\n\u003Cp class=\"mb15\"\u003E\u003Cb\u003EIntroduction:\u003C\u002Fb\u003E The incidence of chronic hepatitis B (CHB) combined with metabolism-associated fatty liver disease (MAFLD) is increasing annually, and the presence of MAFLD may influence the clinical assessment of viral activity and transaminase levels. However, it remains unclear whether MAFLD impacts the achievement of clinical cure in CHB patients treated with polyethylene glycol interferon (Peg-IFN).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003E\u003Cb\u003EMethods:\u003C\u002Fb\u003E A prospective cohort study was conducted to enroll patients with dominant CHB (on NA treatment, HBsAg &#x0003C;1,500&#x202F;IU\u002FmL, HBeAg negative, HBV DNA &#x0003C;10&#x202F;IU\u002FmL) and patients with dominant CHB combined with MAFLD, all of whom were treated with Peg-IFN. The study aimed to assess the efficacy and safety of Peg-IFN treatment and to elucidate the effect of MAFLD on achieving HBsAg clearance in these patients. Additionally, the study explored the T-lymphocyte characteristics of patients with CHB combined with MAFLD, analyzed the role of T-lymphocytes expressing inhibitory receptors in HBsAg clearance, and investigated the immunological mechanisms of HBsAg clearance through single-cell transcriptome sequencing technology.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003E\u003Cb\u003EEthics and dissemination:\u003C\u002Fb\u003E Patients will be recruited at four medical centers in Beijing and Hebei, and written informed consent will be obtained to inform participants of the purpose of the study, potential risks, and benefits. Ethical approval has been granted for the study, which will focus on 48-week HBsAg clearance, and a detailed follow-up and adverse event monitoring plan has been developed.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003E\u003Cb\u003EStrengths and limitations of this study:\u003C\u002Fb\u003E Strengths are that this study fills the gap in treatment strategies for patients with CHB combined with MAFLD and provides important treatment guidance to clinicians; the multicenter design may increase the diversity of the sample size, reduce the bias of single-center studies, and improve the external validity of the results. Limitations are that interferon therapy is often associated with side effects, which may lead to lower patient adherence and affect long-term follow-up and outcome monitoring of the study; the heterogeneity of the MAFLD population may have different effects on the efficacy of interferon therapy.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003E\u003Cb\u003EClinical trial registration:\u003C\u002Fb\u003E \u003Ca href=\"http:\u002F\u002Fwww.chictr.org.cn\u002Fbin\u002Fproject\u002Fedit?pid=231498\"\u003Ehttp:\u002F\u002Fwww.chictr.org.cn\u002Fbin\u002Fproject\u002Fedit?pid=231498\u003C\u002Fa\u003E, identifier ChiCTR2400084913.\u003C\u002Fp\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003C\u002Fdiv\u003E \u003Cdiv class=\"JournalFullText\"\u003E \u003Ca id=\"h2\" name=\"h2\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EIntroduction\u003C\u002Fh2\u003E\n\u003Ch3\u003EBackground and rationale\u003C\u002Fh3\u003E\n\u003Cp class=\"mb15\"\u003EIn 2016, the World Health Organization (WHO) proposed &#x201C;eliminating viral hepatitis as a major public health threat by 2030&#x201D; (\u003Ca href=\"#ref1\"\u003E1\u003C\u002Fa\u003E). In recent years, the incidence of HBV infection has shown a significant downward trend; however, due to its large patient population, China continues to bear the highest disease burden of HBV infection globally, with 74 million affected individuals (\u003Ca href=\"#ref2\"\u003E2\u003C\u002Fa\u003E). This reality indicates that China remains far from meeting the WHO&#x2019;s target, making the task of elimination particularly challenging.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EPrevious studies have concluded that HBV DNA seroclearance significantly reduces the risk of hepatocellular carcinoma (HCC) (\u003Ca href=\"#ref3\"\u003E3\u003C\u002Fa\u003E). However, these patients may still face the risk of reactivation. Among those with undetectable viral loads, patients with low serum HBsAg levels (&#x0003C;1,000&#x202F;IU\u002FmL) have the lowest risk of HCC (\u003Ca href=\"#ref4\"\u003E4\u003C\u002Fa\u003E). Thus, further HBsAg seroclearance is considered the best marker of HBV immune clearance. The 2022 Chinese Guidelines for the Prevention and Control of Chronic Hepatitis B emphasize that &#x201C;for some patients with suitable conditions, a cure for hepatitis B should be pursued.&#x201D; The guidelines further state that patients with undetectable HBV DNA, HBeAg conversion, and HBsAg &#x0003C;1,500&#x202F;IU\u002FmL after nucleotide analog (NA) treatment represent an advantageous population for achieving HBsAg clearance. These patients may be considered for additional treatment with polyethylene glycol interferon (Peg-IFN) in pursuit of a clinical cure (\u003Ca href=\"#ref5\"\u003E5\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EIn addition, non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease in both China and globally. The most recent data report the global prevalence of NAFLD to be 30% and rising (\u003Ca href=\"#ref6\"\u003E6\u003C\u002Fa\u003E, \u003Ca href=\"#ref7\"\u003E7\u003C\u002Fa\u003E). In 2020, the International Fatty Liver Nomenclature Panel redefined fatty liver in individuals with overweight\u002Fobesity, type 2 diabetes mellitus, or multiple metabolic disorders as metabolism-associated fatty liver disease (MAFLD) (\u003Ca href=\"#ref8\"\u003E8\u003C\u002Fa\u003E). In 2023, the European Annual Congress of Liver Diseases, along with the Liver Disease Associations of the United States, Europe, and Latin America, proposed that the alternative term for NAFLD should be metabolic dysfunction-associated steatohepatopathy (MASLD) (\u003Ca href=\"#ref9\"\u003E9\u003C\u002Fa\u003E). The prevalence of MAFLD in China was about 17.6% in 2016, with an estimated 246 million individuals affected, and is projected to rise to 29.1% by 2030, reaching 315 million cases, making MAFLD the most common chronic liver disease (\u003Ca href=\"#ref10\"\u003E10\u003C\u002Fa\u003E). The international expert consensus on metabolism-associated fatty liver disease notes that, with the dramatic global increase in MAFLD prevalence, it often coexists with other liver diseases, such as viral hepatitis. Large North American cohort studies have shown the prevalence of CHB combined with MAFLD to be 31.4% (\u003Ca href=\"#ref11\"\u003E11\u003C\u002Fa\u003E), while a single-center retrospective study in the Netherlands reported an increase from 17.2 to 24.3% in such patients (\u003Ca href=\"#ref12\"\u003E12\u003C\u002Fa\u003E). A recent meta-analysis of 53 studies found the prevalence of MAFLD in patients with CHB to be 32.83% (\u003Ca href=\"#ref13\"\u003E13\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EWhether MAFLD affects the antiviral efficacy of hepatitis B treatments, including HBV DNA suppression, HBeAg conversion, and HBsAg clearance, remains controversial. Most current studies focus on NA treatment, with goals primarily related to HBV DNA suppression and HBeAg conversion. However, research on HBsAg clearance, an indicator of clinical cure, is limited. Notably, the impact of MAFLD on achieving clinical cure in the Peg-IFN treatment-advantaged CHB population has not yet been reported and is in urgent need of investigation. Some studies suggest that the presence of MAFLD could potentially hinder the response to interferon therapy, possibly due to alterations in immune function or liver metabolism (\u003Ca href=\"#ref14\"\u003E14\u003C\u002Fa\u003E). However, the findings are inconsistent, with certain studies indicating no significant impact of MAFLD on Peg-IFN efficacy (\u003Ca href=\"#ref15\"\u003E15\u003C\u002Fa\u003E), while others suggest that MAFLD may contribute to reduced treatment efficacy or slower rates of HBsAg clearance (\u003Ca href=\"#ref16\"\u003E16\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003EThese conflicting results highlight a major gap in the current understanding of how MAFLD affects Peg-IFN therapy outcomes, particularly regarding HBsAg clearance, and underscore the need for further investigation. Our study aims to address this gap by evaluating the impact of MAFLD on the response to Peg-IFN treatment in chronic hepatitis B patients, specifically focusing on the achievement of HBsAg clearance as a marker of clinical cure. Additionally, the impact of hepatic steatosis on the immune status of CHB patients, such as T-lymphocyte function, has not been previously reported, and it remains unclear whether MAFLD affects clinical cure by influencing the immune status of the body.\u003C\u002Fp\u003E\n\u003Ch3\u003EObjectives\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EIn this study, a prospective clinical cohort of Peg-IFN-treated patients with advantageous CHB combined with MAFLD was established to verify the efficacy and safety of Peg-IFN in achieving HBsAg clearance. The study aims to elucidate the impact of MAFLD on HBsAg clearance in these patients and to provide practical guidance for clinicians in accurately screening suitable candidates and adjusting treatment regimens as needed. Flow cytometry was used to examine the number and function of peripheral blood T-lymphocytes expressing inhibitory receptors in both HBsAg-cleared and non-cleared patients at baseline and various time points during treatment. This was done to explore the characteristics of T-lymphocytes in CHB combined with MAFLD and to clarify the role of inhibitory receptor-expressing T-lymphocytes in HBsAg clearance. Additionally, single-cell transcriptome sequencing technology was applied to analyze changes in the gene expression profiles of immune cells in CHB patients with MAFLD treated with Peg-IFN, aiming to trace the genetic information profile changes in immune cells during HBsAg clearance and to explore the genetic-immunological mechanisms underlying HBsAg clearance.\u003C\u002Fp\u003E\n\u003Ch3\u003ETrial design\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EThis prospective study investigates the impact of MAFLD on HBsAg clearance in CHB patients treated with PEG-IFN (135ug\u002F180ug\u002Fweek for 48&#x202F;weeks). Patients are divided into two groups: CHB patients (\u003Ci\u003En\u003C\u002Fi\u003E&#x202F;=&#x202F;100) and CHB with MAFLD patients (\u003Ci\u003En\u003C\u002Fi\u003E&#x202F;=&#x202F;100). After treatment, participants are categorized into HBsAg clearance responders and non-responders. For HBsAg responders and HBsAg non-responders, analyzes differences in HBsAg clearance rates between CHB and CHB with MAFLD patients. Explores the impact of MAFLD on HBsAg clearance mechanisms using IHC and other methods. Compares the immunosuppressive microenvironment between responders and non-responders, focusing on T-cell characteristics. Identifies immune mechanisms contributing to HBsAg clearance. The flow chart of this study is shown in \u003Ca href=\"#fig1\"\u003EFigure 1\u003C\u002Fa\u003E.\u003C\u002Fp\u003E\n\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"Imageheaders\"\u003EFigure 1\u003C\u002Fdiv\u003E \u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g001.jpg\" name=\"figure1\" target=\"_blank\"\u003E\n  \u003Cpicture\u003E\n    \u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=480&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g001.jpg\" media=\"(max-width: 563px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=370&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g001.jpg\" media=\"(max-width: 1024px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=290&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g001.jpg\" media=\"(max-width: 1441px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=410&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g001.jpg\" media=\"\"\u003E\u003Csource type=\"image\u002Fjpg\" srcset=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g001.jpg\" media=\"\"\u003E \u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g001.jpg\" alt=\"www.frontiersin.org\" id=\"fig1\" loading=\"lazy\"\u003E\n  \u003C\u002Fpicture\u003E\n\u003C\u002Fa\u003E\n\u003Cp\u003E\u003Cb\u003EFigure 1\u003C\u002Fb\u003E. Flow chart of the research program.\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E \u003Ca id=\"h3\" name=\"h3\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EMethods: subjects, interventions, and outcomes\u003C\u002Fh2\u003E\n\u003Ch3\u003EStudy setting\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EThis prospective, multicenter, open cohort study will include HBV-infected patients from four large tertiary hospitals in North China. A total of 200 participants are planned, comprising 100 patients with CHB and 100 patients with CHB combined with MAFLD. We used the SPIRIT checklist when writing our report (\u003Ca href=\"#ref17\"\u003E17\u003C\u002Fa\u003E). The Institutional Review Board of Beijing You&#x2019;an Hospital affiliated with Capital Medical University approved the trial protocol (version 9.1, reference number LL-2024-051-K, dated May 10, 2024).\u003C\u002Fp\u003E\n\u003Ch3\u003EEligibility criteria\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EInclusion Criteria:\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;\"\u003E1. Chronic Hepatitis B (CHB): Meets the 2022 Guidelines for the Management of Chronic Hepatitis B: (1) HBsAg positive for &#x0003E;6&#x202F;months; (2) On NA treatment; (3) HBsAg &#x0003C;1,500&#x202F;IU\u002FmL; (4) HBeAg negative; (5) HBV DNA &#x0003C;10&#x202F;IU\u002FmL.\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;\"\u003E2. Metabolism-Associated Fatty Liver Disease (MAFLD):\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003E(1) Diagnosis of hepatic steatosis confirmed by abdominal ultrasound, Fibroscan, or liver steatosis measurement via MRI. Steatosis is categorized as mild, moderate, or severe based on the thresholds of the above tests. (2) Additionally, the patient must meet one of the following three conditions: &#x2460;. Overweight or obesity (BMI&#x202F;&#x02265;&#x202F;23&#x202F;kg\u002Fm\u003Csup\u003E2\u003C\u002Fsup\u003E); &#x02461;. Diabetes mellitus; &#x02462;. Lean or normal-weight patients meeting at least 2 metabolic abnormalities (e.g., \u003Ca href=\"#fig2\"\u003EFigure 2\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"Imageheaders\"\u003EFigure 2\u003C\u002Fdiv\u003E \u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g002.jpg\" name=\"figure2\" target=\"_blank\"\u003E\n  \u003Cpicture\u003E\n    \u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=480&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g002.jpg\" media=\"(max-width: 563px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=370&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g002.jpg\" media=\"(max-width: 1024px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=290&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g002.jpg\" media=\"(max-width: 1441px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=410&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g002.jpg\" media=\"\"\u003E\u003Csource type=\"image\u002Fjpg\" srcset=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g002.jpg\" media=\"\"\u003E \u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g002.jpg\" alt=\"www.frontiersin.org\" id=\"fig2\" loading=\"lazy\"\u003E\n  \u003C\u002Fpicture\u003E\n\u003C\u002Fa\u003E\n\u003Cp\u003E\u003Cb\u003EFigure 2\u003C\u002Fb\u003E. MAFLD diagnostic process and criteria.\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\n\u003Cp class=\"mb0\"\u003EExclusion Criteria: (1) Patients with combined HCV infection or autoimmune liver disease; (2) History of heavy alcohol consumption (alcohol intake &#x0003E;210&#x202F;g\u002Fday for men and&#x202F;&#x0003E;&#x202F;140&#x202F;g\u002Fday for women); (3) Drug-induced secondary hepatic steatosis (e.g., tamoxifen, hormones); (4) Pregnant or lactating women, and those planning to conceive shortly; (5) Patients with a history of or current cirrhosis or hepatocellular carcinoma; (6) Comorbidities with other serious diseases that may affect nutritional status, such as malignant tumors, severe cardiac, pulmonary, renal, or other organic or psychiatric diseases; (7) Neutrophil counts &#x0003C;2&#x202F;&#x000D7;&#x202F;10\u003Csup\u003E9\u003C\u002Fsup\u003E\u002FL and\u002For platelet counts &#x0003C;80&#x202F;&#x000D7;&#x202F;10\u003Csup\u003E9\u003C\u002Fsup\u003E\u002FL, and total bilirubin &#x0003E;34&#x202F;&#x03BC;mol\u002FL before treatment.\u003C\u002Fp\u003E\n\u003Ch3\u003EIntervention description\u003C\u002Fh3\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;\"\u003E1 Peg-IFN dosing:\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;\"\u003E(1) For patients with body weight&#x202F;&#x02265;&#x202F;70&#x202F;kg: 180&#x202F;&#x03BC;g once a week, subcutaneous injection.\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;\"\u003E(2) For patients with body weight&#x202F;&#x0003C;&#x202F;70&#x202F;kg: 135&#x202F;&#x03BC;g once a week, subcutaneous injection.\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;\"\u003E2 Duration:\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;\"\u003E(1) The treatment duration is 48&#x202F;weeks.\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;\"\u003E(2) If the patient achieves HBsAg serologic conversion (HBsAb &#x0003E;300&#x202F;IU\u002FL) and maintains this response for 24&#x202F;weeks, the treatment can be discontinued for observation, even if the full 48&#x202F;weeks have not been completed.\u003C\u002Fp\u003E\n\u003Ch3\u003ECriteria for discontinuing or modifying allocated interventions\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EDiscontinuation Due to Special Requirements: If the patient requires discontinuation of Peg-IFN due to special circumstances (e.g., trauma, surgery, personal preference), the treatment can be resumed once the conditions for using Peg-IFN are met again. Serious Adverse Events (SAEs): If SAEs occur, the necessity to discontinue Peg-IFN will be assessed, and treatment will be adjusted accordingly.\u003C\u002Fp\u003E\n\u003Ch3\u003EStrategies to improve adherence to the intervention\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EIn this study, we provided around-the-clock (24-h) health consultation services to ensure that patients could access professional support and guidance from healthcare providers at any time. Our team offered continuous attention and necessary assistance throughout the study, addressing a range of needs including study-related treatment guidance, management of adverse drug reactions, monitoring of virological breakthroughs, and general health inquiries from patients.\u003C\u002Fp\u003E\n\u003Ch3\u003ERelevant concomitant intervention permitted or prohibited during the trial\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EAdverse effects of PEG-IFN&#x03B1;-2b include transient, early-onset flu-like symptoms such as fatigue, fever, muscle aches, headache, chills, and joint pain, which typically resolve within a few days to a few weeks. Some patients may experience reduced appetite, nausea, abdominal pain, and diarrhea. Additional symptoms include dizziness, hair loss, weight loss, visual disturbances, dry and itchy skin, injection site discomfort, and rashes. Furthermore, patients may encounter cognitive and psychological issues, such as difficulty concentrating, memory impairment, anxiety, irritability, and sleep disorders. Temporary changes in laboratory parameters, including decreases in white blood cell, neutrophil, and platelet counts, as well as alterations in liver biochemical function, have also been observed. PEG-IFN&#x03B1;-2b can cause thyroid dysfunction, exacerbate diabetes, or induce certain immune system disorders. To address these adverse effects, a dedicated team conducts regular follow-ups and provides timely interventions. Management strategies for adverse effects may involve discontinuing therapy, dose modifications, or targeted supportive treatments for specific side effects.\u003C\u002Fp\u003E\n\u003Ch3\u003EOutcome\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EPrimary outcome indicators: 48-week HBsAg clearance rate. Secondary outcome indicators: 48-week HBsAg quantitative decline, HBV DNA undetectable rate, HBsAg serologic conversion rate, Peg-IFN adverse reactions.\u003C\u002Fp\u003E\n\u003Ch3\u003EParticipant timeline\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EA Case Report Form (CRF) form will be established and completed for each enrolled patient, with follow-up visits scheduled every 12&#x202F;weeks (&#x000B1;2&#x202F;weeks) at baseline and throughout the treatment period. Clinical symptoms and signs will be observed during each follow-up visit, and peripheral blood PBMC and plasma specimens will be collected and stored at &#x02212;80&#x000B0;C for future research. The clinical test items at the follow-up visit are shown in \u003Ca href=\"#fig3\"\u003EFigure 3\u003C\u002Fa\u003E.\u003C\u002Fp\u003E\n\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"Imageheaders\"\u003EFigure 3\u003C\u002Fdiv\u003E \u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g003.jpg\" name=\"figure3\" target=\"_blank\"\u003E\n  \u003Cpicture\u003E\n    \u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=480&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g003.jpg\" media=\"(max-width: 563px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=370&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g003.jpg\" media=\"(max-width: 1024px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=290&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g003.jpg\" media=\"(max-width: 1441px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=410&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g003.jpg\" media=\"\"\u003E\u003Csource type=\"image\u002Fjpg\" srcset=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g003.jpg\" media=\"\"\u003E \u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1546182\u002Ffpubh-13-1546182-HTML\u002Fimage_m\u002Ffpubh-13-1546182-g003.jpg\" alt=\"www.frontiersin.org\" id=\"fig3\" loading=\"lazy\"\u003E\n  \u003C\u002Fpicture\u003E\n\u003C\u002Fa\u003E\n\u003Cp\u003E\u003Cb\u003EFigure 3\u003C\u002Fb\u003E. Schedule of enrollment and follow-up.\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\n\u003Ch3\u003ESample size\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003ESince there are no existing literature reports on Peg-IFN treatment for combined MAFLD in the CHB-advantaged population, the sample size for this study is based on the results of our team&#x2019;s previous research. In that study, Peg-IFN treatment of CHB and CHB combined with MAFLD patients for 48&#x202F;weeks resulted in HBsAg clearance rates of 35 and 60%, respectively. Given the lack of established data in this specific population, we chose to use this estimate as it is reflective of our previous work, which involved similar patient profiles and treatment conditions. Setting the test level at \u003Ci\u003E&#x03B1;\u003C\u002Fi\u003E&#x202F;=&#x202F;0.05 and the power of the study (1-\u003Ci\u003E&#x03B2;\u003C\u002Fi\u003E) at 0.90, the required sample size was calculated using the test module for two independent sample rates in PASS 11.0. The calculation indicated that 79 patients should be enrolled in each group. Considering a 15% dropout rate, 92 participants are needed in each group, thus expanding the sample size to 100 cases per group.\u003C\u002Fp\u003E\n\u003Ch3\u003ERecruitment\u003C\u002Fh3\u003E\n\u003Cp class=\"mb15\"\u003EParticipants will be recruited from four medical centers in Beijing and Hebei, China: Beijing You&#x2019;an Hospital of Capital Medical University, Fifth Medical Center of General Hospital of the People&#x2019;s Liberation Army, Beijing Ditan Hospital of Capital Medical University, and Baoding People&#x2019;s Hospital. Each hospital will have a study coordinator to facilitate and coordinate the trial. Patients will be informed of the study&#x2019;s purpose, procedures, and potential risks and benefits. Written informed consent will be obtained from all participants. They will also be allowed to withdraw from the trial at any time without any consequences.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EPatients will be invited to participate in this study shortly after diagnosis. At the screening follow-up, a clinically experienced researcher (physician) will confirm eligibility for enrollment by reviewing symptoms, laboratory results, and imaging such as ultrasound or CT, ensuring that each inclusion and exclusion criterion is met. Recruitment will occur over 24&#x202F;months, from January 2024 to December 2025.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003ENo patients or members of the public other than professional clinicians and researchers were involved in the design, conduct, reporting, or dissemination plans for this study.\u003C\u002Fp\u003E \u003Ca id=\"h4\" name=\"h4\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EMethods: data collection, management, and analysis\u003C\u002Fh2\u003E\n\u003Ch3\u003EPlans for assessment and collection of outcomes\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EData will be collected using specially designed paper-based CRFs. Once completed, these forms will be entered into a database by designated personnel after prior data inspection. The Schedule of enrollment and follow-up (\u003Ca href=\"#fig3\"\u003EFigure 3\u003C\u002Fa\u003E) provides a detailed illustration of both the schedule and the specific nature of data collection required throughout the study period.\u003C\u002Fp\u003E\n\u003Ch3\u003EPlans to promote participant retention and complete follow-up\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EUpon study completion, if a patient achieves HBsAg seroclearance, this outcome is considered the optimal result approaching &#x201C;clinical cure,&#x201D; indicating significantly improved long-term prognosis. For such cases, our research team will develop a follow-up monitoring and health management plan to maintain the therapeutic effect. Conversely, if HBsAg seroclearance is not achieved, clinicians will tailor the treatment strategy based on the patient&#x2019;s specific health condition, aiming to optimize therapeutic outcomes and continue to control disease progression. Regardless of treatment outcomes, we are committed to providing patients with the most suitable personalized follow-up care to ensure they receive optimal health support.\u003C\u002Fp\u003E\n\u003Ch3\u003EData management\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EThe number of sample cases in this subject is large, and the nodes of retained specimens and test items are more, in order to ensure the uniformity and accuracy of the test, we take the following measures: in the process of specimen retention and separation, there are people responsible for the registration, sampling, separation of cells and serum, and freezing; specimens retained at different time nodes are uniformly detected by the specialized inspectors to ensure the reliability and accuracy of the test results. Trial data were collected and stored in accordance with GCP guidelines [China National Medical Products Administration, National Health Committee. Notice on the publication of Good Clinical Practice (no. 57 of 2020). April 26, 2020 (in Chinese). \u003Ca href=\"https:\u002F\u002Fwww.nmpa.gov.cn\u002Fdirectory\u002Fweb\u002Fnmpa\u002Fxxgk\u002Fggtg\u002Fypggtg\u002Fypqtggtg\u002F20200426162401243.html\"\u003Ehttps:\u002F\u002Fwww.nmpa.gov.cn\u002Fdirectory\u002Fweb\u002Fnmpa\u002Fxxgk\u002Fggtg\u002Fypggtg\u002Fypqtggtg\u002F20200426162401243.html\u003C\u002Fa\u003E]. Final approval of the research database will only be granted after successful implementation of these protocols has been confirmed.\u003C\u002Fp\u003E\n\u003Ch3\u003EStatistical methods for primary and secondary outcomes\u003C\u002Fh3\u003E\n\u003Ch4\u003EPrimary outcomes\u003C\u002Fh4\u003E\n\u003Cp class=\"mb0\"\u003EThe Kaplan&#x2013;Meier method was used to estimate the cumulative incidence of HBsAg seroclearance, and the log-rank test was used to compare the cumulative probabilities of different subgroups.\u003C\u002Fp\u003E\n\u003Ch4\u003ESecondary outcomes\u003C\u002Fh4\u003E\n\u003Cp class=\"mb0\"\u003EA linear mixed-effects model was employed to analyze the trends in HBsAg levels over time. Random effects were included to account for inter-individual variability among patients. Fixed effects in the model included time (measured in months), group classification (e.g., responder vs. non-responder, MASLD group vs. non-MASLD group, male vs. female), and the interaction between time and group classification. Additionally, marginal effects of changes in HBsAg levels over time for different groups were estimated using generalized estimating equations (GEE). This approach provided a comprehensive assessment of the temporal variation in HBsAg levels across various patient subgroups.\u003C\u002Fp\u003E\n\u003Ch3\u003EMethods for any additional analyses\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003ESPSS 27.0 statistical software was used for data analysis. Categorical variables were expressed as counts and percentages, while continuous variables were expressed as mean and standard deviation. Clinical data were statistically analyzed using the Kruskal-Wallis test. Variance homogeneity across groups was assessed for each test index. If the variance was homogeneous, the LSD method of one-way ANOVA was applied; if the variance was not homogeneous, the Kruskal-Wallis test was used for comparisons across multiple groups. For comparisons between the two groups, the Mann&#x2013;Whitney \u003Ci\u003EU\u003C\u002Fi\u003E test was employed. Immunological data, including HBsAg levels, HBV DNA titers, and immune marker levels (e.g., T-cell responses, cytokine profiles), will be analyzed using appropriate statistical methods based on the data distribution. Descriptive statistics (mean, SD, median, and IQR) will be used to summarize the data. For longitudinal analysis of immune markers (such as HBsAg clearance and T-cell responses) over the course of treatment, mixed-effects models will be employed to account for repeated measures and correlations within subjects. If immunological data are not normally distributed, non-parametric tests such as the Mann-Whitney U test (for comparisons between two independent groups) or the Kruskal-Wallis test (for comparisons across more than two groups) will be used. Cox proportional hazards regression will be utilized to assess the relationship between immunological markers (e.g., HBsAg clearance, T-cell response) and clinical outcomes, such as sustained HBsAg seroclearance or progression to clinical cure. In addition, we will conduct correlation analyses (Spearman&#x2019;s rank correlation) to explore potential associations between immune parameters (e.g., cytokine levels, T-cell counts) and clinical variables (e.g., liver function, ALT\u002FAST levels). A \u003Ci\u003Ep\u003C\u002Fi\u003E-value of &#x0003C;0.05 was considered statistically significant.\u003C\u002Fp\u003E\n\u003Ch3\u003EMethods used to analyze population and missing data\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EThe missing values of all variables were adjusted by applying Multiple Imputation (MI). If more than 15 per cent of data points are missing, sensitivity analyses of the main results are conducted using multiple imputation techniques. If the missing data is determined to be not missing at random (NMAR), we will explore sensitivity analyses to assess the impact of different assumptions about the missing data mechanism. We will also provide a drop-out analysis to evaluate any potential bias introduced by participant attrition.\u003C\u002Fp\u003E \u003Ca id=\"h5\" name=\"h5\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EMethods: monitoring\u003C\u002Fh2\u003E\n\u003Ch3\u003EData monitoring committee (DMC)\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EThis project adopts a three-tier management system involving the principal investigator, the hospital&#x2019;s Research Department, and the hospital leadership. The principal investigator is responsible for the implementation and management of the project, coordinating periodic inspections and supervision conducted by the Beijing Municipal Health Commission and the hospital. Regular progress reports will be submitted to the higher-level supervisory departments and the hospital&#x2019;s Research Department. Upon completion of the project, the principal investigator will assist relevant supervisory bodies in organizing the acceptance and conclusion of the project in accordance with the implementation plan.\u003C\u002Fp\u003E\n\u003Ch3\u003EInterim analyses\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EThe superior CHB cohort and the CHB combined MEFLD cohort continued to be maintained between 2025&#x2013;01 and 2025&#x2013;12. Regular follow-up observations were made every 12&#x202F;weeks to record HBsAg and HBsAb, HBeAg and HBV DNA data and adverse events. For some of those who completed 48&#x202F;weeks of antiviral therapy, the difference in efficacy between the two groups was initially analyzed.\u003C\u002Fp\u003E\n\u003Ch3\u003EAdverse event reporting\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EAll serious adverse events (SAEs) or unexpected incidents that may impact the safety or rights of study participants must be reported within 24&#x202F;h of detection by the research personnel at the study institution. A comprehensive incident report must be submitted to the principal investigator and the relevant regulatory authorities. Following the report, the coordinating center will oversee the initiation of an investigation by the Ethics Committee supervising drug-related affairs to determine the cause of the adverse event. All SAEs must be thoroughly documented in the participant&#x2019;s medical records or trial files. This documentation must be signed and dated by the investigator responsible for the participant to facilitate future audits and monitoring activities. Furthermore, all reported adverse events must be communicated to the Ethics Committee regularly, at intervals of 6&#x202F;months, in accordance with the specific requirements of the Ethics Committee.\u003C\u002Fp\u003E\n\u003Ch3\u003EFrequency and procedures for auditing trial conduct\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EIn this study, each participating research institution will assign two independent researchers to conduct an initial review and verification of the standardized reporting format (CRF) to ensure accuracy and completeness. Following the preliminary review, a data manager will perform centralized verification to identify and correct any discrepancies or errors, with assistance from clinical monitors before the data is finalized. Additionally, a designated auditor, independent of both the investigators and the principal investigator, will conduct regular audits of the standardized reporting format at each research institution. Throughout the trial, the CRFs will undergo routine review every 6&#x202F;months to ensure data integrity and compliance.\u003C\u002Fp\u003E \u003Ca id=\"h6\" name=\"h6\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EEthics and dissemination\u003C\u002Fh2\u003E\n\u003Ch3\u003EProtocol amendments and approvals\u003C\u002Fh3\u003E\n\u003Cp class=\"mb15\"\u003EAny changes to the study protocol that may affect the study&#x2019;s progress, the potential benefits to participants, or the safety of participants&#x2014;such as modifications to the study objectives, design, patient demographics, sample size, procedures, or significant management details&#x2014;must be formally revised. These amendments must receive approval from the Trial Steering Committee and the Ethics Committee before implementation.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003EModifications proposed due to trial execution must be submitted by the principal investigator and discussed with the Multicenter Coordination Committee. These proposed amendments should be documented and signed by the principal investigator and relevant centers. The modifications can only be implemented after receiving formal approval from the Ethics Committee.\u003C\u002Fp\u003E\n\u003Ch3\u003EInformed consent\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EIn this study, we will thoroughly communicate with the patients to emphasize the importance of antiviral treatment and the significant impact of HBsAg clearance on improving patient prognosis. Informed consent will be obtained from each patient.\u003C\u002Fp\u003E\n\u003Ch3\u003EAdditional consent provisions\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EPatients will be required to visit the hospital for assessments at baseline, Week 12, Week 24, Week 36, and Week 48 after enrollment. Routine examinations will include blood routine tests, liver function biochemistry, thyroid function, HBsAg quantification, and HBV DNA levels. Additionally, 20&#x202F;mL of blood will be collected for immunological and host genetic susceptibility marker analysis.\u003C\u002Fp\u003E\n\u003Ch3\u003EPatient medical record confidentiality\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EThe patient&#x2019;s medical records will be kept securely and in full at the hospital where the patient receives treatment. The physician will document the results of laboratory tests and examinations in the patient&#x2019;s medical records. Any public reports related to the results of this study will not disclose any personal information about the patients. We will make every effort, within the limits of the law, to protect the privacy of the patient&#x2019;s personal medical information.\u003C\u002Fp\u003E\n\u003Ch3\u003EFinancial management of research funds\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EIn strict accordance with the financial management regulations for research projects established by the Beijing Municipal Health Commission&#x2019;s First Fund, the use of research funds will be applied for by the project leader, signed, recorded by the hospital&#x2019;s research office, and approved by hospital leadership before being specifically allocated or reimbursed by the finance department. The project leader will regularly check and supervise the research progress and the usage of funds. Based on the project&#x2019;s implementation, the project leader will propose adjustments to the funding and submit them for review and filing with the hospital&#x2019;s finance department and research office.\u003C\u002Fp\u003E\n\u003Ch3\u003EManagement of adverse events and health changes during the study\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EIf, during the study, a patient experiences any discomfort, new changes in their condition, or any unexpected events, whether related to the study or not, they must promptly notify the relevant research center physician. The physician will assess the situation and provide appropriate medical treatment. The treatment measures may include discontinuation of medication, dose reduction, or other supportive therapies. Adverse reactions during interferon therapy are considered normal; most symptoms will resolve after appropriate management. The research team will closely monitor these reactions and provide timely and appropriate interventions.\u003C\u002Fp\u003E\n\u003Ch3\u003EPlan for dissemination of research findings\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EBy the applicant&#x2019;s previous research foundation and domestic and international literature, this prospective clinical study is expected to obtain a high HBsAg clearance rate, enable more patients with hepatitis B to obtain the clinical cure, greatly improve the prognosis of the patients, which can significantly reduce the transmission of HBV, reduce the incidence of cirrhosis and hepatocellular carcinoma, reduce the long-term expenditures, save more labor force, and create higher socio-economic benefits. It will provide evidence-based medical evidence for the updating of China&#x2019;s chronic hepatitis B prevention and treatment guidelines. The specific research area of this topic is attributed to viral hepatitis. One of the promotion methods is to promote the experience gained in clinical and basic research of PEG-IFN treatment of advantageous CHB to colleagues in the field of hepatology through academic lectures or international and domestic academic conference exchanges. Secondly, we will publish the important experience gained from our research in the form of papers for reference by our colleagues; thirdly, we will organize a workshop on hepatitis B antiviral treatment to promote our experience.\u003C\u002Fp\u003E \u003Ca id=\"h7\" name=\"h7\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EDiscussion\u003C\u002Fh2\u003E\n\u003Cp class=\"mb15\"\u003EThe prevalence of MAFLD is steadily increasing both in the general population and among patients with CHB worldwide. Although fatty liver is recognized as a risk factor for adverse liver outcomes, including cirrhosis and hepatocellular carcinoma, its interactions with HBV and the resulting clinical effects remain complex and not fully understood.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003ESome studies have identified fatty liver as an unfavorable factor affecting antiviral efficacy. In a study of 213 Chinese patients with CHB treated with entecavir (ETV), the rate of HBV DNA undetectability at 24&#x202F;weeks was significantly lower in patients with comorbid steatosis compared to those without hepatic steatosis (47.7% vs. 58.8%, \u003Ci\u003Ep\u003C\u002Fi\u003E&#x202F;=&#x202F;0.01) (\u003Ca href=\"#ref18\"\u003E18\u003C\u002Fa\u003E). Additionally, in a study of 89 HBeAg-positive CHB patients treated with Peg-IFN for 48&#x202F;weeks, those with comorbid steatosis had significantly lower HBV DNA undetectability rates 48&#x202F;weeks after discontinuation compared to those without steatosis. Multifactorial analysis showed that steatosis was an unfavorable factor for sustained viral response (OR&#x202F;=&#x202F;0.012, \u003Ci\u003Ep\u003C\u002Fi\u003E&#x202F;=&#x202F;0.02) (\u003Ca href=\"#ref19\"\u003E19\u003C\u002Fa\u003E). The EFFORT study suggests that new-onset and persistent MAFLD in patients with HBeAg-positive CHB treated with NA may counteract the benefits of antiviral therapy, reduce the rate of ALT normalization, and negatively influence fibrosis improvement (\u003Ca href=\"#ref20\"\u003E20\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EIn contrast, some studies have shown that patients with hepatic steatosis are more likely to achieve HBsAg clearance. The metabolic components and immune alterations associated with MAFLD progression may directly inhibit HBV replication or indirectly induce antiviral immune responses. In patients with chronic HBV infection, comorbid MAFLD has been found to inhibit HBV replication and is associated with spontaneous HBsAg clearance (\u003Ca href=\"#ref21\"\u003E21\u003C\u002Fa\u003E). An international multicenter randomized controlled study of 4,769 patients with treatment-na&#x000EF;ve CHB, treated with either entecavir (ETV) or tenofovir (TDF), with a median follow-up time of approximately 5.16&#x202F;years, found that 58 patients achieved HBsAg clearance, and hepatic steatosis was identified as a favorable factor for HBsAg clearance (HR&#x202F;=&#x202F;1.84) (\u003Ca href=\"#ref22\"\u003E22\u003C\u002Fa\u003E). Additionally, a previous study by our group showed that the 96-week HBsAg clearance rate was higher in inactive HBsAg carriers with moderate steatosis compared to those without steatosis (\u003Ca href=\"#ref23\"\u003E23\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EIn contrast, some studies have shown that steatosis is not associated with antiviral efficacy. In a retrospective study of 555 CHB patients treated with lamivudine (LAM), adefovir (ADV), entecavir (ETV), or tenofovir (TDF), multivariate analysis revealed no significant difference in HBV DNA suppression between patients with or without comorbid NAFLD (\u003Ca href=\"#ref24\"\u003E24\u003C\u002Fa\u003E). Another retrospective study from Taiwan involving 196 patients with HBeAg-positive CHB treated with NA monotherapy (LAM, ADV, LdT, ETV, or TDF) found that steatosis had no significant effect on HBeAg clearance (54.9% vs. 57.4%) (\u003Ca href=\"#ref25\"\u003E25\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EThere are differing conclusions and opinions on whether MAFLD affects antiviral efficacy. Most current studies have primarily focused on NA treatment, with therapeutic targets related to HBV DNA suppression and HBeAg conversion. However, studies on HBsAg clearance, the indicator of clinical cure, are rare. Notably, it remains unreported whether MAFLD affects the clinical cure in patients with predominantly CHB undergoing Peg-IFN treatment. This study aims to elucidate the impact of MAFLD on the clinical cure of dominant CHB patients, with the hope of guiding clinicians to more accurately screen suitable patients and promptly adjust treatment regimens.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003ET lymphocytes play a crucial role in the progression of HBV disease, including viral clearance, the development of hepatitis, cirrhosis, and hepatocellular carcinoma, as well as in response to antiviral therapy. CD8+ T cells are particularly important, as they can induce apoptosis in virus-infected hepatocytes. Additionally, they inhibit HBV gene expression and replication in hepatocytes through a non-cytolytic mechanism by secreting IFN-\u003Ci\u003E&#x03B3;\u003C\u002Fi\u003E. This dual function of CD8+ T cells&#x2014;mediating apoptosis and inhibiting viral replication&#x2014;highlights their essential role in controlling HBV infection. When HBV infection becomes chronic, T cells gradually become dysfunctional and lose their immune efficacy as the infection progresses and antigen exposure continues. This dysfunction is characterized by a decrease in the secretion of cytotoxic factors, such as IL-2, IFN-&#x03B3;, and TNF (\u003Ca href=\"#ref26\"\u003E26\u003C\u002Fa\u003E, \u003Ca href=\"#ref27\"\u003E27\u003C\u002Fa\u003E), and an increase in the secretion of immunosuppressive factors like IL-10 and transforming growth factor-beta (TGF-\u003Ci\u003E&#x03B2;\u003C\u002Fi\u003E). Additionally, there is increased expression of inhibitory receptors such as programmed death protein 1 (PD-1), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and T-cell immunoglobulin and mucin structural domain-3 (Tim-3) (\u003Ca href=\"#ref28\"\u003E28\u003C\u002Fa\u003E, \u003Ca href=\"#ref29\"\u003E29\u003C\u002Fa\u003E). Inhibitory receptors are likely the primary reason for the loss of T-lymphocyte function, leading to the body&#x2019;s inability to effectively clear HBV (\u003Ca href=\"#ref30\"\u003E30\u003C\u002Fa\u003E). A therapeutic strategy that rescues functionally exhausted T cells by blocking inhibitory receptor signaling pathways, thereby enhancing the immune response, could integrate immunotherapy with antiviral therapy. This approach holds promise as a reliable option for patients with chronic HBV infection to achieve a functional cure.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003ERecent studies have reported that hepatic CD8+ T cells in MAFLD mice may play a role in alleviating hepatic inflammation and fibrosis (\u003Ca href=\"#ref31\"\u003E31\u003C\u002Fa\u003E). Additionally, the number of peripheral blood Th1 cells in patients with MAFLD is significantly higher than in healthy individuals, leading to the hypothesis that Th1 cells may have a pro-inflammatory role (\u003Ca href=\"#ref32\"\u003E32\u003C\u002Fa\u003E). However, the state of T-lymphocyte immunocompetence in patients with CHB combined with MAFLD has not yet been reported.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EBased on a cohort of CHB or CHB-combined MAFLD patients receiving Peg-IFN antiviral therapy, along with a comprehensive clinical database and specimen bank, this study aims to investigate the number and function of T lymphocytes expressing inhibitory receptors in the peripheral blood of HBsAg-cleared and non-cleared patients at various time points, both at baseline and during treatment, using flow cytometry. The goal is to characterize the T-lymphocytes in patients with CHB combined with MAFLD, clarify the role of T lymphocytes expressing inhibitory receptors in HBsAg clearance, explore potential therapeutic targets, and provide insights for the development of new drugs aimed at achieving a clinical cure for hepatitis B.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003ESequencing of immune cells, such as T lymphocytes and DC cells, from liver cancer patients has revealed the characteristics of immune cells within the liver cancer environment, aiding in the development of more effective immunotherapeutic targets (\u003Ca href=\"#ref33\"\u003E33\u003C\u002Fa\u003E). However, the application of single-cell sequencing technology in populations with CHB combined with MAFLD has not yet been explored, particularly in investigating the mechanisms involved in HBsAg clearance. In this study, we aim to use transcriptome single-cell sequencing to explore the immunomolecular mechanisms of HBsAg clearance in CHB patients with MAFLD who are receiving Peg-IFN treatment. This approach will provide a multi-stage, dynamic, and high-resolution immune landscape of the HBsAg clearance process, clarify the gene regulation of immune cells during HBsAg clearance, uncover the immune cytogenetic basis of this clearance, and identify the molecular immunogenetic markers that determine successful HBsAg clearance. In addition, although this study has adopted a prospective and multicenter study protocol to reduce sampling and follow-up bias, there are still some limitations: (1) Given that the study is multicenter and cohort-based, there may be variability in treatment outcomes due to differences in patient populations, hospital settings, and clinician practices. While we aim to include a representative sample, the findings may not be generalizable to all HBV patients, particularly those outside of the study centers or those with more advanced liver disease. (2) The study relies on patient adherence to treatment protocols, including Peg-IFN therapy, and the potential for non-compliance or early dropout could impact the results, particularly the achievement of HBsAg clearance. (3) While we will attempt to control for common confounding factors such as age, gender, and baseline liver function, there may be other unmeasured factors (e.g., genetic predispositions, lifestyle habits, or co-infections) that could influence the treatment response and the success of Peg-IFN therapy.\u003C\u002Fp\u003E \u003Ca id=\"h8\" name=\"h8\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EExperimental state\u003C\u002Fh2\u003E\n\u003Cp class=\"mb15\"\u003EThe study has received all approvals from the Ethics Committee to start in all participating hospitals. The study was registered on May 28, 2024 (ChiCTR2400084913). Patient enrollment started on June 1, 2024.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003ETimeline and Milestones:\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003EBy December 2024:\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;\"\u003E(1) Develop and finalize various SOPs.\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;\"\u003E(2) Enroll eligible CHB patients.\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;\"\u003E(3) Peg-IFN combined with NA therapy should be administered to both the dominant CHB population and the CHB combined with MAFLD patients.\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;\"\u003E(4) Conduct regular follow-ups to monitor patient progress.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EJanuary 2025 to December 2025:\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EComplete the enrollment of all patients.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003EJanuary 2026 to December 2026:\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:1em;margin-bottom:0em;text-align:left;\"\u003E(1) Analyze and compare the number and function of inhibitory receptor T-lymphocytes between the two groups.\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;\"\u003E(2) Assess differences in HBsAg clearance rates.\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:0em;text-align:left;\"\u003E(3) Compare the number and function of inhibitory receptor T-lymphocytes between HBsAg-cleared and non-cleared patients.\u003C\u002Fp\u003E\n\u003Cp style=\"margin-left:1em;text-indent:-1em;margin-top:0em;margin-bottom:1em;text-align:left;\"\u003E(4) Use single-cell sequencing technology to analyze the mechanisms underlying HBsAg clearance.\u003C\u002Fp\u003E \u003Ca id=\"h9\" name=\"h9\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EEthics statement\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EThe studies involving humans were approved by Ethics Committee of Beijing You&#x2019;an Hospital affiliated with Capital Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.\u003C\u002Fp\u003E \u003Ca id=\"h10\" name=\"h10\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EAuthor contributions\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EDZ: Writing &#x2013; original draft. CZ: Conceptualization, Data curation, Resources, Writing &#x2013; review &#x00026; editing. LZ: Conceptualization, Data curation, Investigation, Writing &#x2013; review &#x00026; editing. JJ: Conceptualization, Investigation, Resources, Writing &#x2013; review &#x00026; editing. JF: Formal analysis, Methodology, Supervision, Writing &#x2013; review &#x00026; editing. ZC: Conceptualization, Data curation, Project administration, Writing &#x2013; review &#x00026; editing.\u003C\u002Fp\u003E \u003Ca id=\"h11\" name=\"h11\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EFunding\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EThe author(s) declare that financial support was received for the research and\u002For publication of this article. Capitals&#x2019;s Funds for Health Improvement and Research, No. 2024-1-2182.\u003C\u002Fp\u003E \u003Ca id=\"h12\" name=\"h12\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EAcknowledgments\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EThe study involves a range of disciplines including clinical practice, immunology, and molecular biology. Clinical experts will oversee patient recruitment, clinical treatment protocols, and management of coexisting conditions such as diabetes and obesity. Immunology and molecular biology specialists will be responsible for performing in-depth analyses of immune markers and evaluating their correlation with treatment response, as well as investigating genetic factors that may influence treatment outcomes and the molecular mechanisms of the interaction between HBV and MAFLD. These disciplines are critical to addressing the complexities of chronic hepatitis B (CHB) and metabolism-associated fatty liver disease (MAFLD). The research team is comprised of experts in these fields, and their collaborative efforts are critical to the success of the study.\u003C\u002Fp\u003E \u003Ca id=\"h13\" name=\"h13\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EConflict of interest\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C\u002Fp\u003E \u003Ca id=\"h14\" name=\"h14\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EGenerative AI statement\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EThe authors declare that no Gen AI was used in the creation of this manuscript.\u003C\u002Fp\u003E \u003Ca id=\"h15\" name=\"h15\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EPublisher&#x2019;s note\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EAll claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C\u002Fp\u003E \u003Ca id=\"h16\" name=\"h16\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EReferences\u003C\u002Fh2\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref1\" id=\"ref1\"\u003E\u003C\u002Fa\u003E1. Njuguna, HN, Hiebert, L, Harris, A, Morgan, RL, Gupta, N, and Ward, JW. An assessment of National Strategic Action Plans for viral hepatitis elimination, 2016-2021. \u003Ci\u003EJ Infect Dis\u003C\u002Fi\u003E. (2023) 228:S148&#x2013;s153. doi: 10.1093\u002Finfdis\u002Fjiad346 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37703342\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1093\u002Finfdis\u002Fjiad346\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=HN+Njuguna&#x00026;author=L+Hiebert&#x00026;author=A+Harris&#x00026;author=RL+Morgan&#x00026;author=N+Gupta&#x00026;author=JW+Ward&#x00026;publication_year=2023&#x00026;title=An+assessment+of+National+Strategic+Action+Plans+for+viral+hepatitis+elimination+2016-2021&#x00026;journal=J+Infect+Dis&#x00026;volume=228&#x00026;pages=S148-s153\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref2\" id=\"ref2\"\u003E\u003C\u002Fa\u003E2. Sandhu, HS, Roesel, S, Sharifuzzaman, M, Chunsuttiwat, S, and Tohme, RA. Progress toward hepatitis B control - South-East Asia region, 2016-2019. \u003Ci\u003EMMWR Morb Mortal Wkly Rep\u003C\u002Fi\u003E. (2020) 69:988&#x2013;92. doi: 10.15585\u002Fmmwr.mm6930a2 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32730237\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.15585\u002Fmmwr.mm6930a2\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=HS+Sandhu&#x00026;author=S+Roesel&#x00026;author=M+Sharifuzzaman&#x00026;author=S+Chunsuttiwat&#x00026;author=RA+Tohme&#x00026;publication_year=2020&#x00026;title=Progress+toward+hepatitis+B+control+-+South-East+Asia+region+2016-2019&#x00026;journal=MMWR+Morb+Mortal+Wkly+Rep&#x00026;volume=69&#x00026;pages=988-92\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref3\" id=\"ref3\"\u003E\u003C\u002Fa\u003E3. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. \u003Ci\u003EJ Viral Hepat\u003C\u002Fi\u003E. (2004) 11:97&#x2013;107. doi: 10.1046\u002Fj.1365-2893.2003.00487.x \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F14996343\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1046\u002Fj.1365-2893.2003.00487.x\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=D+Lavanchy&#x00026;publication_year=2004&#x00026;title=Hepatitis+B+virus+epidemiology+disease+burden+treatment+and+current+and+emerging+prevention+and+control+measures&#x00026;journal=J+Viral+Hepat&#x00026;volume=11&#x00026;pages=97-107\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref4\" id=\"ref4\"\u003E\u003C\u002Fa\u003E4. Liu, J, Yang, HI, Lee, MH, Lu, SN, Jen, CL, Batrla-Utermann, R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. \u003Ci\u003EGut\u003C\u002Fi\u003E. (2014) 63:1648&#x2013;57. doi: 10.1136\u002Fgutjnl-2013-305785 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F24225939\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1136\u002Fgutjnl-2013-305785\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=J+Liu&#x00026;author=HI+Yang&#x00026;author=MH+Lee&#x00026;author=SN+Lu&#x00026;author=CL+Jen&#x00026;author=R+Batrla-Utermann&#x00026;publication_year=2014&#x00026;title=Spontaneous+seroclearance+of+hepatitis+B+seromarkers+and+subsequent+risk+of+hepatocellular+carcinoma&#x00026;journal=Gut&#x00026;volume=63&#x00026;pages=1648-57\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref5\" id=\"ref5\"\u003E\u003C\u002Fa\u003E5. Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). \u003Ci\u003EZhonghua Gan Zang Bing Za Zhi\u003C\u002Fi\u003E. (2022) 30:1309&#x2013;31. doi: 10.3760\u002Fcma.j.cn501113-20221204-00607\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.3760\u002Fcma.j.cn501113-20221204-00607\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?publication_year=2022&#x00026;title=Guidelines+for+the+prevention+and+treatment+of+chronic+hepatitis+B+(version+2022)&#x00026;journal=Zhonghua+Gan+Zang+Bing+Za+Zhi&#x00026;volume=30&#x00026;pages=1309-31\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref6\" id=\"ref6\"\u003E\u003C\u002Fa\u003E6. Younossi, ZM, Golabi, P, Paik, JM, Henry, A, Van Dongen, C, and Henry, L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. \u003Ci\u003EHepatology\u003C\u002Fi\u003E. (2023) 77:1335&#x2013;47. doi: 10.1097\u002Fhep.0000000000000004 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F36626630\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1097\u002Fhep.0000000000000004\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=ZM+Younossi&#x00026;author=P+Golabi&#x00026;author=JM+Paik&#x00026;author=A+Henry&#x00026;author=C+Van+Dongen&#x00026;author=L+Henry&#x00026;publication_year=2023&#x00026;title=The+global+epidemiology+of+nonalcoholic+fatty+liver+disease+(NAFLD)+and+nonalcoholic+steatohepatitis+(NASH):+a+systematic+review&#x00026;journal=Hepatology&#x00026;volume=77&#x00026;pages=1335-47\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref7\" id=\"ref7\"\u003E\u003C\u002Fa\u003E7. Quek, J, Chan, KE, Wong, ZY, Tan, C, Tan, B, Lim, WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. \u003Ci\u003ELancet Gastroenterol Hepatol\u003C\u002Fi\u003E. (2023) 8:20&#x2013;30. doi: 10.1016\u002Fs2468-1253(22)00317-x \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F36400097\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs2468-1253(22)00317-x\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=J+Quek&#x00026;author=KE+Chan&#x00026;author=ZY+Wong&#x00026;author=C+Tan&#x00026;author=B+Tan&#x00026;author=WH+Lim&#x00026;publication_year=2023&#x00026;title=Global+prevalence+of+non-alcoholic+fatty+liver+disease+and+non-alcoholic+steatohepatitis+in+the+overweight+and+obese+population:+a+systematic+review+and+meta-analysis&#x00026;journal=Lancet+Gastroenterol+Hepatol&#x00026;volume=8&#x00026;pages=20-30\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref8\" id=\"ref8\"\u003E\u003C\u002Fa\u003E8. Eslam, M, Newsome, PN, Sarin, SK, Anstee, QM, Targher, G, Romero-Gomez, M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. \u003Ci\u003EJ Hepatol\u003C\u002Fi\u003E. (2020) 73:202&#x2013;9. doi: 10.1016\u002Fj.jhep.2020.03.039 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32278004\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jhep.2020.03.039\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=M+Eslam&#x00026;author=PN+Newsome&#x00026;author=SK+Sarin&#x00026;author=QM+Anstee&#x00026;author=G+Targher&#x00026;author=M+Romero-Gomez&#x00026;publication_year=2020&#x00026;title=A+new+definition+for+metabolic+dysfunction-associated+fatty+liver+disease:+an+international+expert+consensus+statement&#x00026;journal=J+Hepatol&#x00026;volume=73&#x00026;pages=202-9\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref9\" id=\"ref9\"\u003E\u003C\u002Fa\u003E9. Rinella, ME, Lazarus, JV, Ratziu, V, Francque, SM, Sanyal, AJ, Kanwal, F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. \u003Ci\u003EJ Hepatol\u003C\u002Fi\u003E. (2023) 79:1542&#x2013;56. doi: 10.1016\u002Fj.jhep.2023.06.003 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37364790\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jhep.2023.06.003\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=ME+Rinella&#x00026;author=JV+Lazarus&#x00026;author=V+Ratziu&#x00026;author=SM+Francque&#x00026;author=AJ+Sanyal&#x00026;author=F+Kanwal&#x00026;publication_year=2023&#x00026;title=A+multisociety+Delphi+consensus+statement+on+new+fatty+liver+disease+nomenclature&#x00026;journal=J+Hepatol&#x00026;volume=79&#x00026;pages=1542-56\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref10\" id=\"ref10\"\u003E\u003C\u002Fa\u003E10. Younossi, ZM, Koenig, AB, Abdelatif, D, Fazel, Y, Henry, L, and Wymer, M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. \u003Ci\u003EHepatology\u003C\u002Fi\u003E. (2016) 64:73&#x2013;84. doi: 10.1002\u002Fhep.28431 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26707365\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1002\u002Fhep.28431\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=ZM+Younossi&#x00026;author=AB+Koenig&#x00026;author=D+Abdelatif&#x00026;author=Y+Fazel&#x00026;author=L+Henry&#x00026;author=M+Wymer&#x00026;publication_year=2016&#x00026;title=Global+epidemiology+of+nonalcoholic+fatty+liver+disease-Meta-analytic+assessment+of+prevalence+incidence+and+outcomes&#x00026;journal=Hepatology&#x00026;volume=64&#x00026;pages=73-84\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref11\" id=\"ref11\"\u003E\u003C\u002Fa\u003E11. Khalili, M, Kleiner, DE, King, WC, Sterling, RK, Ghany, MG, Chung, RT, et al. Hepatic steatosis and steatohepatitis in a large north American cohort of adults with chronic hepatitis B. \u003Ci\u003EAm J Gastroenterol\u003C\u002Fi\u003E. (2021) 116:1686&#x2013;97. doi: 10.14309\u002Fajg.0000000000001257 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33840726\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.14309\u002Fajg.0000000000001257\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=M+Khalili&#x00026;author=DE+Kleiner&#x00026;author=WC+King&#x00026;author=RK+Sterling&#x00026;author=MG+Ghany&#x00026;author=RT+Chung&#x00026;publication_year=2021&#x00026;title=Hepatic+steatosis+and+steatohepatitis+in+a+large+north+American+cohort+of+adults+with+chronic+hepatitis+B&#x00026;journal=Am+J+Gastroenterol&#x00026;volume=116&#x00026;pages=1686-97\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref12\" id=\"ref12\"\u003E\u003C\u002Fa\u003E12. van der Spek, DPC, Katwaroe, WK, van Kleef, LA, Brakenhoff, S, de Man, RA, de Knegt, RJ, et al. Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020. \u003Ci\u003EEur J Intern Med\u003C\u002Fi\u003E. (2023) 107:86&#x2013;92. doi: 10.1016\u002Fj.ejim.2022.11.012 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F36396524\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ejim.2022.11.012\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=DPC+van+der+Spek&#x00026;author=WK+Katwaroe&#x00026;author=LA+van+Kleef&#x00026;author=S+Brakenhoff&#x00026;author=RA+de+Man&#x00026;author=RJ+de+Knegt&#x00026;publication_year=2023&#x00026;title=Time-trends+in+disease+characteristics+and+comorbidities+in+patients+with+chronic+hepatitis+B+in+the+period+1980-2020&#x00026;journal=Eur+J+Intern+Med&#x00026;volume=107&#x00026;pages=86-92\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref13\" id=\"ref13\"\u003E\u003C\u002Fa\u003E13. Zheng, Q, Zou, B, Wu, Y, Yeo, Y, Wu, H, Stave, CD, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. \u003Ci\u003EAliment Pharmacol Ther\u003C\u002Fi\u003E. (2021) 54:1100&#x2013;9. doi: 10.1111\u002Fapt.16595 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F34469587\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1111\u002Fapt.16595\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=Q+Zheng&#x00026;author=B+Zou&#x00026;author=Y+Wu&#x00026;author=Y+Yeo&#x00026;author=H+Wu&#x00026;author=CD+Stave&#x00026;publication_year=2021&#x00026;title=Systematic+review+with+meta-analysis:+prevalence+of+hepatic+steatosis+fibrosis+and+associated+factors+in+chronic+hepatitis+B&#x00026;journal=Aliment+Pharmacol+Ther&#x00026;volume=54&#x00026;pages=1100-9\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref14\" id=\"ref14\"\u003E\u003C\u002Fa\u003E14. Enomoto, H, Aizawa, N, Hasegawa, K, Ikeda, N, Sakai, Y, Yoh, K, et al. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients. \u003Ci\u003EInt J Mol Sci\u003C\u002Fi\u003E (2020) 21 (In eng). doi: 10.3390\u002Fijms21093089\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.3390\u002Fijms21093089\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=H+Enomoto&#x00026;author=N+Aizawa&#x00026;author=K+Hasegawa&#x00026;author=N+Ikeda&#x00026;author=Y+Sakai&#x00026;author=K+Yoh&#x00026;publication_year=2020&#x00026;title=Possible+Relevance+of+PNPLA3+and+TLL1+Gene+Polymorphisms+to+the+Efficacy+of+PEG-IFN+Therapy+for+HBV-Infected+Patients&#x00026;journal=Int+J+Mol+Sci&#x00026;\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref15\" id=\"ref15\"\u003E\u003C\u002Fa\u003E15. Zhong, W, Wang, C, Wang, J, and Chen, T. Machine learning models to further identify advantaged populations that can achieve functional cure of chronic hepatitis B virus infection after receiving Peg-IFN alpha treatment. \u003Ci\u003EInt J Med Inform\u003C\u002Fi\u003E (2025) 193:105660. (In eng). doi: 10.1016\u002Fj.ijmedinf.2024.105660\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijmedinf.2024.105660\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=W+Zhong&#x00026;author=C+Wang&#x00026;author=J+Wang&#x00026;author=T+Chen&#x00026;publication_year=2025&#x00026;title=Machine+learning+models+to+further+identify+advantaged+populations+that+can+achieve+functional+cure+of+chronic+hepatitis+B+virus+infection+after+receiving+Peg-IFN+alpha+treatment&#x00026;journal=Int+J+Med+Inform&#x00026;volume=193&#x00026;pages=105660\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref16\" id=\"ref16\"\u003E\u003C\u002Fa\u003E16. Liang, H, Liu, Y, Jiang, X, Zheng, X, Tang, J, Yang, J, et al. Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFN&#x03B1;-2a in Patients with Chronic Hepatitis B and the Associated Mechanism. \u003Ci\u003EGastroenterol Res Pract\u003C\u002Fi\u003E (2020) 2020:1794769. (In eng). doi: 10.1155\u002F2020\u002F1794769\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1155\u002F2020\u002F1794769\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=H+Liang&#x00026;author=Y+Liu&#x00026;author=X+Jiang&#x00026;author=X+Zheng&#x00026;author=J+Tang&#x00026;author=J+Yang&#x00026;publication_year=2020&#x00026;title=Impact+of+Hepatic+Steatosis+on+the+Antiviral+Effects+of+PEG-IFN&#x03B1;-2a+in+Patients+with+Chronic+Hepatitis+B+and+the+Associated+Mechanism&#x00026;journal=Gastroenterol+Res+Pract&#x00026;volume=2020&#x00026;pages=1794769\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref17\" id=\"ref17\"\u003E\u003C\u002Fa\u003E17. Chan, AW, Tetzlaff, JM, G&#x000F8;tzsche, PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. \u003Ci\u003EBMJ\u003C\u002Fi\u003E. (2013) 346:e7586. doi: 10.1136\u002Fbmj.e7586 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F23303884\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1136\u002Fbmj.e7586\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=AW+Chan&#x00026;author=JM+Tetzlaff&#x00026;author=PC+G&#x000F8;tzsche&#x00026;publication_year=2013&#x00026;title=SPIRIT+2013+explanation+and+elaboration:+guidance+for+protocols+of+clinical+trials&#x00026;journal=BMJ&#x00026;volume=346&#x00026;pages=e7586\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref18\" id=\"ref18\"\u003E\u003C\u002Fa\u003E18. Jin, X, Chen, YP, Yang, YD, Li, YM, Zheng, L, and Xu, CQ. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. \u003Ci\u003EPLoS One\u003C\u002Fi\u003E. (2012) 7:e34198. doi: 10.1371\u002Fjournal.pone.0034198 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F22479562\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0034198\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=X+Jin&#x00026;author=YP+Chen&#x00026;author=YD+Yang&#x00026;author=YM+Li&#x00026;author=L+Zheng&#x00026;author=CQ+Xu&#x00026;publication_year=2012&#x00026;title=Association+between+hepatic+steatosis+and+entecavir+treatment+failure+in+Chinese+patients+with+chronic+hepatitis+B&#x00026;journal=PLoS+One&#x00026;volume=7&#x00026;pages=e34198\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref19\" id=\"ref19\"\u003E\u003C\u002Fa\u003E19. Gong, L, Liu, J, Wang, J, Lou, GQ, and Shi, JP. Hepatic steatosis as a predictive factor of antiviral effect of Pegylated interferon therapy in patients with hepatitis B. \u003Ci\u003ETransplant Proc\u003C\u002Fi\u003E. (2015) 47:2886&#x2013;91. doi: 10.1016\u002Fj.transproceed.2015.10.023 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26707308\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.transproceed.2015.10.023\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=L+Gong&#x00026;author=J+Liu&#x00026;author=J+Wang&#x00026;author=GQ+Lou&#x00026;author=JP+Shi&#x00026;publication_year=2015&#x00026;title=Hepatic+steatosis+as+a+predictive+factor+of+antiviral+effect+of+Pegylated+interferon+therapy+in+patients+with+hepatitis+B&#x00026;journal=Transplant+Proc&#x00026;volume=47&#x00026;pages=2886-91\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref20\" id=\"ref20\"\u003E\u003C\u002Fa\u003E20. Tang, Y, Fan, R, Lan, Z, Xie, Q, Zhang, J, Liang, X, et al. Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B. \u003Ci\u003EJ Med Virol\u003C\u002Fi\u003E. (2023) 95:e28501. doi: 10.1002\u002Fjmv.28501 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F36655747\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1002\u002Fjmv.28501\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=Y+Tang&#x00026;author=R+Fan&#x00026;author=Z+Lan&#x00026;author=Q+Xie&#x00026;author=J+Zhang&#x00026;author=X+Liang&#x00026;publication_year=2023&#x00026;title=Impact+of+nonalcoholic+fatty+liver+disease+status+change+on+antiviral+efficacy+of+nucleos(t)ide+analogues+in+HBeAg-positive+chronic+hepatitis+B&#x00026;journal=J+Med+Virol&#x00026;volume=95&#x00026;pages=e28501\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref21\" id=\"ref21\"\u003E\u003C\u002Fa\u003E21. Liu, L, Li, H, Zhang, Y, Zhang, J, and Cao, Z. Hepatitis B virus infection combined with nonalcoholic fatty liver disease: interaction and prognosis. \u003Ci\u003EHeliyon\u003C\u002Fi\u003E. (2023) 9:e13113. doi: 10.1016\u002Fj.heliyon.2023.e13113 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F36747946\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.heliyon.2023.e13113\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=L+Liu&#x00026;author=H+Li&#x00026;author=Y+Zhang&#x00026;author=J+Zhang&#x00026;author=Z+Cao&#x00026;publication_year=2023&#x00026;title=Hepatitis+B+virus+infection+combined+with+nonalcoholic+fatty+liver+disease:+interaction+and+prognosis&#x00026;journal=Heliyon&#x00026;volume=9&#x00026;pages=e13113\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref22\" id=\"ref22\"\u003E\u003C\u002Fa\u003E22. Hsu, YC, Yeh, ML, Wong, GL, et al. Incidences and determinants of functional cure during Entecavir or Tenofovir Disoproxil fumarate for chronic hepatitis B. \u003Ci\u003EJ Infect Dis\u003C\u002Fi\u003E. (2021) 224:1890&#x2013;9. doi: 10.1093\u002Finfdis\u002Fjiab241 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33999179\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1093\u002Finfdis\u002Fjiab241\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=YC+Hsu&#x00026;author=ML+Yeh&#x00026;author=GL+Wong&#x00026;publication_year=2021&#x00026;title=Incidences+and+determinants+of+functional+cure+during+Entecavir+or+Tenofovir+Disoproxil+fumarate+for+chronic+hepatitis+B&#x00026;journal=J+Infect+Dis&#x00026;volume=224&#x00026;pages=1890-9\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref23\" id=\"ref23\"\u003E\u003C\u002Fa\u003E23. Li, H, Liang, S, Liu, L, Zhou, D, Liu, Y, Zhang, Y, et al. Clinical cure rate of inactive HBsAg carriers with HBsAg &#x0003C;200 IU\u002Fml treated with pegylated interferon. \u003Ci\u003EFront Immunol\u003C\u002Fi\u003E. (2022) 13:1091786. doi: 10.3389\u002Ffimmu.2022.1091786 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F36618361\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffimmu.2022.1091786\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=H+Li&#x00026;author=S+Liang&#x00026;author=L+Liu&#x00026;author=D+Zhou&#x00026;author=Y+Liu&#x00026;author=Y+Zhang&#x00026;publication_year=2022&#x00026;title=Clinical+cure+rate+of+inactive+HBsAg+carriers+with+HBsAg+&#x0003C;200+IU\u002Fml+treated+with+pegylated+interferon&#x00026;journal=Front+Immunol&#x00026;volume=13&#x00026;pages=1091786\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref24\" id=\"ref24\"\u003E\u003C\u002Fa\u003E24. Li, J, Le, AK, Chaung, KT, et al. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. \u003Ci\u003ELiver Int\u003C\u002Fi\u003E. (2020) 40:1052&#x2013;61. doi: 10.1111\u002Fliv.14415 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32086988\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1111\u002Fliv.14415\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=J+Li&#x00026;author=AK+Le&#x00026;author=KT+Chaung&#x00026;publication_year=2020&#x00026;title=Fatty+liver+is+not+independently+associated+with+the+rates+of+complete+response+to+oral+antiviral+therapy+in+chronic+hepatitis+B+patients&#x00026;journal=Liver+Int&#x00026;volume=40&#x00026;pages=1052-61\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref25\" id=\"ref25\"\u003E\u003C\u002Fa\u003E25. Chen, YC, Jeng, WJ, Hsu, CW, and Lin, CY. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. \u003Ci\u003EBMC Gastroenterol\u003C\u002Fi\u003E. (2020) 20:146. doi: 10.1186\u002Fs12876-020-01289-w \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32397963\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12876-020-01289-w\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=YC+Chen&#x00026;author=WJ+Jeng&#x00026;author=CW+Hsu&#x00026;author=CY+Lin&#x00026;publication_year=2020&#x00026;title=Impact+of+hepatic+steatosis+on+treatment+response+in+nuclesos(t)ide+analogue-treated+HBeAg-positive+chronic+hepatitis+B:+a+retrospective+study&#x00026;journal=BMC+Gastroenterol&#x00026;volume=20&#x00026;pages=146\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref26\" id=\"ref26\"\u003E\u003C\u002Fa\u003E26. Wherry, EJ. T cell exhaustion. \u003Ci\u003ENat Immunol\u003C\u002Fi\u003E. (2011) 12:492&#x2013;9. doi: 10.1038\u002Fni.2035 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F21739672\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fni.2035\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=EJ+Wherry&#x00026;publication_year=2011&#x00026;title=T+cell+exhaustion&#x00026;journal=Nat+Immunol&#x00026;volume=12&#x00026;pages=492-9\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref27\" id=\"ref27\"\u003E\u003C\u002Fa\u003E27. Wherry, EJ, and Kurachi, M. Molecular and cellular insights into T cell exhaustion. \u003Ci\u003ENat Rev Immunol\u003C\u002Fi\u003E. (2015) 15:486&#x2013;99. doi: 10.1038\u002Fnri3862 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26205583\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnri3862\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=EJ+Wherry&#x00026;author=M+Kurachi&#x00026;publication_year=2015&#x00026;title=Molecular+and+cellular+insights+into+T+cell+exhaustion&#x00026;journal=Nat+Rev+Immunol&#x00026;volume=15&#x00026;pages=486-99\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref28\" id=\"ref28\"\u003E\u003C\u002Fa\u003E28. Blackburn, SD, Shin, H, Haining, WN, Zou, T, Workman, CJ, Polley, A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. \u003Ci\u003ENat Immunol\u003C\u002Fi\u003E. (2009) 10:29&#x2013;37. doi: 10.1038\u002Fni.1679 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F19043418\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fni.1679\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=SD+Blackburn&#x00026;author=H+Shin&#x00026;author=WN+Haining&#x00026;author=T+Zou&#x00026;author=CJ+Workman&#x00026;author=A+Polley&#x00026;publication_year=2009&#x00026;title=Coregulation+of+CD8++T+cell+exhaustion+by+multiple+inhibitory+receptors+during+chronic+viral+infection&#x00026;journal=Nat+Immunol&#x00026;volume=10&#x00026;pages=29-37\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref29\" id=\"ref29\"\u003E\u003C\u002Fa\u003E29. Crawford, A, and Wherry, EJ. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. \u003Ci\u003ECurr Opin Immunol\u003C\u002Fi\u003E. (2009) 21:179&#x2013;86. doi: 10.1016\u002Fj.coi.2009.01.010 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F19264470\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.coi.2009.01.010\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=A+Crawford&#x00026;author=EJ+Wherry&#x00026;publication_year=2009&#x00026;title=The+diversity+of+costimulatory+and+inhibitory+receptor+pathways+and+the+regulation+of+antiviral+T+cell+responses&#x00026;journal=Curr+Opin+Immunol&#x00026;volume=21&#x00026;pages=179-86\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref30\" id=\"ref30\"\u003E\u003C\u002Fa\u003E30. Keam, SJ. Tremelimumab: First Approval. \u003Ci\u003EDrugs\u003C\u002Fi\u003E. (2023) 83:93&#x2013;102. doi: 10.1007\u002Fs40265-022-01827-8 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F36571670\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs40265-022-01827-8\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=SJ+Keam&#x00026;publication_year=2023&#x00026;title=Tremelimumab:+First+Approval&#x00026;journal=Drugs&#x00026;volume=83&#x00026;pages=93-102\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref31\" id=\"ref31\"\u003E\u003C\u002Fa\u003E31. Koda, Y, Teratani, T, Chu, PS, Hagihara, Y, Mikami, Y, Harada, Y, et al. CD8(+) tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells. \u003Ci\u003ENat Commun\u003C\u002Fi\u003E. (2021) 12:4474. doi: 10.1038\u002Fs41467-021-24734-0 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F34294714\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41467-021-24734-0\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=Y+Koda&#x00026;author=T+Teratani&#x00026;author=PS+Chu&#x00026;author=Y+Hagihara&#x00026;author=Y+Mikami&#x00026;author=Y+Harada&#x00026;publication_year=2021&#x00026;title=CD8(+)+tissue-resident+memory+T+cells+promote+liver+fibrosis+resolution+by+inducing+apoptosis+of+hepatic+stellate+cells&#x00026;journal=Nat+Commun&#x00026;volume=12&#x00026;pages=4474\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref32\" id=\"ref32\"\u003E\u003C\u002Fa\u003E32. Rau, M, Schilling, AK, Meertens, J, Hering, I, Weiss, J, Jurowich, C, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\u002Fresting regulatory T cell ratio in peripheral blood and in the liver. \u003Ci\u003EJ Immunol\u003C\u002Fi\u003E. (2016) 196:97&#x2013;105. doi: 10.4049\u002Fjimmunol.1501175 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26621860\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.4049\u002Fjimmunol.1501175\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=M+Rau&#x00026;author=AK+Schilling&#x00026;author=J+Meertens&#x00026;author=I+Hering&#x00026;author=J+Weiss&#x00026;author=C+Jurowich&#x00026;publication_year=2016&#x00026;title=Progression+from+nonalcoholic+fatty+liver+to+nonalcoholic+steatohepatitis+is+marked+by+a+higher+frequency+of+Th17+cells+in+the+liver+and+an+increased+Th17\u002Fresting+regulatory+T+cell+ratio+in+peripheral+blood+and+in+the+liver&#x00026;journal=J+Immunol&#x00026;volume=196&#x00026;pages=97-105\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref33\" id=\"ref33\"\u003E\u003C\u002Fa\u003E33. Sun, Y, Wu, L, Zhong, Y, Zhou, K, Hou, Y, Wang, Z, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. \u003Ci\u003ECell\u003C\u002Fi\u003E. (2021) 184:404&#x2013;421.e16. doi: 10.1016\u002Fj.cell.2020.11.041 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33357445\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.cell.2020.11.041\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=Y+Sun&#x00026;author=L+Wu&#x00026;author=Y+Zhong&#x00026;author=K+Zhou&#x00026;author=Y+Hou&#x00026;author=Z+Wang&#x00026;publication_year=2021&#x00026;title=Single-cell+landscape+of+the+ecosystem+in+early-relapse+hepatocellular+carcinoma&#x00026;journal=Cell&#x00026;volume=184&#x00026;pages=404-421.e16\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003C\u002Fdiv\u003E \u003Cdiv class=\"thinLineM20\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"AbstractSummary\"\u003E\n\u003Cp\u003E\u003Cspan\u003EKeywords:\u003C\u002Fspan\u003E hepatitis B virus, chronic hepatitis B, metabolism-associated fatty liver disease, peginterferon, HBsAg clearance, clinical cure\u003C\u002Fp\u003E\n\u003Cp\u003E\u003Cspan\u003ECitation:\u003C\u002Fspan\u003E Zhou D, Zhang C, Zhang L, Jia J, Fu J and Cao Z (2025) A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure. \u003Ci\u003EFront. Public Health\u003C\u002Fi\u003E. 13:1546182. doi: 10.3389\u002Ffpubh.2025.1546182\u003C\u002Fp\u003E\n\u003Cp class=\"timestamps\"\u003E\u003Cspan\u003EReceived:\u003C\u002Fspan\u003E 16 December 2024; \u003Cspan\u003EAccepted:\u003C\u002Fspan\u003E 17 February 2025;\u003Cbr\u003E \u003Cspan\u003EPublished:\u003C\u002Fspan\u003E 14 March 2025.\u003C\u002Fp\u003E \u003Cdiv\u003E\n\u003Cp\u003EEdited by:\u003C\u002Fp\u003E \u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1702500\u002Foverview\"\u003ERitthideach Yorsaeng\u003C\u002Fa\u003E, Chulalongkorn University, Thailand\u003C\u002Fdiv\u003E \u003Cdiv\u003E\n\u003Cp\u003EReviewed by:\u003C\u002Fp\u003E \u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1434331\u002Foverview\"\u003EWenjun Wang\u003C\u002Fa\u003E, Xi&#x2019;an Jiaotong University, China\u003Cbr\u003E \u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1652166\u002Foverview\"\u003EXu Liang\u003C\u002Fa\u003E, Tianjin Second People&#x2019;s Hospital, China\u003C\u002Fdiv\u003E\n\u003Cp\u003E\u003Cspan\u003ECopyright\u003C\u002Fspan\u003E &#x000A9; 2025 Zhou, Zhang, Zhang, Jia, Fu and Cao. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http:\u002F\u002Fcreativecommons.org\u002Flicenses\u002Fby\u002F4.0\u002F\" target=\"_blank\"\u003ECreative Commons Attribution License (CC BY)\u003C\u002Fa\u003E. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C\u002Fp\u003E\n\u003Cp\u003E\u003Cspan\u003E&#x0002A;Correspondence:\u003C\u002Fspan\u003E Zhenhuan Cao, \u003Ca id=\"encmail\"\u003EY2Fvemhlbmh1YW55dUBtYWlsLmNjbXUuZWR1LmNu\u003C\u002Fa\u003E\u003C\u002Fp\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003C\u002Fdiv\u003E",menuHtml:"\u003Cul class=\"flyoutJournal\"\u003E \u003Cli\u003E\u003Ca href=\"#h1\"\u003EAbstract\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h2\"\u003EIntroduction\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h3\"\u003EMethods: subjects, interventions, and outcomes\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h4\"\u003EMethods: data collection, management, and analysis\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h5\"\u003EMethods: monitoring\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h6\"\u003EEthics and dissemination\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h7\"\u003EDiscussion\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h8\"\u003EExperimental state\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h9\"\u003EEthics statement\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h10\"\u003EAuthor contributions\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h11\"\u003EFunding\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h12\"\u003EAcknowledgments\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h13\"\u003EConflict of interest\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h14\"\u003EGenerative AI statement\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h15\"\u003EPublisher&#x2019;s note\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h16\"\u003EReferences\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003C\u002Ful\u003E"},files:[{name:"fpubh-13-1546182.xml",fileServerPackageEntryId:"fpubh-13-1546182\u002Ffpubh-13-1546182.xml",type:{code:"NLM_XML",name:"xml"}},{name:"Publishers-proof.pdf",fileServerPackageEntryId:f,type:{code:"PDF",name:"pdf"}},{name:"EPUB.epub",fileServerPackageEntryId:f,type:{code:"EPUB",name:"epub"}}]},currentArticlePageMetaInfo:{title:ay,link:[{rel:"canonical",href:az}],meta:[{hid:x,property:x,name:x,content:f},{hid:aA,property:aA,name:"title",content:ay},{hid:aB,property:aB,name:x,content:f},{hid:aC,name:aC,content:"chronic hepatitis B,hepatitis B virus,metabolism-associated fatty liver disease,HBsAg clearance,clinical cure,peginterferon"},{hid:aD,property:aD,name:"site_name",content:y},{hid:aE,property:aE,name:E,content:X},{hid:aF,property:aF,name:"type",content:"article"},{hid:aG,property:aG,name:"url",content:az},{hid:aH,name:aH,content:"summary_large_image"},{hid:aI,name:aI,content:"13"},{hid:aJ,name:aJ,content:o},{hid:aK,name:aK,content:y},{hid:aL,name:aL,content:G},{hid:aM,name:aM,content:H},{hid:aN,name:aN,content:aa},{hid:aO,name:aO,content:"1546182"},{hid:aP,name:aP,content:"English"},{hid:aQ,name:aQ,content:J},{hid:aR,name:aR,content:"chronic hepatitis B; hepatitis B virus; metabolism-associated fatty liver disease; HBsAg clearance; clinical cure; peginterferon"},{hid:aS,name:aS,content:f},{hid:aT,name:aT,content:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Farticles\u002F10.3389\u002Ffpubh.2025.1546182\u002Fpdf"},{hid:aU,name:aU,content:"2025\u002F02\u002F17"},{hid:aV,name:aV,content:"2025\u002F03\u002F14"},{hid:"citation_author_0",name:q,content:"Zhou, Daqiong"},{hid:"citation_author_institution_0",name:r,content:aW},{hid:"citation_author_1",name:q,content:"Zhang, Chao"},{hid:"citation_author_institution_1",name:r,content:aX},{hid:"citation_author_2",name:q,content:"Zhang, Lu"},{hid:"citation_author_institution_2",name:r,content:"Beijing Ditan Hospital, Capital Medical University, China"},{hid:"citation_author_3",name:q,content:"Jia, Jianru"},{hid:"citation_author_institution_3",name:r,content:"Baoding Municipal People's Hospital, China"},{hid:"citation_author_4",name:q,content:"Fu, Junliang"},{hid:"citation_author_institution_4",name:r,content:aX},{hid:"citation_author_5",name:q,content:"Cao, Zhenhuan"},{hid:"citation_author_institution_5",name:r,content:aW},{hid:aY,name:aY,content:"doi:10.3389\u002Ffpubh.2025.1546182"}],script:[{src:"https:\u002F\u002Fcdnjs.cloudflare.com\u002Fpolyfill\u002Fv3\u002Fpolyfill.min.js?features=es6",body:h,async:h},{src:"https:\u002F\u002Fcdnjs.cloudflare.com\u002Fajax\u002Flibs\u002Fmathjax\u002F2.7.1\u002FMathJax.js?config=TeX-MML-AM_CHTML",body:h,async:h},{src:"https:\u002F\u002Fd1bxh8uas1mnw7.cloudfront.net\u002Fassets\u002Faltmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",body:h,async:h},{src:"https:\u002F\u002Fapi.altmetric.com\u002Fv1\u002Fdoi\u002F10.3389\u002Ffpubh.2025.1546182?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",body:h,async:h},{src:"https:\u002F\u002Fcrossmark-cdn.crossref.org\u002Fwidget\u002Fv2.0\u002Fwidget.js",body:h,async:h}]},articleHubArticlesList:[],showCrossmarkWidget:h,hasSupplementalData:l,isPreviewArticlePage:l,settingsFeaturesSwitchers:{displayTitlePillLabels:h,displayRelatedArticlesBox:h,showEditors:h,showReviewers:h,showLoopImpactLink:h,enableFigshare:l},tenantConfig:{spaceId:c,name:y,availableJournalPages:[aZ,a_,a$,"volumes","about"],announcement:{sys:{id:"2tE5oIdYfULBQILAgR2OSx",__typename:"Sys"},preHeader:"Research integrity at Frontiers",title:"94% of researchers rate our articles as excellent or good",description:"Learn more about the work of our research integrity team to safeguard the quality of each article we publish.",image:[{id:"0B4B1380-42EB-4FD5-9D7E2DBC603E79F8",src:ba,name:bb,tags:["ultra","sunset","achieving","summer","challenge","winning","extreme","workout","hike","path","action","uphill","effort","athlete","physical","height","activity","mountaineering","endurance","mount","runner","nordic","race","male","achieve","nature","run","adventure",F,"perseverance","freedom","fitness","backcountry","altitude","sports","man","hill","mountain","outdoor","exercise","energetic","trail","climb","skyrunning","lifestyle"],type:E,width:7100,height:4733,archive:m,brandId:V,limited:m,fileSize:16838862,isPublic:m,original:e,copyright:e,extension:[W],thumbnails:{mini:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002Fmini-C4875379-1478-416F-B03DF68FE3D8DBB5.png",thul:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002Fthul-C4875379-1478-416F-B03DF68FE3D8DBB5.png",webimage:ba,Guidelines:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002FGuidelines-C4875379-1478-416F-B03DF68FE3D8DBB5.png",WebsiteJpg_XL:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002FWebsiteJpg_XL-C4875379-1478-416F-B03DF68FE3D8DBB5.jpg",WebsiteWebP_L:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002FWebsiteWebP_L-C4875379-1478-416F-B03DF68FE3D8DBB5.webp",WebsiteWebP_M:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002FWebsiteWebP_M-C4875379-1478-416F-B03DF68FE3D8DBB5.webp",WebsiteWebP_XL:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002FWebsiteWebP_XL-C4875379-1478-416F-B03DF68FE3D8DBB5.webp"},dateCreated:"2022-12-14T15:44:00Z",description:bb,orientation:F,watermarked:m,dateModified:"2023-01-26T09:08:47Z",datePublished:"2022-12-14T16:40:06Z",videoPreviewURLs:[],textMetaproperties:[]}],link:{text:"Find out more ",url:bc,target:g,ariaLabel:"About our research integrity team",__typename:v},__typename:"Announcement"}},components:{ibar:{tenantLogo:f,journalLogo:f,aboutUs:[{title:"Who we are",links:[{text:"Mission and values",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fmission",target:g,ariaLabel:e},{text:"History",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fhistory",target:g,ariaLabel:e},{text:"Leadership",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fleadership",target:g,ariaLabel:e},{text:"Awards",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fawards",target:g,ariaLabel:e}]},{title:"Impact and progress",links:[{text:"Frontiers' impact",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fimpact",target:g,ariaLabel:e},{text:"Progress Report 2022",url:"https:\u002F\u002Fprogressreport.frontiersin.org\u002F?utm_source=fweb&utm_medium=frep&utm_campaign=pr20",target:k,ariaLabel:e},{text:"All annual reports",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fannual-reports",target:g,ariaLabel:e}]},{title:"Publishing model",links:[{text:bd,url:be,target:g,ariaLabel:e},{text:"Open access",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fopen-access",target:g,ariaLabel:e},{text:"Peer review",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fpeer-review",target:g,ariaLabel:e},{text:"Research integrity",url:bc,target:g,ariaLabel:e},{text:bf,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fresearch-topics",target:g,ariaLabel:e},{text:"FAIR² Data Management",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Ffair-data-management",target:g,ariaLabel:e},{text:bg,url:bh,target:g,ariaLabel:e}]},{title:"Services",links:[{text:"Societies",url:"https:\u002F\u002Fpublishingpartnerships.frontiersin.org\u002F",target:k,ariaLabel:e},{text:"National consortia",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fopen-access-agreements\u002Fconsortia",target:g,ariaLabel:e},{text:"Institutional partnerships",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fopen-access-agreements",target:g,ariaLabel:e},{text:"Collaborators",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fcollaborators",target:g,ariaLabel:e}]},{title:"More from Frontiers",links:[{text:"Frontiers Forum",url:bi,target:k,ariaLabel:"this link will take you to the Frontiers Forum website"},{text:bj,url:bk,target:k,ariaLabel:bl},{text:"Press office",url:"https:\u002F\u002Fpressoffice.frontiersin.org\u002F",target:k,ariaLabel:"this link will take you to the Frontiers press office website"},{text:"Sustainability",url:"https:\u002F\u002Fwww.frontiersin.orgabout\u002Fsustainability",target:g,ariaLabel:"link to information about Frontiers' sustainability"},{text:bm,url:bn,target:k,ariaLabel:"this link will take you to the Frontiers careers website"},{text:"Contact us",url:bo,target:g,ariaLabel:"this link will take you to the help pages to contact our support team"}]}],submitUrl:"https:\u002F\u002Fwww.frontiersin.org\u002Fsubmission\u002Fsubmit?domainid=2&fieldid=70&specialtyid=0&entitytype=2&entityid=609",showSubmitButton:h,journal:{id:t,name:o,slug:u,sections:[{id:1560,name:"Aging and Public Health",slug:"aging-and-public-health"},{id:621,name:"Children and Health",slug:"children-and-health"},{id:753,name:"Digital Public Health",slug:"digital-public-health"},{id:702,name:"Disaster and Emergency Medicine",slug:bp},{id:690,name:"Environmental Health and Exposome",slug:"environmental-health-and-exposome"},{id:1310,name:"Health Economics",slug:"health-economics"},{id:av,name:aw,slug:ax},{id:3297,name:"Injury Prevention and Control",slug:"injury-prevention-and-control"},{id:1495,name:"Life-Course Epidemiology and Social Inequalities in Health",slug:"life-course-epidemiology-and-social-inequalities-in-health"},{id:744,name:"Occupational Health and Safety",slug:"occupational-health-and-safety"},{id:1458,name:"Planetary Health",slug:"planetary-health"},{id:637,name:"Public Health Education and Promotion",slug:"public-health-education-and-promotion"},{id:652,name:"Public Health Policy",slug:"public-health-policy"},{id:2192,name:"Public Health and Nutrition",slug:"public-health-and-nutrition"},{id:695,name:"Public Mental Health",slug:"public-mental-health"},{id:778,name:"Radiation and Health",slug:"radiation-and-health"},{id:3408,name:"Substance Use Disorders and Behavioral Addictions",slug:"substance-use-disorders-and-behavioral-addictions"}]},sectionTerm:"Sections",aboutJournal:[{title:"Scope",links:[{text:"Field chief editors",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-editors",target:g,ariaLabel:e},{text:"Mission & scope",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-scope",target:g,ariaLabel:e},{text:"Facts",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-facts",target:g,ariaLabel:e},{text:"Journal sections",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-submission",target:g,ariaLabel:e},{text:"Open access statement",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-open",target:g,ariaLabel:e},{text:"Copyright statement",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#copyright-statement",target:g,ariaLabel:e},{text:"Quality",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-quality",target:g,ariaLabel:e}]},{title:"For authors",links:[{text:"Why submit?",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Fwhy-submit",target:g,ariaLabel:e},{text:"Article types",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Farticle-types",target:g,ariaLabel:e},{text:bq,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Fauthor-guidelines",target:g,ariaLabel:e},{text:br,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Feditor-guidelines",target:g,ariaLabel:e},{text:"Publishing fees",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Fpublishing-fees",target:g,ariaLabel:e},{text:"Submission checklist",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Fsubmission-checklist",target:g,ariaLabel:e},{text:"Contact editorial office",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Fcontact-editorial-office",target:g,ariaLabel:e}]}],mainLinks:[{text:"All journals",url:bs,target:g,ariaLabel:e},{text:"All articles",url:bt,target:g,ariaLabel:e}],journalLinks:[{text:bu,url:aZ,target:g,ariaLabel:e},{text:bf,url:a$,target:g,ariaLabel:e},{text:"Editorial board",url:a_,target:g,ariaLabel:e}],helpCenterLink:{text:z,url:bv,target:k,ariaLabel:z}},footer:{blocks:[{title:"Guidelines",links:[{text:bq,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fguidelines\u002Fauthor-guidelines",target:g,ariaLabel:e},{text:br,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fguidelines\u002Feditor-guidelines",target:g,ariaLabel:e},{text:"Policies and publication ethics",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fguidelines\u002Fpolicies-and-publication-ethics",target:g,ariaLabel:e},{text:bg,url:bh,target:g,ariaLabel:e}]},{title:"Explore",links:[{text:bu,url:bt,target:g,ariaLabel:e},{text:"Research Topics ",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fresearch-topics",target:g,ariaLabel:e},{text:"Journals",url:bs,target:g,ariaLabel:e},{text:bd,url:be,target:g,ariaLabel:e}]},{title:"Outreach",links:[{text:"Frontiers Forum ",url:bi,target:k,ariaLabel:"Frontiers Forum website"},{text:"Frontiers Policy Labs ",url:"https:\u002F\u002Fpolicylabs.frontiersin.org\u002F",target:k,ariaLabel:e},{text:bw,url:"https:\u002F\u002Fkids.frontiersin.org\u002F",target:k,ariaLabel:"Frontiers for Young Minds journal"},{text:bj,url:bk,target:k,ariaLabel:bl}]},{title:"Connect",links:[{text:z,url:bv,target:k,ariaLabel:z},{text:"Emails and alerts ",url:"https:\u002F\u002Floop.frontiersin.org\u002Fsettings\u002Femail-preferences?a=publishers",target:k,ariaLabel:"Subscribe to Frontiers emails"},{text:"Contact us ",url:bo,target:g,ariaLabel:"Subscribe to newsletter"},{text:"Submit",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fsubmission\u002Fsubmit",target:g,ariaLabel:e},{text:bm,url:bn,target:k,ariaLabel:e}]}],socialLinks:[{link:{text:bx,url:"https:\u002F\u002Fwww.facebook.com\u002FFrontiersin",target:k,ariaLabel:bx},type:v,color:A,icon:"Facebook",size:B,hiddenText:h},{link:{text:"Frontiers Twitter",url:"https:\u002F\u002Ftwitter.com\u002Ffrontiersin",target:k,ariaLabel:e},type:v,color:A,icon:"Twitter",size:B,hiddenText:h},{link:{text:"Frontiers LinkedIn",url:"https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Ffrontiers",target:k,ariaLabel:e},type:v,color:A,icon:"LinkedIn",size:B,hiddenText:h},{link:{text:"Frontiers Instagram",url:"https:\u002F\u002Fwww.instagram.com\u002Ffrontiersin_",target:k,ariaLabel:e},type:v,color:A,icon:"Instagram",size:B,hiddenText:h}],copyright:"Frontiers Media S.A. All rights reserved",termsAndConditionsUrl:"https:\u002F\u002Fwww.frontiersin.org\u002Flegal\u002Fterms-and-conditions",privacyPolicyUrl:"https:\u002F\u002Fwww.frontiersin.org\u002Flegal\u002Fprivacy-policy"},newsletterComponent:e,snackbarItems:[]},mainHeader:{title:f,image:I,breadcrumbs:[],linksCollection:{total:m,items:[]},metricsCollection:{total:m,items:[]}},user:{loggedUserInfo:I},journals:[{id:by,name:bz,slug:bA,abbreviation:bB,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2445,name:bz,slug:bA,abbreviation:bB,space:{id:c,domainName:d,__typename:b},__typename:a},{id:N,name:"Test SSPH Journal",slug:"test-ssph-journal",abbreviation:"testjournal",space:{id:s,domainName:C,__typename:b},__typename:a},{id:bC,name:"TEST ALF Journal",slug:"test-alf-journal",abbreviation:"talfj",space:{id:w,domainName:O,__typename:b},__typename:a},{id:i,name:bD,slug:bE,abbreviation:bF,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2360,name:bD,slug:bE,abbreviation:bF,space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Smoke Test Field",slug:"smoke-test-field",abbreviation:"FJST",space:{id:P,domainName:bG,__typename:b},__typename:a},{id:bC,name:bH,slug:bI,abbreviation:bJ,space:{id:s,domainName:C,__typename:b},__typename:a},{id:2077,name:bH,slug:bI,abbreviation:bJ,space:{id:c,domainName:d,__typename:b},__typename:a},{id:N,name:bK,slug:bL,abbreviation:bM,space:{id:w,domainName:O,__typename:b},__typename:a},{id:N,name:bK,slug:bL,abbreviation:bM,space:{id:c,domainName:d,__typename:b},__typename:a},{id:bN,name:bO,slug:bP,abbreviation:bQ,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3776,name:bO,slug:bP,abbreviation:bQ,space:{id:c,domainName:d,__typename:b},__typename:a},{id:K,name:bR,slug:bS,abbreviation:bT,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3765,name:bR,slug:bS,abbreviation:bT,space:{id:c,domainName:d,__typename:b},__typename:a},{id:14,name:bU,slug:bV,abbreviation:bW,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3414,name:bU,slug:bV,abbreviation:bW,space:{id:c,domainName:d,__typename:b},__typename:a},{id:20,name:bX,slug:bY,abbreviation:bZ,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3754,name:bX,slug:bY,abbreviation:bZ,space:{id:c,domainName:d,__typename:b},__typename:a},{id:P,name:b_,slug:b$,abbreviation:ca,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2444,name:b_,slug:b$,abbreviation:ca,space:{id:c,domainName:d,__typename:b},__typename:a},{id:cb,name:cc,slug:cd,abbreviation:ce,space:{id:s,domainName:C,__typename:b},__typename:a},{id:cb,name:cc,slug:cd,abbreviation:ce,space:{id:c,domainName:d,__typename:b},__typename:a},{id:i,name:"GSL Test",slug:"gsl-test",abbreviation:"gslt",space:{id:n,domainName:Q,__typename:b},__typename:a},{id:2356,name:"Frontiers in the Internet of Things",slug:"the-internet-of-things",abbreviation:"friot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:656,name:"Frontiers in Zoological Science",slug:"zoological-science",abbreviation:"fzoos",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1720,name:"Frontiers in Zoological Research",slug:"zoological-research",abbreviation:"fzolr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3162,name:"Frontiers in Wound Care",slug:"wound-care",abbreviation:"fwoca",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3136,name:"Frontiers in Worm Science",slug:"worm-science",abbreviation:"fwors",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3583,name:"Frontiers in Wind Energy",slug:"wind-energy",abbreviation:"fwinde",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1451,name:"Frontiers in Water",slug:"water",abbreviation:"frwa",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1561,name:"Frontiers in Virtual Reality",slug:"virtual-reality",abbreviation:"frvir",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2000,name:"Frontiers in Virology",slug:"virology",abbreviation:"fviro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:649,name:"Frontiers in Veterinary Science",slug:"veterinary-science",abbreviation:"fvets",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2176,name:"Frontiers in Urology",slug:"urology",abbreviation:"fruro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3099,name:"Frontiers in Tuberculosis",slug:"tuberculosis",abbreviation:"ftubr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1843,name:"Frontiers in Tropical Diseases",slug:"tropical-diseases",abbreviation:"fitd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2417,name:"Frontiers in Transplantation",slug:"transplantation",abbreviation:"frtra",space:{id:c,domainName:d,__typename:b},__typename:a},{id:473,name:"Frontiers in Toxicology",slug:"toxicology",abbreviation:"ftox",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2105,name:"Frontiers in Thermal Engineering",slug:"thermal-engineering",abbreviation:"fther",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3190,name:"Frontiers in The Neurobiology of Pain",slug:"the-neurobiology-of-pain",abbreviation:f,space:{id:c,domainName:d,__typename:b},__typename:a},{id:1967,name:"Frontiers in Test_Field_Science_Archive",slug:"testfieldsciencearchive",abbreviation:"fntesc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1347,name:"Frontiers in Test_Field_Humanities_Archive",slug:"testfieldhumanitiesarchive",abbreviation:"fntes",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3573,name:"Frontiers in Taxonomy",slug:"taxonomy",abbreviation:"Front. Taxon.",space:{id:c,domainName:d,__typename:b},__typename:a},{id:s,name:"Frontiers in Systems Neuroscience",slug:"systems-neuroscience",abbreviation:"fnsys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1721,name:"Frontiers in Systems Biology",slug:"systems-biology",abbreviation:"fsysb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3381,name:"Frontiers in Synthetic Biology",slug:"synthetic-biology",abbreviation:"fsybi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:22,name:"Frontiers in Synaptic Neuroscience",slug:"synaptic-neuroscience",abbreviation:"fnsyn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2299,name:"Frontiers in Sustainable Tourism",slug:"sustainable-tourism",abbreviation:"frsut",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2483,name:"Frontiers in Sustainable Resource Management",slug:"sustainable-resource-management",abbreviation:"fsrma",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1335,name:"Frontiers in Sustainable Food Systems",slug:"sustainable-food-systems",abbreviation:"fsufs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2726,name:"Frontiers in Sustainable Energy Policy",slug:"sustainable-energy-policy",abbreviation:"fsuep",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1468,name:"Frontiers in Sustainable Cities",slug:"sustainable-cities",abbreviation:"frsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1397,name:"Frontiers in Sustainable Business",slug:"sustainable-business",abbreviation:"fisb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1547,name:"Frontiers in Sustainability",slug:"sustainability",abbreviation:"frsus",space:{id:c,domainName:d,__typename:b},__typename:a},{id:604,name:"Frontiers in Surgery",slug:"surgery",abbreviation:"fsurg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2504,name:"Frontiers in Structural Biology",slug:"structural-biology",abbreviation:"frsbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:U,name:"Frontiers in Stroke",slug:"stroke",abbreviation:"fstro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3434,name:"Frontiers in Stem Cells",slug:"stem-cells",abbreviation:"fstce",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1482,name:"Frontiers in Sports and Active Living",slug:"sports-and-active-living",abbreviation:"fspor",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1695,name:"Frontiers in Space Technologies",slug:"space-technologies",abbreviation:"frspt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3519,name:"Frontiers in Solar Energy",slug:"solar-energy",abbreviation:"fsoln",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1718,name:"Frontiers in Soil Science",slug:"soil-science",abbreviation:"fsoil",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2346,name:"Frontiers in Soft Matter",slug:"soft-matter",abbreviation:"frsfm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1213,name:"Frontiers in Sociology",slug:"sociology",abbreviation:"fsoc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:R,name:"Frontiers in Society Journal Archive",slug:"society-journal-archive",abbreviation:S,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2690,name:"Frontiers in Social Psychology",slug:"social-psychology",abbreviation:"frsps",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2819,name:"Frontiers in Smart Grids",slug:"smart-grids",abbreviation:"frsgr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2288,name:"Frontiers in Sleep",slug:"sleep",abbreviation:"frsle",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2552,name:"Frontiers in Skin Cancer",slug:"skin-cancer",abbreviation:"fskcr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1786,name:"Frontiers in Signal Processing",slug:"signal-processing",abbreviation:"frsip",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1704,name:"Frontiers in Sensors",slug:"sensors",abbreviation:"fsens",space:{id:c,domainName:d,__typename:b},__typename:a},{id:s,name:"Frontiers in Science archive",slug:"science-archive",abbreviation:D,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3737,name:"Frontiers in Science Diplomacy",slug:"science-diplomacy",abbreviation:"fsdip",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2766,name:"Frontiers in Science",slug:"science",abbreviation:"fsci",space:{id:c,domainName:d,__typename:b},__typename:a},{id:657,name:"Frontiers in Robotics and AI",slug:"robotics-and-ai",abbreviation:"frobt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1606,name:"Frontiers in Research Metrics and Analytics",slug:"research-metrics-and-analytics",abbreviation:"frma",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1479,name:"Frontiers in Reproductive Health",slug:"reproductive-health",abbreviation:"frph",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1830,name:"Frontiers in Remote Sensing",slug:"remote-sensing",abbreviation:"frsen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:659,name:"Frontiers in Rehabilitation Sciences",slug:"rehabilitation-sciences",abbreviation:"fresc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3550,name:"Frontiers in Regenerative Medicine",slug:"regenerative-medicine",abbreviation:"fregm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1949,name:"Frontiers in Radiology",slug:"radiology",abbreviation:"fradi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3189,name:"Frontiers in RNA Research",slug:"rna-research",abbreviation:"frnar",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2306,name:"Frontiers in Quantum Science and Technology",slug:"quantum-science-and-technology",abbreviation:"frqst",space:{id:c,domainName:d,__typename:b},__typename:a},{id:R,name:"Frontiers in Public Health Archive",slug:"public-health-archive",abbreviation:S,space:{id:s,domainName:C,__typename:b},__typename:a},{id:t,name:o,slug:u,abbreviation:Z,space:{id:c,domainName:d,__typename:b},__typename:a},{id:36,name:"Frontiers in Psychology",slug:"psychology",abbreviation:"fpsyg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:71,name:"Frontiers in Psychiatry",slug:"psychiatry",abbreviation:"fpsyt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3267,name:"Frontiers in Protistology",slug:"protistology",abbreviation:"frpro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2452,name:"Frontiers in Proteomics",slug:"proteomics",abbreviation:"fprot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3171,name:"Frontiers in Prosthetics and Orthotics",slug:"prosthetics-and-orthotics",abbreviation:"fpror ",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3643,name:"Frontiers in Polymer Science",slug:"polymer-science",abbreviation:"fplms",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1558,name:"Frontiers in Political Science",slug:"political-science",abbreviation:"fpos",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3615,name:"Frontiers in Polar Science",slug:"polar-science",abbreviation:"fposc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:373,name:"Frontiers in Plant Science",slug:"plant-science",abbreviation:"fpls",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3477,name:"Frontiers in Plant Physiology",slug:"plant-physiology",abbreviation:"fphgy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3589,name:"Frontiers in Plant Genomics",slug:"plant-genomics",abbreviation:"fpgen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3579,name:"Frontiers in Plant Ecology",slug:"plant-ecology",abbreviation:"fpley",space:{id:c,domainName:d,__typename:b},__typename:a},{id:210,name:"Frontiers in Physiology",slug:"physiology",abbreviation:"fphys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:616,name:"Frontiers in Physics",slug:"physics",abbreviation:"fphy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1803,name:"Frontiers in Photonics",slug:"photonics",abbreviation:"fphot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3604,name:"Frontiers in Photobiology",slug:"photobiology",abbreviation:"fphbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:176,name:"Frontiers in Pharmacology",slug:"pharmacology",abbreviation:"fphar",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3388,name:"Frontiers in Personality Disorders",slug:"personality-disorders",abbreviation:"fprsd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:606,name:"Frontiers in Pediatrics",slug:"pediatrics",abbreviation:"fped",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2554,name:"Frontiers in Pediatric Dermatology",slug:"pediatric-dermatology",abbreviation:"fpdm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:R,name:"Frontiers in Pathology and Oncology Archive",slug:"pathology-and-oncology-archive",abbreviation:S,space:{id:w,domainName:O,__typename:b},__typename:a},{id:610,name:cf,slug:cg,abbreviation:ch,space:{id:c,domainName:d,__typename:b},__typename:a},{id:3351,name:cf,slug:cg,abbreviation:ch,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2705,name:"Frontiers in Parasitology",slug:"parasitology",abbreviation:"fpara",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1727,name:"Frontiers in Pain Research",slug:"pain-research",abbreviation:"fpain",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2679,name:"Frontiers in Organizational Psychology",slug:"organizational-psychology",abbreviation:"forgp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1702,name:"Frontiers in Oral Health",slug:"oral-health",abbreviation:"froh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2232,name:"Frontiers in Ophthalmology",slug:"ophthalmology",abbreviation:"fopht",space:{id:c,domainName:d,__typename:b},__typename:a},{id:451,name:"Frontiers in Oncology",slug:"oncology",abbreviation:"fonc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3123,name:"Frontiers in Ocean Sustainability",slug:"ocean-sustainability",abbreviation:"focsu",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2612,name:"Frontiers in Occupational Therapy",slug:"occupational-therapy",abbreviation:"froct",space:{id:c,domainName:d,__typename:b},__typename:a},{id:628,name:"Frontiers in Nutrition",slug:"nutrition",abbreviation:"fnut",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2062,name:"Frontiers in Nuclear Medicine",slug:"nuclear-medicine",abbreviation:"fnume",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2172,name:"Frontiers in Nuclear Engineering",slug:"nuclear-engineering",abbreviation:"fnuen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Frontiers in Neuroscience",slug:"neuroscience",abbreviation:"fnins",space:{id:c,domainName:d,__typename:b},__typename:a},{id:M,name:"Frontiers in Neurorobotics",slug:"neurorobotics",abbreviation:"fnbot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3056,name:"Frontiers in Neuropsychiatry",slug:"neuropsychiatry",abbreviation:"fnpsy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:141,name:"Frontiers in Neurology",slug:"neurology",abbreviation:"fneur",space:{id:c,domainName:d,__typename:b},__typename:a},{id:ci,name:"Frontiers in Neuroinformatics",slug:"neuroinformatics",abbreviation:"fninf",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3283,name:"Frontiers in Neuroinflammation",slug:"neuroinflammation",abbreviation:"fnein",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1973,name:"Frontiers in Neuroimaging",slug:"neuroimaging",abbreviation:"fnimg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1833,name:"Frontiers in Neuroergonomics",slug:"neuroergonomics",abbreviation:"fnrgo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:L,name:"Frontiers in Neuroengineering",slug:"neuroengineering",abbreviation:"fneng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:cj,name:"Frontiers in Neuroenergetics",slug:"neuroenergetics",abbreviation:"fnene",space:{id:c,domainName:d,__typename:b},__typename:a},{id:w,name:"Frontiers in Neuroanatomy",slug:"neuroanatomy",abbreviation:"fnana",space:{id:c,domainName:d,__typename:b},__typename:a},{id:K,name:"Frontiers in Neural Circuits",slug:"neural-circuits",abbreviation:"fncir",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2021,name:"Frontiers in Network Physiology",slug:"network-physiology",abbreviation:"fnetp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3130,name:"Frontiers in Network Neuroscience",slug:"network-neuroscience",abbreviation:"fnnsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2357,name:"Frontiers in Nephrology",slug:"nephrology",abbreviation:"fneph",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2320,name:"Frontiers in Natural Products",slug:"natural-products",abbreviation:"fntpr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1528,name:"Frontiers in Nanotechnology",slug:"nanotechnology",abbreviation:"fnano",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2882,name:"Frontiers in Musculoskeletal Disorders",slug:"musculoskeletal-disorders",abbreviation:"fmscd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3275,name:"Frontiers in Multiple Sclerosis",slug:"multiple-sclerosis",abbreviation:"fmscr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3152,name:"Frontiers in Mollusk Science",slug:"mollusk-science",abbreviation:"fmlsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2031,name:"Frontiers in Molecular Neuroscience",slug:"molecular-neuroscience",abbreviation:"fnmol",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2086,name:"Frontiers in Molecular Medicine",slug:"molecular-medicine",abbreviation:"fmmed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:698,name:"Frontiers in Molecular Biosciences",slug:"molecular-biosciences",abbreviation:"fmolb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2807,name:"Frontiers in Microbiomes",slug:"microbiomes",abbreviation:"frmbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:310,name:"Frontiers in Microbiology",slug:"microbiology",abbreviation:"fmicb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2327,name:"Frontiers in Metals and Alloys",slug:"metals-and-alloys",abbreviation:"ftmal",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2307,name:"Frontiers in Membrane Science and Technology",slug:"membrane-science-and-technology",abbreviation:"frmst",space:{id:c,domainName:d,__typename:b},__typename:a},{id:602,name:"Frontiers in Medicine",slug:"medicine",abbreviation:"fmed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1573,name:"Frontiers in Medical Technology",slug:"medical-technology",abbreviation:"fmedt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3135,name:"Frontiers in Medical Engineering",slug:"medical-engineering",abbreviation:"fmede",space:{id:c,domainName:d,__typename:b},__typename:a},{id:950,name:"Frontiers in Mechanical Engineering",slug:"mechanical-engineering",abbreviation:"fmech",space:{id:c,domainName:d,__typename:b},__typename:a},{id:608,name:"Frontiers in Materials",slug:"materials",abbreviation:"fmats",space:{id:c,domainName:d,__typename:b},__typename:a},{id:655,name:"Frontiers in Marine Science",slug:"marine-science",abbreviation:"fmars",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2100,name:"Frontiers in Manufacturing Technology",slug:"manufacturing-technology",abbreviation:"fmtec",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2931,name:"Frontiers in Mammal Science",slug:"mammal-science",abbreviation:"fmamm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2896,name:"Frontiers in Malaria",slug:"malaria",abbreviation:"fmala",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3107,name:"Frontiers in Lupus",slug:"lupus",abbreviation:"flupu",space:{id:c,domainName:d,__typename:b},__typename:a},{id:435,name:"Frontiers in Linguistics",slug:"linguistics",abbreviation:"fling",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2636,name:"Frontiers in Language Sciences",slug:"language-sciences",abbreviation:"flang",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2670,name:"Frontiers in Lab on a Chip Technologies",slug:"lab-on-a-chip-technologies",abbreviation:"frlct",space:{id:c,domainName:d,__typename:b},__typename:a},{id:ck,name:"Frontiers in Integrative Neuroscience",slug:"integrative-neuroscience",abbreviation:"fnint",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1723,name:"Frontiers in Insect Science",slug:"insect-science",abbreviation:"finsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3093,name:"Frontiers in Influenza",slug:"influenza",abbreviation:"finfl",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3073,name:"Frontiers in Inflammation",slug:"inflammation",abbreviation:"finmn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3200,name:"Frontiers in Industrial Microbiology",slug:"industrial-microbiology",abbreviation:"finmi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3291,name:"Frontiers in Industrial Engineering",slug:"industrial-engineering",abbreviation:"fieng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2765,name:"Frontiers in Impact Journals",slug:"impact-journals",abbreviation:f,space:{id:c,domainName:d,__typename:b},__typename:a},{id:3078,name:"Frontiers in Immunotherapeutics",slug:"immunotherapeutics",abbreviation:"fimms",space:{id:c,domainName:d,__typename:b},__typename:a},{id:276,name:"Frontiers in Immunology",slug:"immunology",abbreviation:"fimmu",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2379,name:"Frontiers in Imaging",slug:"imaging",abbreviation:"fimag",space:{id:c,domainName:d,__typename:b},__typename:a},{id:629,name:"Frontiers in ICT",slug:"ict",abbreviation:"fict",space:{id:c,domainName:d,__typename:b},__typename:a},{id:16,name:"Frontiers in Humanities and Social Sciences Archive",slug:"humanities-and-social-sciences-archive",abbreviation:D,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3759,name:"Frontiers in Human Rights",slug:"human-rights",abbreviation:f,space:{id:c,domainName:d,__typename:b},__typename:a},{id:1588,name:"Frontiers in Human Neuroscience",slug:"human-neuroscience",abbreviation:"fnhum",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1533,name:"Frontiers in Human Dynamics",slug:"human-dynamics",abbreviation:"fhumd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2733,name:"Frontiers in Horticulture",slug:"horticulture",abbreviation:"fhort",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3316,name:"Frontiers in Histology",slug:"histology",abbreviation:"frhis",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2378,name:"Frontiers in High Performance Computing",slug:"high-performance-computing",abbreviation:"fhpcp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2456,name:"Frontiers in Hematology",slug:"hematology",abbreviation:"frhem",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2063,name:"Frontiers in Health Services",slug:"health-services",abbreviation:"frhs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:w,name:"Frontiers in Health Archive",slug:"health-archive",abbreviation:D,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3508,name:"Frontiers in Green Chemistry",slug:"green-chemistry",abbreviation:"fgrch",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1728,name:"Frontiers in Global Women's Health",slug:"global-womens-health",abbreviation:"fgwh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2918,name:"Frontiers in Geochemistry",slug:"geochemistry",abbreviation:"fgeoc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1540,name:"Frontiers in Genome Editing",slug:"genome-editing",abbreviation:"fgeed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:240,name:"Frontiers in Genetics",slug:"genetics",abbreviation:"fgene",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3496,name:"Frontiers in Genetic Microbiology",slug:"genetic-microbiology",abbreviation:"fgemi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3227,name:"Frontiers in Genetic Disorders",slug:"genetic-disorders",abbreviation:"frged",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2333,name:"Frontiers in Gastroenterology",slug:"gastroenterology",abbreviation:"fgstr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1529,name:"Frontiers in Future Transportation",slug:"future-transportation",abbreviation:"ffutr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1725,name:"Frontiers in Fungal Biology",slug:"fungal-biology",abbreviation:"ffunb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2826,name:"Frontiers in Fuels",slug:"fuels",abbreviation:"ffuel",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3207,name:"Frontiers in Freshwater Science",slug:"freshwater-science",abbreviation:"ffwsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1366,name:"Frontiers in Forests and Global Change",slug:"forests-and-global-change",abbreviation:"ffgc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2689,name:"Frontiers in Forensic Science",slug:"forensic-science",abbreviation:f,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2289,name:"Frontiers in Food Science and Technology",slug:"food-science-and-technology",abbreviation:"frfst",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3559,name:"Frontiers in Fluorescence",slug:"fluorescence",abbreviation:"fflur",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2987,name:"Frontiers in Fish Science",slug:"fish-science",abbreviation:"frish",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3489,name:"Frontiers in Fire Science and Technology",slug:"fire-science-and-technology",abbreviation:"firtc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2749,name:"Frontiers in Financial Economics",slug:"financial-economics",abbreviation:"ffecn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Frontiers in FSHIP Test Journal",slug:"fship-test-journal",abbreviation:"ftest",space:{id:i,domainName:j,__typename:b},__typename:a},{id:bN,name:"Frontiers in Evolutionary Neuroscience",slug:"evolutionary-neuroscience",abbreviation:"fnevo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2955,name:"Frontiers in Ethology",slug:"ethology",abbreviation:"fetho",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3032,name:"Frontiers in Epigenetics and Epigenomics",slug:"epigenetics-and-epigenomics",abbreviation:"freae",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2394,name:"Frontiers in Epidemiology",slug:"epidemiology",abbreviation:"fepid",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3450,name:"Frontiers in Environmental Toxicology",slug:"environmental-toxicology",abbreviation:"fentx",space:{id:c,domainName:d,__typename:b},__typename:a},{id:627,name:"Frontiers in Environmental Science",slug:"environmental-science",abbreviation:"fenvs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2888,name:"Frontiers in Environmental Health",slug:"environmental-health",abbreviation:"fenvh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2851,name:"Frontiers in Environmental Engineering",slug:"environmental-engineering",abbreviation:"fenve",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2547,name:"Frontiers in Environmental Economics",slug:"environmental-economics",abbreviation:"frevc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1697,name:"Frontiers in Environmental Chemistry",slug:"environmental-chemistry",abbreviation:"fenvc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2756,name:"Frontiers in Environmental Archaeology",slug:"environmental-archaeology",abbreviation:"fearc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:15,name:"Frontiers in Engineering archive",slug:"engineering-archive",abbreviation:D,space:{id:i,domainName:j,__typename:b},__typename:a},{id:626,name:"Frontiers in Energy Research",slug:"energy-research",abbreviation:"fenrg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3115,name:"Frontiers in Energy Efficiency",slug:"energy-efficiency",abbreviation:"fenef",space:{id:c,domainName:d,__typename:b},__typename:a},{id:106,name:"Frontiers in Endocrinology",slug:"endocrinology",abbreviation:"fendo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1696,name:"Frontiers in Electronics",slug:"electronics",abbreviation:"felec",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1800,name:"Frontiers in Electronic Materials",slug:"electronic-materials",abbreviation:"femat",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2998,name:"Frontiers in Educational Psychology",slug:"educational-psychology",abbreviation:"fepys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1239,name:"Frontiers in Education",slug:"education",abbreviation:"feduc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:625,name:"Frontiers in Economics",slug:"economics",abbreviation:"fecon",space:{id:c,domainName:d,__typename:b},__typename:a},{id:471,name:"Frontiers in Ecology and Evolution",slug:"ecology-and-evolution",abbreviation:"fevo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Frontiers in Earth Science Archive",slug:"earth-science-archive",abbreviation:"gslfj",space:{id:n,domainName:Q,__typename:b},__typename:a},{id:654,name:"Frontiers in Earth Science",slug:"earth-science",abbreviation:"feart",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3309,name:"Frontiers in Earth Observation and Land Monitoring",slug:"earth-observation-and-land-monitoring",abbreviation:"feolm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2161,name:"Frontiers in Drug Safety and Regulation",slug:"drug-safety-and-regulation",abbreviation:"fdsfr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2137,name:"Frontiers in Drug Discovery",slug:"drug-discovery",abbreviation:"fddsv",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2136,name:"Frontiers in Drug Delivery",slug:"drug-delivery",abbreviation:"fddev",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2775,name:"Frontiers in Disaster and Emergency Medicine",slug:bp,abbreviation:"femer",space:{id:c,domainName:d,__typename:b},__typename:a},{id:788,name:"Frontiers in Digital Humanities",slug:"digital-humanities",abbreviation:"fdigh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1534,name:"Frontiers in Digital Health",slug:"digital-health",abbreviation:"fdgth",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2999,name:"Frontiers in Developmental Psychology",slug:"developmental-psychology",abbreviation:"fdpys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2873,name:"Frontiers in Detector Science and Technology",slug:"detector-science-and-technology",abbreviation:"fdest",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3611,name:"Frontiers in Design Engineering",slug:"design-engineering",abbreviation:"fdese",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2550,name:"Frontiers in Dermatological Research",slug:"dermatological-research",abbreviation:"fdmre",space:{id:c,domainName:d,__typename:b},__typename:a},{id:607,name:"Frontiers in Dental Medicine",slug:"dental-medicine",abbreviation:"fdmed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2597,name:"Frontiers in Dementia",slug:"dementia",abbreviation:"frdem",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1785,name:"Frontiers in Control Engineering",slug:"control-engineering",abbreviation:"fcteg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1724,name:"Frontiers in Conservation Science",slug:"conservation-science",abbreviation:"fcosc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3454,name:"Frontiers in Condensed Matter",slug:"condensed-matter",abbreviation:"fconm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1511,name:"Frontiers in Computer Science",slug:"computer-science",abbreviation:"fcomp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3566,name:"Frontiers in Computational Physiology",slug:"computational-physiology",abbreviation:"fcphy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:by,name:"Frontiers in Computational Neuroscience",slug:"computational-neuroscience",abbreviation:"fncom",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3234,name:"Frontiers in Complex Systems",slug:"complex-systems",abbreviation:"fcpxs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1787,name:"Frontiers in Communications and Networks",slug:"communications-and-networks",abbreviation:"frcmn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1238,name:"Frontiers in Communication",slug:"communication",abbreviation:"fcomm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2535,name:"Frontiers in Cognition",slug:"cognition",abbreviation:"fcogn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2857,name:"Frontiers in Coatings, Dyes and Interface Engineering",slug:"coatings-dyes-and-interface-engineering",abbreviation:"frcdi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3222,name:"Frontiers in Clinical Microbiology",slug:"clinical-microbiology",abbreviation:"fclmi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1729,name:"Frontiers in Clinical Diabetes and Healthcare",slug:"clinical-diabetes-and-healthcare",abbreviation:"fcdhc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2551,name:"Frontiers in Clinical Dermatology",slug:"clinical-dermatology",abbreviation:"fcldm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1490,name:"Frontiers in Climate",slug:"climate",abbreviation:"fclim",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3338,name:"Frontiers in Chromosome Research",slug:"chromosome-research",abbreviation:f,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2587,name:"Frontiers in Child and Adolescent Psychiatry",slug:"child-and-adolescent-psychiatry",abbreviation:"frcha",space:{id:c,domainName:d,__typename:b},__typename:a},{id:601,name:"Frontiers in Chemistry",slug:"chemistry",abbreviation:"fchem",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1532,name:"Frontiers in Chemical Engineering",slug:"chemical-engineering",abbreviation:"fceng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3038,name:"Frontiers in Chemical Biology",slug:"chemical-biology",abbreviation:"fchbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3322,name:"Frontiers in Ceramics",slug:"ceramics",abbreviation:"fceic",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1440,name:"Frontiers in Cellular and Infection Microbiology",slug:"cellular-and-infection-microbiology",abbreviation:"fcimb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1523,name:"Frontiers in Cellular Neuroscience",slug:"cellular-neuroscience",abbreviation:"fncel",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3084,name:"Frontiers in Cellular Immunology",slug:"cellular-immunology",abbreviation:"fcimy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:403,name:"Frontiers in Cell and Developmental Biology",slug:"cell-and-developmental-biology",abbreviation:"fcell",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3178,name:"Frontiers in Cell Signaling",slug:"cell-signaling",abbreviation:"fcsig",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2655,name:"Frontiers in Cell Death",slug:"cell-death",abbreviation:"fceld",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1901,name:"Frontiers in Catalysis",slug:"catalysis",abbreviation:"fctls",space:{id:c,domainName:d,__typename:b},__typename:a},{id:755,name:"Frontiers in Cardiovascular Medicine",slug:"cardiovascular-medicine",abbreviation:"fcvm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2662,name:"Frontiers in Carbon",slug:"carbon",abbreviation:"frcrb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3513,name:"Frontiers in Cancer Interception",slug:"cancer-interception",abbreviation:"fcint",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3433,name:"Frontiers in Cancer Control and Society",slug:"cancer-control-and-society",abbreviation:"fcacs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:921,name:"Frontiers in Built Environment",slug:"built-environment",abbreviation:"fbuil",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1418,name:"Frontiers in Blockchain",slug:"blockchain",abbreviation:"fbloc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2971,name:"Frontiers in Bird Science",slug:"bird-science",abbreviation:"fbirs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3300,name:"Frontiers in Biophysics",slug:"biophysics",abbreviation:"frbis",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2222,name:"Frontiers in Biomaterials Science",slug:"biomaterials-science",abbreviation:"fbiom",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1722,name:"Frontiers in Bioinformatics",slug:"bioinformatics",abbreviation:"fbinf",space:{id:c,domainName:d,__typename:b},__typename:a},{id:452,name:"Frontiers in Bioengineering and Biotechnology",slug:"bioengineering-and-biotechnology",abbreviation:"fbioe",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1380,name:"Frontiers in Big Data",slug:"big-data",abbreviation:"fdata",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1589,name:"Frontiers in Behavioral Neuroscience",slug:"behavioral-neuroscience",abbreviation:"fnbeh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2432,name:"Frontiers in Behavioral Economics",slug:"behavioral-economics",abbreviation:"frbhe",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2796,name:"Frontiers in Bee Science",slug:"bee-science",abbreviation:"frbee",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3214,name:"Frontiers in Batteries and Electrochemistry",slug:"batteries-and-electrochemistry",abbreviation:"fbael",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3011,name:"Frontiers in Bacteriology",slug:"bacteriology",abbreviation:"fbrio",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3040,name:"Frontiers in Audiology and Otology",slug:"audiology-and-otology",abbreviation:"fauot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:603,name:"Frontiers in Astronomy and Space Sciences",slug:"astronomy-and-space-sciences",abbreviation:"fspas",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1437,name:"Frontiers in Artificial Intelligence",slug:"artificial-intelligence",abbreviation:"frai",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2940,name:"Frontiers in Arachnid Science",slug:"arachnid-science",abbreviation:"frchs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2834,name:"Frontiers in Aquaculture",slug:"aquaculture",abbreviation:"faquc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:981,name:"Frontiers in Applied Mathematics and Statistics",slug:"applied-mathematics-and-statistics",abbreviation:"fams",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3417,name:"Frontiers in Applied Environmental Microbiology",slug:"applied-environmental-microbiology",abbreviation:"faemi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2714,name:"Frontiers in Antibiotics",slug:"antibiotics",abbreviation:"frabi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3443,name:"Frontiers in Anti-Cancer Therapies",slug:"anti-cancer-therapies",abbreviation:"facth",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3253,name:"Frontiers in Antennas and Propagation",slug:"antennas-and-propagation",abbreviation:"fanpr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1719,name:"Frontiers in Animal Science",slug:"animal-science",abbreviation:"fanim",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2513,name:"Frontiers in Anesthesiology",slug:"anesthesiology",abbreviation:"fanes",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1989,name:"Frontiers in Analytical Science",slug:"analytical-science",abbreviation:"frans",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2909,name:"Frontiers in Amphibian and Reptile Science",slug:"amphibian-and-reptile-science",abbreviation:"famrs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1705,name:"Frontiers in Allergy",slug:"allergy",abbreviation:"falgy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1541,name:"Frontiers in Agronomy",slug:"agronomy",abbreviation:"fagro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3631,name:"Frontiers in Agricultural Engineering",slug:"agricultural-engineering",abbreviation:"faeng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2477,name:"Frontiers in Aging Neuroscience",slug:"aging-neuroscience",abbreviation:"fnagi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1566,name:"Frontiers in Aging",slug:"aging",abbreviation:"fragi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2449,name:"Frontiers in Aerospace Engineering",slug:"aerospace-engineering",abbreviation:"fpace",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2195,name:"Frontiers in Adolescent Medicine",slug:"adolescent-medicine",abbreviation:"fradm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3426,name:"Frontiers in Acoustics",slug:"acoustics",abbreviation:"facou",space:{id:c,domainName:d,__typename:b},__typename:a},{id:979,name:bw,slug:"frontiers-for-young-minds",abbreviation:"frym",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3260,name:"Frontiers In Ocean Engineering",slug:"frontiers-in-ocean-engineering",abbreviation:"focen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:M,name:"FSHIP Test Journal 2",slug:"fship-test-journal-2",abbreviation:"FTJ2",space:{id:i,domainName:j,__typename:b},__typename:a},{id:i,name:cl,slug:cm,abbreviation:cn,space:{id:P,domainName:bG,__typename:b},__typename:a},{id:3746,name:cl,slug:cm,abbreviation:cn,space:{id:c,domainName:d,__typename:b},__typename:a},{id:ci,name:co,slug:cp,abbreviation:cq,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3231,name:co,slug:cp,abbreviation:cq,space:{id:c,domainName:d,__typename:b},__typename:a},{id:n,name:cr,slug:cs,abbreviation:ct,space:{id:n,domainName:Q,__typename:b},__typename:a},{id:2078,name:cr,slug:cs,abbreviation:ct,space:{id:c,domainName:d,__typename:b},__typename:a},{id:ck,name:cu,slug:cv,abbreviation:cw,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2359,name:cu,slug:cv,abbreviation:cw,space:{id:c,domainName:d,__typename:b},__typename:a},{id:8,name:cx,slug:cy,abbreviation:cz,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2446,name:cx,slug:cy,abbreviation:cz,space:{id:c,domainName:d,__typename:b},__typename:a},{id:10,name:cA,slug:cB,abbreviation:cC,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3230,name:cA,slug:cB,abbreviation:cC,space:{id:c,domainName:d,__typename:b},__typename:a},{id:n,name:cD,slug:cE,abbreviation:cF,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2358,name:cD,slug:cE,abbreviation:cF,space:{id:c,domainName:d,__typename:b},__typename:a},{id:3660,name:"Advanced Optical Technologies",slug:"advanced-optical-technologies",abbreviation:"aot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:cj,name:cG,slug:cH,abbreviation:cI,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3659,name:cG,slug:cH,abbreviation:cI,space:{id:c,domainName:d,__typename:b},__typename:a},{id:L,name:cJ,slug:cK,abbreviation:"abp",space:{id:i,domainName:j,__typename:b},__typename:a},{id:3695,name:cJ,slug:cK,abbreviation:"ABP",space:{id:c,domainName:d,__typename:b},__typename:a}]},serverRendered:h,routePath:"\u002Fjournals\u002Fpublic-health\u002Farticles\u002F10.3389\u002Ffpubh.2025.1546182\u002Ffull",config:{baseUrl:"https:\u002F\u002Fwww.frontiersin.org",appName:"article-pages-2022",spaceId:c,spaceName:y,domain:d,loopUrl:"https:\u002F\u002Floop.frontiersin.org",ssMainDomain:d,googleRecaptchaKeyName:"FrontiersRecaptchaV2",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase\u003E\u003E article",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Review Editor\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country\u002Fregion\",\"frontiersDefaultTerm\":\"country\u002Fregion\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries\u002Fregions\",\"frontiersDefaultTerm\":\"countries\u002Fregions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Review Editors\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"}]}'\n",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmServerUrl:"https:\u002F\u002Ftag-manager.frontiersin.org",gtmPreview:"env-1",faviconSize512:"https:\u002F\u002Fbrand.frontiersin.org\u002Fm\u002Fed3f9ce840a03d7\u002Ffavicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https:\u002F\u002Fbrand.frontiersin.org\u002Fm\u002F1c8bcb536c789e11\u002FGuidelines-Frontiers_Logo_1200x628_1-91to1.png",_app:{basePath:"\u002F",assetsPath:"\u002Farticle-pages\u002F_nuxt\u002F",cdnURL:e}},apollo:{contentfulJournalsDelivery:Object.create(null),contentfulJournalsPreview:Object.create(null),contentfulHomeDelivery:Object.create(null),contentfulHomePreview:Object.create(null),frontiersGraph:Object.create(null)}}}("journal_journal","public_space",1,"frontiersin.org",null,"","_self",true,3,"frontierspartnerships.org","_blank",false,0,2,"Frontiers in Public Health","China","citation_author","citation_author_institution",5,609,"public-health","Link",4,"description","Frontiers","Help center","Grey","Medium","ssph-journal.org","fship","image","landscape","Front. Public Health","2296-2565",void 0,"A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure",11,18,13,1920,"por-journal.com",7,"escubed.org",1918,"fipp","https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002Fwebimage-F7837330-160A-426F-A7EBDF4B8DECDD06.png",2497,"22C10171-81B3-4DA6-99342F272A32E8BB","jpg","https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002FD992F897-6BC2-466D-90902EADFBEAB887\u002FWebsiteWebP_XL-FPUBH_Main Visual_Cyan_Website.webp","2022-06-27T10:00:52Z","fpubh",70,"journal_field","10.3389\u002Ffpubh.2025.1546182","Daqiong","Beijing Youan Hospital, Capital Medical University",670990,"Chao","Zhang","The Fifth Medical Center of Chinese PLA General Hospital",1585997,"Lu","Jianru",1805685,"Junliang",1640317,"Zhenhuan",1702500,"Ritthideach",1434331,"Wenjun",1652166,"Xu",{},3460,"Infectious Diseases: Epidemiology and Prevention","infectious-diseases-epidemiology-and-prevention","Frontiers | A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure","https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Farticles\u002F10.3389\u002Ffpubh.2025.1546182\u002Ffull","og:title","og:description","keywords","og:site_name","og:image","og:type","og:url","twitter:card","citation_volume","citation_journal_title","citation_publisher","citation_journal_abbrev","citation_issn","citation_doi","citation_firstpage","citation_language","citation_title","citation_keywords","citation_abstract","citation_pdf_url","citation_online_date","citation_publication_date","Beijing Youan Hospital, Capital Medical University, China","The Fifth Medical Center of Chinese PLA General Hospital, China","dc.identifier","articles","editors","research-topics","https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002Fwebimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png","Man ultramarathon runner in the mountains he trains at sunset","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fresearch-integrity","How we publish","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fhow-we-publish","Research Topics","Fee policy","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Ffee-policy","https:\u002F\u002Fforum.frontiersin.org\u002F","Frontiers Planet Prize","https:\u002F\u002Fwww.frontiersplanetprize.org\u002F","this link will take you to the Frontiers Planet Prize website","Career opportunities","https:\u002F\u002Fcareers.frontiersin.org\u002F","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fcontact","disaster-and-emergency-medicine","Author guidelines","Editor guidelines","https:\u002F\u002Fwww.frontiersin.org\u002Fjournals","https:\u002F\u002Fwww.frontiersin.org\u002Farticles","Articles","https:\u002F\u002Fhelpcenter.frontiersin.org","Frontiers for Young Minds","Frontiers Facebook",9,"Transplant International","transplant-international","ti",1921,"Spanish Journal of Soil Science","spanish-journal-of-soil-science","sjss","ebm-journal.org","Public Health Reviews","public-health-reviews","phrs","Pathology and Oncology Research","pathology-and-oncology-research","pore",21,"Pastoralism: Research, Policy and Practice","pastoralism-research-policy-and-practice","past","Oncology Reviews","oncology-reviews","or","Journal of Pharmacy & Pharmaceutical Sciences","journal-of-pharmacy-pharmaceutical-sciences","jpps","Journal of Cutaneous Immunology and Allergy","journal-of-cutaneous-immunology-and-allergy","JCIA","Journal of Abdominal Wall Surgery","journal-of-abdominal-wall-surgery","jaws",1919,"International Journal of Public Health","international-journal-of-public-health","ijph","Frontiers in Pathology","pathology","fpath",12,17,6,"Experimental Biology and Medicine","experimental-biology-and-medicine","EBM","European Journal of Cultural Management and Policy","european-journal-of-cultural-management-and-policy","ejcmp","Earth Science, Systems and Society","earth-science-systems-and-society","esss","Dystonia","dystonia","dyst","British Journal of Biomedical Science","british-journal-of-biomedical-science","bjbs","Aerospace Research Communications","aerospace-research-communications","arc","Advances in Drug and Alcohol Research","advances-in-drug-and-alcohol-research","adar","Acta Virologica","acta-virologica","av","Acta Biochimica Polonica","acta-biochimica-polonica"));</script><script src="/article-pages/_nuxt/e397d1a.js" defer></script><script src="/article-pages/_nuxt/a5e7651.js" defer></script><script src="/article-pages/_nuxt/f548f7f.js" defer></script><script src="/article-pages/_nuxt/e3c5a8f.js" defer></script><script src="/article-pages/_nuxt/0d6d8e5.js" defer></script><script src="/article-pages/_nuxt/ed7fc59.js" defer></script><script src="/article-pages/_nuxt/2abb6c5.js" defer></script><script src="/article-pages/_nuxt/701e3a3.js" defer></script><script src="/article-pages/_nuxt/71728a1.js" defer></script><script data-n-head="ssr" src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" data-body="true" async></script><script data-n-head="ssr" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" data-body="true" async></script><script data-n-head="ssr" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" data-body="true" async></script><script data-n-head="ssr" src="https://api.altmetric.com/v1/doi/10.3389/fpubh.2025.1546182?callback=_altmetric.embed_callback&amp;domain=www.frontiersin.org&amp;key=3c130976ca2b8f2e88f8377633751ba1&amp;cache_until=14-15" data-body="true" async></script><script data-n-head="ssr" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" data-body="true" async></script>
</body>

</html>